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Infectious diseases are one of the leading causes of morbidity and mortality worldwide. 
Diseases caused by single-celled organisms, such as bacteria and protista, cause billions of 
infections per year. One of the leading weapons in the fight against infectious diseases are 
antimicrobials. However, the efficacy of antimicrobials is decreasing as the development of 
antimicrobial resistance increases. At the same time as increasing levels of resistance are 
observed there is a lack of new antimicrobial agents entering the market and many big 
pharmaceutical companies have suspended antimicrobial drug discovery programs as financial 
return is small. Due to the lack of novel treatments for infectious diseases and increasing 
treatment failures it is essential that new chemical entities are explored to fill this gap.  
In this thesis a novel library of compounds based on the structure of robenidine, an approved 
antimicrobial used to prevent coccidiosis in chickens and rabbits, was investigated as potential 
antimicrobial agents. Initial experiments focussed on the antibacterial activity of the library 
against representative pathogenic bacteria. Activity was assessed according to CLSI guidelines. 
The spectrum of activity of the majority of analogues investigated was limited to Gram-positive 
bacteria, with promising MICs as low as 1.3 µM. However, through the use of outer-membrane 
permeabilising agents and spheroplast induction, it was discovered that the target site of 
robenidine and some of the related analogues was also present in Gram-negative organisms. 
This led to the development of a small subset of analogues which demonstrated intrinsic 
activity against the Gram-negative pathogens Escherichia coli and Pseudomonas aeruginosa 
with MICs as low as 52 µM. Furthermore, kill kinetic studies revealed that robenidine and 
related analogues had a bactericidal mechanism of action. 
The next series of experiments focussed on the characterisation of the antiparasitic activity of 
the library against the protists Trypanosoma brucei, Leishmania donovani and Giardia 
duodenalis. Several of the analogues demonstrated activity against these parasites with some 
promising results against Leishmania donovani including a small number of analogues with 
selectivity indices (SI) for the parasite above 20 (an SI of >10 is considered selective). In 
addition, activity against G. duodenalis was also promising (IC50 <1 µM). In total 121 
analogues were tested against G. duodenalis with 13 being selective for Giardia with no 
antibacterial activity and limited, if any, toxicity towards mammalian cells. MICs for the most 
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promising analogues were ≤ 2.8 µM. Electron microscopy studies to elucidate the mechanism 
or site of action of this class of antimicrobials against G. duodenalis demonstrated that the two 
most promising compounds both caused rapid disintegration of the cell membrane and the 
development of cyst-like structures, while one analogue also appeared to interfere with cell 
division.  
Finally, in order to test in vivo efficacy an animal model was effectively established in neonatal 
mice.  
In conclusion this thesis demonstrated for the first time the potential for this library of 
compounds to become therapeutic agents for a range of infectious diseases. In particular, the 
selective activity of several analogues for Giardia over other microorganisms and mammalian 
cells was demonstrated for the first time, highlighting the potential for this library of analogues. 
In addition, insight into the unique mechanism of action of a select group of compounds against 
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Before the introduction of antimicrobial agents, infectious diseases were the leading cause of 
death worldwide. In pre-antimicrobial America 30% of deaths were caused by pneumonia, 
tuberculosis or diarrhoeal disease. Infant mortality was high (10%) and life expectancy was low 
(47 years)(Cohen, 2000). With the discovery and clinical introduction of antibiotics starting in 
the 1930s and extending into the 1970s, mortality from bacterial infectious disease decreased 
rapidly while life expectancy increased dramatically. Similarly, after the introduction of 
antimicrobials in the UK, death in childhood due to Streptococcus pyogenes decreased by 50% 
(Cohen, 2000). This led to antimicrobials receiving the title of ‘miracle drugs’ and optimism 
for the treatment of infectious agents with antimicrobial compounds was high and it was 
believed that most bacterial infectious diseases would be brought under control or completely 
eradicated (Cohen, 2000; Fauci, 2005). This optimism lasted into the early 1970s as numerous 
new antimicrobial compounds were released onto the market (Spellberg, 2008). Currently, 
however, infectious diseases are the second highest cause of death worldwide (Fauci, 2005). 
Adding to this dilemma is the alarming increase of antimicrobial resistance seen in many 
pathogens worldwide while the number of antimicrobial drugs being developed is decreasing 
(French, 2010; Norrby et al., 2005; Spellberg et al., 2004; Ventola, 2015)  
1.2 Antimicrobial discovery 
There are two main pathways for the discovery of new antimicrobial agents; the traditional ‘top-
down’ or activity centred approach and the ‘bottom-up’ or target centred approach (Debouck 
and Goodfellow, 1999; Tejman-Yarden and Eckmann, 2011). The activity centred approach 
has delivered all the currently used antimicrobial agents for bacterial species and enteric 
pathogenic protista. The target centred approach is a more recent strategy to discover new drugs 
as technology has improved significantly since the discovery of the first antimicrobials, 
potentially allowing the design of compounds that will exploit specific drug targets. However, 
this approach has proven disappointing as it is difficult to predict the in vivo efficacy of potential 
newly synthesised compounds (Mills, 2003; Tejman-Yarden and Eckmann, 2011). 
A third approach to drug development becoming more frequently utilised focusses on the 
‘repurposing’ of an already registered, approved or known drug for alternative indications. This 
method has received recent attention as the cost and time to development of potential drugs can 
be reduced significantly. Repurposing may be an important tool to plug the gap in combating 




1.3 Robenidine as a potential antibacterial agent 
Neoculi Pty. Ltd. is a small pharmaceutical company which has identified robenidine, a widely 
used anticoccidial in the poultry industry, as a potential treatment for bacterial infections and 
other protista. Preliminary research instigated by the company has identified potent in vitro 
activity of robenidine against Gram-positive bacteria including methicillin-resistant 
Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus spp. (VRE), 
prompting the development of a large library of structural analogues of robenidine.   
Robenidine is a non-chiral, synthetic, chlorophenylbenzylidine derivative with a guanidine core 
which has been used as an anticoccidial agent in the poultry industry since 1972 and is also 
used in the commercial rabbit industry (Kantor et al., 1970). It is used in the poultry industry to 
control coccidial infections caused by Eimeria tenella, E. necatrix, E. acervulina, E. brunetti 
and E. maxima and in the commercial rabbit industry to control Eimeria intestinalis, E. 
flavescens, E. magna, E. media, E. perforans and E. stiedai (Aquilina et al., 2011; Kantor et al., 
1970).  
1.3.1 Safety and toxicity of robenidine 
Robenidine is considered to be a relatively safe drug with no identifiable genotoxicity or 
mutagenicity. There is also a large gap between doses required to kill coccidian parasites and 
that which induce reproductive effects in the host (mainly an increase in stillbirth and decreased 
weight gain of rabbit kits). Several studies into the sub-chronic and chronic effects of the drug 
have been completed which did not show any adverse effects. However, these studies were 
lacking in detail and therefore an official ‘no observable adverse effect level (NOAEL) could 
not be identified (Aquilina et al., 2011). 
1.3.2 Spectrum of activity of robenidine 
As mentioned before, robenidine is effective against Eimeria spp. in poultry and rabbits. It has 
also been tested against a range of other parasites in vitro, including Entamoeba, Neospora, 
Cryptosporidium and Toxoplasma, with varying reports of efficacy (Lindsay et al., 1994; 
Ricketts and Pfefferkorn, 1993). In addition, a recent study found robenidine to be an effective 
treatment for Babesia microti infection in mice (Yao et al., 2015). 
Few studies investigating the antibacterial activity of robenidine have been performed, mainly 
in relation to the potential environmental effect robenidine could have when chicken manure is 
used as a fertiliser. In one particular study, robenidine, in addition to several breakdown 
products, was found to effectively prevent growth of unknown soil bacteria with an EC50 as low 
as 2.4 μM (Hansen et al., 2009). A small study to determine if robenidine would be an effective 
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control drug for Clostridium perfringens in rabbits found that robenidine was able to inhibit 
growth of several isolates of the bacteria at concentrations of 4 μg/ml. This study also used S. 
aureus and E. faecalis as controls which where inhibited by concentrations of 4 and 8 μg/ml of 
robenidine respectively (Marien et al., 2008). 
Preliminary studies into the potential antibacterial activity of robenidine and a single structural 
analogue named NCL 062 (identical to robenidine except for methyl imine substitutions) was 
commissioned by Neoculi Pty. Ltd. This study demonstrated that both compounds are narrow 
spectrum, inhibiting Gram-positive organisms, including S. aureus, E. faecalis and S. 
pneumoniae. Both compounds were equally effective against methicillin-sensitive (MSSA) and 
methicillin-resistant strains of S. aureus and vancomycin-resistant and -sensitive strains of E. 
faecalis (VSE). Robenidine was most effective against VRE with a reported minimum 
inhibitory concentration (MIC) range of 2 – 4 μg/ml, MIC50 of 2 μg/ml, MIC90 of 2 μg/ml, and 
an MIC mode of 2 μg/ml (Neoculi; personal communication). Preliminary activity of 
robenidine against S. aureus was undertaken by The University of Adelaide. An overall MIC50 
of 4 μg/ml, MIC90 of 8 μg/ml and an MIC range of 2 – 8 μg/ml were observed. The MBC range, 
MBC50 and MBC90 were the same as the MIC (i.e.: 2 -8 μg/ml, 4 μg/ml and 8 μg/ml, 
respectively) (Ogunniyi et al., 2017). Interestingly, it was found that robenidine had lower 
MIC’s against MSSA and community-acquired MRSA (CA-MRSA) compared to hospital-
acquired MRSA strains (HA-MRSA)(Ogunniyi et al., 2017). Finally, robenidine has been tested 
against S. pneumoniae with an MIC50, MIC90, MBC50 and MBC90 of 8 μg/ml, and an MIC range 
and MBC range of 4 -8 μg/ml (Ogunniyi et al., 2017). Due to the similarity of the MIC and 
MBC concentrations, these data suggest that robenidine and related compounds are bactericidal 
rather than bacteriostatic in activity (Marr et al., 2006). 
1.3.3 Mechanism of action of robenidine 
Exploration into the mechanism of action of robenidine against coccidian parasites has been 
attempted previously in the 1970s. The coccidian parasite has a complex lifecycle consisting of 
several rounds of merogony which result in formation of merozoites followed by sexual 
reproduction and release of oocysts from the host. The oocysts sporulate in the environment 
and go on to infect a new host and the cycle is repeated (McDonald and Shirley, 2009). Through 
inducing experimental coccidiosis in chickens, it is possible to determine at which stage of the 
lifecycle an anticoccidial drug will work by delaying drug treatment for defined periods of time. 
The defined periods of time correspond to the development of different stages of the parasite. 
Using this approach, it was determined that robenidine inhibits the parasite at the stage directly 
preceding the formation of first generation merozoites. It was also determined that the primary 
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action of robenidine is coccidiostatic as short exposure to the drug results in a return of 
infection. However robenidine is possibly coccidiocidal if treatment is long enough (Ryley and 
Wilson, 1971).  
The precise mechanism of action of robenidine has been investigated in two published studies. 
Robenidine was found to inhibit ADP stimulated respiration in intact and submitochondrial 
fractions of rat mitochondria suggesting that robenidine is an inhibitor of oxidative 
phosphorylation (Wong et al., 1972). However, electron microscopy studies of both in vivo and 
in vitro grown parasitic coccidia exposed to robenidine demonstrated that the mitochondria 
were affected last and the effect was probably due to disintegration of the cell rather than a 
direct effect of the drug itself (Lee and Millard, 1972). In this second study, the drug was mainly 
observed to affect the perinuclear space, golgi apparatus and endoplasmic reticulum, resulting 
in distension occasionally accompanied by visible membrane disintegration. After longer 
exposure to the drug, lysosomal like bodies were observed in the parasite and the host cell and 
finally the outer membrane of the cell began to break down. The authors suggest that based on 
these observations the primary site of action may be the ribosomes, which stimulate the over-
production of proteins resulting in self-destruction of the cell (Lee and Millard, 1972). All of 
these observations could be artifacts of an agent that primarily acts on the cell wall. 
Unpublished research initiated by Neoculi Pty. Ltd. has looked into the mechanism of action of 
robenidine against bacteria. In initial studies the inhibition of macromolecular pathways in S. 
aureus by robenidine was determined. This study identified that all 5 pathways tested (DNA 
synthesis, RNA synthesis, protein synthesis, lipid synthesis and cell wall synthesis) were 
equally inhibited (100%). The fact that global inhibition was observed suggests that robenidine 
has a mechanism of action that targets the cell membrane causing a leakage of ions and 
metabolites essential to all 5 processes ((Ogunniyi et al., 2017); Figure 1.1).  
 
Figure 1.1 Inhibition of macromolecular synthesis by robenidine. The inhibition of DNA, RNA, protein, lipid and cell wall 
synthesis by robenidine. Data unpublished, provided by Dr. Stephen Page, Neoculi. 
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Following this a second assay was commissioned which measured the ATP leakage for S. 
aureus cells. Leakage of ATP can indicate that the integrity of the cell membrane has been lost 
(Higgins et al., 2005). It was found that robenidine at concentrations inhibitory to S. aureus 
growth, resulted in a large increase in extracellular ATP. This result in conjunction with the 
previous assay suggests that robenidine may target the cell membrane in Gram-positive bacteria 
((Ogunniyi et al., 2017); Figure 1.2). 
 
Figure 1.2 The effect of robenidine on ATP release from S. aureus ATCC 29213. NCL812 = robendine. The fall in ATP 
concentration at higher concentrations of robenidine may be due to precipitation of robenidine causing a reduction in dissolved 
and therefore biologically available compound. Data provided by Dr. Stephen Page, Neoculi. 
In addition to the initial studies performed with S. aureus, further studies have been performed 
with S. pneumoniae using transmission electron microscopy (TEM). S. pneumoniae cells 
exposed to robenidine for 6 or 12 hours were examined using TEM. After only six hours of 
exposure to 16 μg/ml of robenidine an increase in the thickness of the cell membrane and 
periplasmic space was observed. It has been proposed that the increased thickness of the cell 
membrane could be due to the accumulation of electron dense material beneath the cell 
membrane, while the increase in the thickness of the periplasmic space may be due to disruption 
of the cell membrane, either by depolarisation or the inhibition of ATPase (Ogunniyi et al., 
2017). However, the increase in both cases was not extensive and the results are preliminary, 
suggesting further studies are required. 
In an attempt to continue to understand the mechanism of action of robenidine a closely related 
analogue has also been included in this review. CGP 40215A was a very promising lead 
candidate in the discovery of new therapeutic agents for African trypanosomiasis but was 
abandoned due to the inability of the compound to cross the blood-brain barrier and therefore 
cure late stages of the disease (Brun et al., 2001a). Nevertheless, before the compound was 
abandoned the mechanism of action was extensively studied. CGP 40215A is considered an 
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analogue of methylglyoxalbisguanylhydrazone (MGBG) and therefore a polyamine synthesis 
inhibitor. It is also a structural analogue of robenidine where the aromatic chloride molecules 
have been replaced with amidine moieties (Figure 1.3). CGP 40215A has been shown to inhibit 
the S-adenosylmethionine (AdoMet) decarboxylase enzyme isolated from Trypanosoma brucei 
cells, however this inhibition is much lower than other known decarboxylase inhibitors. In 
addition, whole cells were exposed to CGP 40215A before the AdoMet decarboxylase activity 
in cell extracts were measured and it was found that this drug decreased activity of the target 
enzyme by 68%. Furthermore, the putrescine levels were increased by 20% and the spermidine 
levels decreased by 36%, a secondary indicator that the AdoMet decarboxylase enzyme was 
not working optimally in these cells (Bacchi et al., 1996; Brun et al., 2001a). Further research 
with CGP 40215A to examine the mechanism of action in Plasmodium falciparum, as CGP 
40215A is a potent inhibitor of P. falciparum in vitro, found that the drug did not affect cellular 
polyamine levels and inhibition could not be antagonized by the addition of spermidine or 
putrescine, unlike other inhibitors of polyamine synthesis (Das Gupta et al., 2005). 
 
Figure 1.3: Structure of CGP 40215A (left) and robenidine (812) (right). 
Additionally, CGP 40215A forms a strong bond with the AT region of DNA, which was 
unexpected, as the shape of the molecule does not match the curvature of the grove. Based on 
X-ray crystallography, the linker NH groups, which are conserved in robenidine, form direct 
hydrogen bonds with the thymine associated oxygen groups in the DNA helix. In addition, the 
amidine groups directly interact with the DNA. While only one amidine group is able to form 
direct bonds with the DNA at any time, due to the shape of the molecule, the linker guanine 
group acts as a hinge, so that the two amidines can switch between direct and indirect DNA 
interactions (Nguyen et al., 2002). 
Given the information available in the literature, it is not possible to make a conclusion about 
the precise mechanism of action of robendine. While robenidine was able to inhibit enzymes 
involved in oxidative phosphorylation in rat mitochondria, robenidine was only observed to 
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affect the mitochondria of Eimeria parasites after long exposure times and this effect is thought 
to be the result of the loss of cell integrity, not a direct action of robenidine itself (Lee and 
Millard, 1972; Wong et al., 1972). Although studies with the structural analogue CGP 20415A 
presented conflicting results in the ability of the drug to inhibit polyamine synthesis in different 
organisms, it was also found to bind strongly to the AATT region of DNA through the NH 
moieties in the core of the structure, a structural feature which is also found in robenidine 
(Bacchi et al., 1996; Das Gupta et al., 2005; Nguyen et al., 2002). Recent data obtained by 
Neoculi Pty. Ltd. have demonstrated the global inhibition of all macromolecular synthesis 
pathways in addition to the release of cellular ATP in S. aureus after exposure to the drug 
((Ogunniyi et al., 2017); Figure 1.2). In addition, preliminary work has shown that robenidine 
increases the thickness of the periplasmic space and cell membrane of S. pneumoniae (Ogunniyi 
et al., 2017). TEM studies examining the effect of robenidine on the coccidian parasite Eimeria 
noted the distension of several membrane bound organelles in conjunction with membrane 
degradation (Lee and Millard, 1972). Taking this information into account it is likely that 
robenidine has a primary target within/of the cell membrane which would result in inhibition 
of oxidative phosphorylation and effect polyamine synthesis in addition to other essential cell 
functions. It is also possible that robenidine binds to DNA, as it shares the same linker as CGP 
40215A, and this may be a secondary mechanism of action. However, to properly understand 
the mechanism of action of robenidine, further investigation is required. 
1.3.4 The repurposing of robenidine 
Robenidine has been used extensively in various animal production industries but has the 
potential for ‘repurposing’ for the treatment of alternative infectious diseases in animals, and 
possibly humans. Considering the history of use, safety profile and the preliminary data 
obtained by Neoculi Pty Ltd. robenidine appears to be an ideal candidate for further 
investigation as an antibacterial and antiparasitic agent.  
1.4 Bacterial infections 
Bacterial infections account for a significant proportion of global infections and are the leading 
cause of hospital acquired infections, with the two most prevalent causes of hospital acquired 
infections being MRSA and VRE (Fan et al., 2011; Zetola et al., 2005). While multidrug-
resistant bacteria were originally only considered a problem in hospitals, serious community 
associated (CA)-MRSA strains that have a greater array of virulence factors are becoming more 
common. These strains differ in their degree of multidrug resistance when compared to hospital 
acquired strains and, unlike the hospital acquired strains, may cause serious disease in otherwise 
healthy individuals, including necrotising pneumonia (Zetola et al., 2005). Gram-negative 
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organisms such as Enterobacteriaceae spp. including Escherichia coli, Klebsiella, 
Enterobacter and Pseudomonas aeruginosa which are resistant to multiple antimicrobials, 
including those conferred by extended-spectrum beta-lactamases and carbapenemases, are also 
causing significant problems worldwide, especially in hospitals (Poole, 2003; Umland et al., 
2014). 
Although multi-drug resistant (MDR) hospital acquired infections are a significant threat to 
public health, there are also several pathogens prevalent in the community causing serious 
issues. For example, up to 30% of S. pneumoniae isolates, the leading cause of pneumonia 
worldwide resulting in ~ 1 million child deaths per year, are MDR (Neu, 1992; O'Brien et al., 
2009). The development of MDR tuberculosis and now extensive drug resistant tuberculosis is 
a major concern for international health (Gandhi et al., 2010). Currently there are organisms 
that are pan-resistant to all available antimicrobials, making the need for new antimicrobial 
drugs extremely urgent (Pendleton et al., 2013; Rice, 2008). 
1.4.1 Bacterial resistance mechanisms  
The two main types of antimicrobial resistance in bacteria are intrinsic resistance, which may 
be a result of mechanisms that prevent drug access through the outer membrane of Gram-
negative organisms, or acquired resistance such as an increase in efflux pumps (Kaye and Kaye, 
2000). 
1.4.1.1 Intrinsic Resistance 
Intrinsic resistance is a form of resistance inherent in a microorganism. A very relevant form of 
intrinsic resistance in drug discovery is biofilm formation (Kaye and Kaye, 2000). Biofilms are 
formed on a surface when bacteria encase themselves in a complex matrix (Stewart and 
Costerton, 2001; Suh et al., 2010). This protective matrix can house thousands of bacterial cells 
and provide up to a 1000 times more resistance to many antimicrobials than the individual 
bacterial cells would otherwise have (Suh et al., 2010). Biofilms are able to persist after 
antimicrobial therapy causing recurrent symptomatic infections (Rendueles et al., 2013). Due 
to the presence of metabolically inactive persistor cells within the biofilm matrix, many of the 
currently registered antibiotics are ineffective in biofilm eradication. This is due to the fact that 
many of the currently registered antimicrobials are only effective against metabolically active 
cells as they target the metabolic synthesis pathways of proteins, nucleic acids and the cell wall 
(Hurdle et al., 2011). 
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1.4.1.2 Acquired Resistance 
Acquired resistance is a change in the genetic structure of an organism which confers resistance 
to an antimicrobial to which that organism was once susceptible (Kaye and Kaye, 2000). 
Genetic resistance can be encoded on chromosomal or plasmid DNA. Plasmid-encoded 
antimicrobial resistance can be easily transferred from one bacterium to another and can even 
be passed between species, e.g. from Enterococcus spp. to Staphylococcus spp. (Tenover, 
2006). There are four recognised phenotypic expressions of genetic resistance; the action of 
efflux pumps, which transport the antimicrobial out of the cell so it cannot affect the target, the 
production of antimicrobial altering or degrading enzymes, which inactivate the antimicrobial 
and stop it from working, alterations in the target site such as changing the binding site and 
acquiring new pathways to bypass the antimicrobial targeted pathways (Neu, 1992).  
1.4.2 Antimicrobials that affect bacterial membranes 
The majority of current antimicrobial agents target one of five biosynthetic processes (synthesis 
of RNA, DNA, protein, folic acid or peptidoglycan) that are present in metabolically active 
bacteria (Hurdle et al., 2011). However, many infections are caused by stationary or quiescent 
bacteria that are not significantly metabolically active, therefore the traditional antimicrobials 
prove ineffective in eradicating these infections (Hurdle et al., 2011). Recently it has been noted 
that molecules that target the membrane of bacteria are able to kill metabolically active as well 
as metabolically inactive bacteria due to the necessity of the bacterial membrane for cell 
viability in both states. This discovery has led to the suggestion that bacterial membrane 
function is an ideal target for treating chronic bacterial infections, such as biofilms, but would 
also be effective in treating metabolically reproducing cells (Hurdle et al., 2011). In addition, 
there is experimental evidence that antimicrobials that affect the cell membrane are effective in 
treating parasitic protists such as Plasmodium and Leishmania (Torrent et al., 2012). The two 
main advantages of using cell membrane inhibitors, apart from the fact that they can destroy 
persistent infections, is the difficulty in developing resistant isolates and a multi-target effect 
(Hurdle et al., 2011; Ooi et al., 2009). This thesis focusses on the potential of repurposing 
robenidine as an antimicrobial agent. Based on preliminary data it has been suggested that 
robenidine potentially affects the cell membrane of target cells (Ogunniyi et al., 2017). 
Therefore, due to the large number of antibacterials available, only antimicrobials that affect 
the cell membrane and therefore could provide some insight into the mechanism of action of 
robenidine have been included in this review.  There are currently a number of cell membrane 
inhibitors on the market including daptomycin, the polymyxins and the gramicidins, all of 
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which are classified as antimicrobial peptides (Hancock and Sahl, 2006; Straus and Hancock, 
2006).  
1.4.2.1 Antimicrobial peptides 
Antimicrobial peptides are produced by all living organisms from bacteria to humans and form 
part of the innate immune response. Although there is a large variety of compounds in this 
group they all consist, at least in some part, of various combinations of amino acids (Epand and 
Vogel, 1999; Fan et al., 2011). All the antimicrobial peptides currently in clinical use originate 
from microbial organisms with the majority targeting the bacterial cell membrane, however 
there are some exceptions such as vancomycin which inhibits cell wall synthesis (Allen and 
Nicas, 2003; Mangili et al., 2005; Reynolds, 1961). For the purpose of this review, only 
antimicrobial peptides that target the cell membrane will be mentioned. The three main classes 
of antimicrobial peptides that contain compounds that target the cytoplasmic membrane are 
cationic antimicrobial peptides, lipopeptides and glycopeptides (Allen and Nicas, 2003; Hale 
and Hancock, 2007; Straus and Hancock, 2006). 
1.4.2.2 Cationic antimicrobial peptides 
Cationic antimicrobial peptides (CAMPs) are positively charged amphiphilic molecules 
composed of amino acids (usually between 15 – 50) that have shown antimicrobial activity 
under physiological conditions (Fox, 2013). CAMPs generally have broad spectrum 
antibacterial activity and most commonly form stabilised β-sheets or α-helices (Deslouches et 
al., 2005a; Hancock, 1997). Several CAMPs have successfully been taken into pre-clinical and 
clinical trials, however gramicidins are the only class of CAMPs currently in clinical use. 
Gramicidins are small linear peptides with the exception of gramicidin S which is a dimer 
forming a cyclic structure. Gramicidins have toxic side effects, limiting them to topical or local 
applications only (Deslouches et al., 2005a; Hancock, 1997). Work on other pre-clinical 
CAMPs indicate that toxicity issues are easily overcome via slight modifications to amino acid 
composition, which could possibly be applied to the gramicidins to expand their possible 
clinical uses (Deslouches et al., 2007; Deslouches et al., 2005a).  
Currently there are several CAMPs that are in clinical or pre-clinical trials including MX-266, 
Omiganan, A3-APO, WLBU2 and Ctriporin. Both MX-266 and Omiganan are presently in 
phase III clinical trials, MX-266 for the treatment of mild to moderate acne and Omiganan for 
the prevention of catheter associated infections (Deslouches et al., 2005a; Fan et al., 2011; 
Hancock and Sahl, 2006; Marr et al., 2006; Szabo et al., 2010). A3-APO, WLBU2 and Ctriporin 
have been shown to be promising candidates in mouse models for the treatment of Gram-
negative (A3-APO and WLBU2) or Gram-positive (Ctriporin) infections. Both A3-APO and 
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WLBU2 have potential use as systemic peptides, over gramicidins, curing mice of septicaemia 
while ctriporin has potential application as a topical ointment for the treatment of MRSA and 
other multi-drug resistant Gram-positive infections (Deslouches et al., 2005a; Fan et al., 2011; 
Hancock and Sahl, 2006; Marr et al., 2006; Szabo et al., 2010) 
1.4.2.3 Lipopeptides 
The lipopeptides have proven to be the most successful antimicrobial peptides in clinical 
settings. The majority of lipopeptides are cyclic with a fatty acyl side chain which allows 
interaction with the cell membrane (Qian et al., 2012). The two most prominent antibacterial 
lipopeptides are daptomycin and the polymyxins. Both are cyclic lipopeptides, however 
daptomycin is anionic showing specificity towards Gram-positive organisms while polymyxins 
are cationic showing specificity towards Gram-negative organisms (Jeu and Fung, 2004; Mogi 
and Kita, 2009). 
1.4.2.4 Glycopeptides 
Glycopeptides are peptides that contain carbohydrates and as antimicrobial compounds are 
generally considered to inhibit peptidoglycan synthesis. There is a small sub-group of this class 
which has recently been approved for use in the USA and Europe, known as lipoglycopeptides, 
which have been shown to be effective against cell membranes. Currently available compounds 
from this class include dalbavancin and telavancin (Bouza et al., 2017; Gudiol et al., 2017). 
This sub-group contains fatty acyl side chains as well as carbohydrates. (Zhanel et al., 2010; 
Zhanel et al., 2012).  
1.4.2.5 Advantages and disadvantages of using antimicrobial peptides 
There are several advantages in the use of peptides as antimicrobial agents. Firstly, it is difficult 
to select for resistance to antimicrobial peptides in microorganisms, secondly they tend to be 
bactericidal rather than bacteriostatic, thirdly they have a multi-target effect and finally they are 
usually effective in the treatment of biofilms (Bahar and Ren, 2013; Overhage et al., 2008). 
The main disadvantages of using antimicrobial peptides in medicine is potential toxicity to the 
host, their sensitivity to proteases and the cost of production (Fox, 2013). The first two issues 
can be easily overcome by creating small chemical modifications to the peptides which 
significantly reduce toxicity and decrease sensitivity to proteases as proven by the synthetic 
peptide WLBU2 (Bahar and Ren, 2013; Deslouches et al., 2007; Deslouches et al., 2005b). The 
high cost of peptide production is the main hindrance in their clinical use with a single dose 
costing hundreds of dollars to produce in some cases. There has been research into the potential 
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of large-scale production of antimicrobial peptides at a reasonable price using bacterial 
recombinant expression systems (Hancock and Lehrer, 1998).  
Another concern raised in the use of antimicrobial peptides is the development of cross-
resistance in bacterial populations to the innate immune peptides, particularly when human 
derived peptides are used. Although this is a possibility, it seems highly unlikely to cause major 
problems as development of resistance to peptides seems to be rare (Hancock and Sahl, 2006). 
1.4.2.6 Other classes of bacterial cell membrane inhibitors 
1.4.2.7 Porphyrins 
Only one member of this class, XF-73 with a Gram-positive spectrum, has been identified. It 
has a structure distinct from other antimicrobial classes and it targets the bacterial cell 
membrane with activity against slow growing organisms observed. After 55 passages at sub-
inhibitory levels of XF-73, no resistant organisms were identified (Ooi et al., 2009; Ooi et al., 
2010). 
1.4.2.8 Quinoline-like molecules 
Quinoline molecules are a group of related natural and synthetic compounds which share a 
bicyclic core structure and commonly have antibacterial activity (Aldred et al., 2014). HT61 
was discovered in 2010 after screening a large number of possible antimicrobial agents for 
activity against 10-day old stationary phase S. aureus cells (Hu et al., 2010). HT61 was 
identified as a quinoline-like molecule which is active against the cell membrane of Gram-
positive bacteria, but not Gram-negative bacteria (Hu et al., 2010).  HT61 is very effective at 
killing stationary phase cells when compared with currently available drugs. Additionally, 
animal trials show that a skin infection of stationary phase S. aureus can be completely killed 
in 2 hours (Hu et al., 2010). Further investigation is needed to determine if there is similar 
activity towards biofilms as was seen against stationary cells, which have different 
antimicrobial defence systems. 
1.4.2.9 Riminophenazines 
Define riminophenazines as a class of compounds where the ‘imino’ part of the molecule has 
been modified (Reddy et al., 1999). Clofazimine is a synthetic riminophenazine antimicrobial 
that is known to be effective against mycobacteria including tuberculosis and leprosy. Although 
the drug was first identified in 1957 it wasn’t until 1998 that its activity against Gram –positive 
organisms such as S. aureus was identified (Oliva et al., 2004; Reddy et al., 1999). Initial studies 
into the mechanism of action of clofazimine suggested the main target of clofazimine was RNA 
and DNA. However more recent studies suggest that clofazimine causes non-specific 
33 
 
membrane damage, resulting in inhibition of RNA, DNA and protein synthesis (Oliva et al., 
2004). 
1.5 Protistan infections 
Protists are an extremely diverse group of primarily unicellular eukaryotic organisms 
encompassing both free-living and parasitic groups. Some of the most devastating human 
parasitic pathogens belong to this kingdom including Plasmodium, Trypanosoma, Trichomonas 
and Giardia. Encompassed within this kingdom are the flagellates – a group of organisms that 
move via the use of one or more flagella at some stage within their lifecycle. Several parasitic 
protists belong to this group and cause widespread human and animal disease. For the purposes 
of this review, and the thesis in general, three model organisms from this group will be 
discussed - Giardia duodenalis, a diplomonad, Trypanosoma brucei and Leishmania donovani, 
both kinetoplasts. G. duodenalis is the most common cause of waterborne diarrhoea worldwide, 
contributing to numerous deaths (Lloyd and Williams, 2014), while T. brucei and L. donovani 
contribute to 100 000 deaths per year with over 3 million people at risk (Alvar et al., 2012; 
Turrens 2004; Stuart et al., 2008). 
1.5.1 Kinetoplasts – Trypanosoma brucei and Leishmania donovani 
The kinetoplastid protists that cause leishmaniasis and human African trypanosomiasis (HAT) 
share similar biochemical features, such as a unique thiol metabolism system, and have a similar 
structure, characterised by a kinetoplast, which is a discretely structured DNA body located in 
the mitochondrion. Other shared structural features include a glycosome; specific organelles 
for glycolysis, a single mitochondrion and a sub-pellicular microtubular corset (Barrett and 
Croft, 2012; Stuart et al., 2008). 
Leishmaniasis, often considered as a disease complex, is caused by several different species of 
Leishmania, including L. donovani. There are two major manifestations of the disease, 
cutaneous leishmaniasis and visceral leishmaniasis (kala azar), with several rarer manifestations 
including mucocutaneous leishmaniasis and post-kala azar dermal leishmaniasis (Barrett and 
Croft, 2012; Grevelink and Lerner; Stuart et al., 2008). It is estimated that there are currently 
0.2 - 0.5 million cases per year of visceral leishmaniasis predominantly caused by L. donovani, 
which is fatal if left untreated (Alvar et al., 2012; Stuart et al., 2008). While cutaneous 
leishmaniasis (CL) establishes as an open sore at the location of the vector bite, it will usually 
heal spontaneously leaving a scar (Barrett and Croft, 2012). Visceral leishmaniasis manifests 
initially as skin lesions before developing into gross inflammation within the viscera – in 
particular the liver and spleen (Barrett and Croft, 2012). L. donovani is transmitted by an insect 
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vector, the Phlebotomus sandflies. The sandfly ingests cells infected with Leishmania 
amastigotes. The amastigotes transform into promastigotes in the gut of the sandfly, multiply 
and migrate to the probiscus. Promastigotes are transferred from the sandfly to the victim during 
a blood meal. The parasites are phagocytized by mononuclear phagocytic cells where they 
transform into amastigotes and replicate (Figure 1.3).  
 
Figure 1.4 Lifecycle of Leishmania. Promastigotes are released into the human bloodstream via an infected sandfly as it bites. 
The promastigotes are phagocytosed and transform into amastigotes. The amastigotes multiply in the cells before moving on 
to infect naive cells. The parasite is transferred to the sandfly during a blood meal as amastigotes which transform into 
promastigotes in the sandfly gut. Image in the public domain credited to CDC-DPDx/Alexander J. da Silva, PhD. 
Trypanosomiasis, in particular caused by T. brucei, is endemic to various regions of the sub-
Saharan Africa and commonly known as sleeping sickness as late stages of the disease include 
altered sleep-wake cycles (Barrett and Croft, 2012; Field et al., 2017). It was estimated in 2006 
that ~ 70 000 individuals were infected (Lutje et al., 2013). Infection is transmitted via the bite 




Figure 1.5 Lifecycle of Trypanosoma sp. Parasites are injected into the bloodstream via the bite of the tsetse fly. They 
multiply in various bodily fluids. Parasites are transferred to the Tsetse fly during a blood meal where they multiply in the 
midgut, transform into epimastigotes and travel to the salivary glands. Image in the public domain credited to CDC-
DPDx/Alexander J. da Silva, PhD. 
In the first stage of the disease parasites proliferate in the lymphatic system and blood, causing 
symptoms such as headaches, intermittent fever and lymphadenopathy (Barrett and Croft, 2012; 
Buscher et al., 2017; Lutje et al., 2013; Stuart et al., 2008). The second stage of the disease is 
characterised by the invasion by parasites of the central nervous system, including the brain. 
Symptoms of the second stage of disease are a result of neurological breakdown and include 
altered sleep-wake cycles, narcolepsy, semi coma, chronic meningoencephalitis and psychiatric 
disorders including depression. The rate of progression from stage 1 to stage 2 disease depends 
on the subspecies of trypanosome causing the disease but varies from 2 weeks to 18 months 
(Barrett and Croft, 2012; Lutje et al., 2013; Stuart et al., 2008). The disease is invariably fatal 
if left without treatment and is considered one of the hardest diseases to control in sub-Saharan 
Africa due to difficulty in diagnosis and treatment as well as civil unrest (Buscher et al., 2017; 
Lutje et al., 2013). 
Chagas disease, caused by T. cruzi, is also a significant problem. Chronic reactivation and 
congenital Chagas disease is likely to cause significant problems in the future with an estimated 
16 million people already infected (Hemmige et al., 2012). 
1.5.2 Current drugs in the treatment of leishmaniasis and trypanosomiasis 
Leishmaniasis 
There are five available drugs for the treatment of leishmaniasis; pentavalent antimonials, 
amphotericin B, miltefosine, paromomycin and pentamidine, with varying efficacy against 
different Leishmania sp. (Barrett and Croft, 2012; Croft, 2008; de Menezes et al., 2015). 
Pentavalent antimonials have been widely used historically. There is variable effectiveness 
against different forms of leishmaniasis (35 – 95%) and resistance is common in certain places 
making the drug obselete (e.g. >65% in Bihar, India) (Barrett and Croft, 2012; Croft, 2008; de 
Menezes et al., 2015). Administration can be intravenous, intramuscular or intralymphatic once 
per day for 20 days (de Menezes et al., 2015). Serious side effects of using antimonials include 
vomiting, anorexia, myalgia and headaches. In rare cases, antimonials can cause fatal cardiac 
arrhythmia (de Menezes et al., 2015). 
Amphotericin B has become the first line drug in certain states in India where resistance to 
pentavalent antimonials has restricted their use (Croft, 2008). It is also used to treat specific 
types of cutaneous leishmaniasis in South America (Barrett and Croft, 2012). Amphotericin B 
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is delivered intravenously which causes infusion-related reactions such as rigor, fever and chills 
and the drug itself has been associated with more serious side effects such as myocarditis and 
nephrotoxicity (de Menezes et al., 2015). Alternative formulations to reduce toxicity have been 
developed. These formulations do not remove all side effects and are much more expensive but 
they significantly shorten treatment times, from once per day for 20 days to a single dose (de 
Menezes et al., 2015). 
Pentamidine has an efficacy of treatment from 35 – 96% depending on the Leishmania species 
being targeted (de Menezes et al., 2015) and is generally limited to the treatment of specific 
types of cutaneous leishmaniasis in South America (Barrett and Croft, 2012). Intramuscular 
administration over 8 days is required and a high rate of hyperglycemia is reported (de Menezes 
et al., 2015).  
Paromomycin has been used to treat leishmaniasis in various formulations for several decades 
(Barrett and Croft, 2012). It is delivered either intramuscularly for visceral leishmaniasis or 
topically to cutaneous forms of the disease daily for 17- 21 days. It is relatively cheap and 
highly efficacious in India with the major side effects including severe nephrotoxicity, 
ototoxicity and hepatotoxicity (de Menezes et al., 2015).  
Miltefosine is the first oral drug to be developed for the treatment of leishmaniasis (Croft, 
2008). It is highly efficacious in both India and Africa requiring daily dosing for 28 days (de 
Menezes et al., 2015). There has been some variable species dependent effectiveness against 
CL reported (Barrett and Croft, 2012). Miltefosine is contraindicated for use in pregnant women 
due to teratogenic effects seen in rodents. Side effects of miltefosine use include vomiting, 
diarrhea, hepatotoxicity and nephrotoxicity (de Menezes et al., 2015). 
Trypanosomiasis 
 There are five drugs currently used for the treatment of human African trypanosomiasis (HAT), 
but only four have been approved for clinical use (Barrett and Croft, 2012; Buscher et al., 2017; 
Fairlamb, 2003; Field et al., 2017). All of these drugs were introduced for use ≥ 40 years ago. 
Currently suramin and pentamidine are recommended for early stage disease while melarsoprol 
and eflornithine are used in the late stage of disease. Nifurtimox is used on compassionate 
grounds to treat late stage disease when other drugs fail (Fairlamb, 2003). Unfortunately, all 
current therapies for HAT are unsatisfactory due to toxicity, poor efficacy, resistance and 
undesirable administration requirements (Barrett and Croft, 2012; Fairlamb, 2003).  
Pentamidine was introduced in 1973 and is the first line treatment for stage 1 infections caused 
by T. b. gambiense. It is only used as a secondary treatment for stage 1 T. b. rhodesiense 
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infections when Suramin is contra-indicated (due to lower reliability) (Fairlamb, 2003).  
Pentamidine is not used to treat 2nd stage disease as it does not effectively cross the blood-brain 
barrier. Pentamidine can cause damage to several organs including the pancreas which can lead 
to diabetes (Fairlamb, 2003). Intramuscular administration is preferred as the drug has poor oral 
availability and intravenous administration can cause severe hypotensive reactions (Barrett and 
Croft, 2012; Fairlamb, 2003).  
Suramin was introduced in the early 1900s and is the first treatment option for early stage 
disease caused by T. b. rhodesiense. Administration is via slow intravenous injection over a 4-
week period. Immediate side effects include nausea, vomiting, collapse and shock while long 
term toxic side effects can include pyrexia, nephrotoxicity, urticarial neuropathy, severe 
diarrhea and haemolytic anaemia (Barrett and Croft, 2012; Fairlamb, 2003). 
Melarsoprol, an arsenical, was first introduced as a treatment for HAT in 1949. It is used to 
treat the late stage of disease after parasites have crossed into the CNS (Fairlamb, 2003). It is 
the only treatment option for stage 2 T. b. rhodesiense. Serious reactive encephalopathy afflicts 
5-10% of patients, half of which die. Other side effects include pyrexia, headache, pruritus, 
thrombocytopaenia, vomiting, abdominal colic and heart failure (Barrett and Croft, 2012; 
Fairlamb, 2003). Administration is via intravenous injection over 10 days (Barrett and Croft, 
2012). Resistance to melarsoprol is becoming a problem in the field (Barrett and Croft, 2012). 
Eflornithine is used as a first line treatment for late stage disease cause by T. b. gambiense. It 
is not very effective in treatment of disease caused by T. b. rhodesiense and therefore is not 
recommended (Barrett and Croft, 2012; Fairlamb, 2003). Administration is time consuming and 
costly requiring intravenous infusion multiple times per day for up to 14 days (Barrett and Croft, 
2012; Fairlamb, 2003). Side effects include fever, headache, hypertension, macular rash, 
peripheral neuropathy, tremor and gastrointestinal problems e.g. diarrhea (Barrett and Croft, 
2012). 
Although Nifurtimox is registered for the treatment of Chagas disease, caused by T. cruzi, it is 
only used on compassionate grounds for the treatment of late stage HAT when melarsoprol and 
eflornithine fail (Fairlamb, 2003). There is also a promising new drug undergoing clinical trials, 
fexinidazole, which could be approved as early as 2018 (Maxmen, 2017). 
1.5.3 Diplomonads - Giardia duodenalis  
Giardia duodenalis (syn. G. lamblia, G. intestinalis) is the most common enteric parasitic 
protist worldwide with estimates of 1 billon infections annually, mostly occurring in children 
in resource poor communities where infection rates can be as high as 100%. In developed 
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nations infection is generally estimated at 7% (Fletcher et al., 2012; Halliez and Buret, 2013; 
Upcroft and Upcroft, 1998; Upcroft and Upcroft, 2001a). Due to the association of infection 
with undeveloped countries, Giardia has been included as part of the WHO neglected diseases 
initiative (Savioli et al., 2006). Infectious cysts are ingested by the host through contaminated 
food or water or directly via the faecal oral route with symptoms being noticed several days to 
weeks after exposure. Symptoms may include diarrhoea, abdominal cramps, flatulence, 
bloating and weight loss which can last for several weeks if left untreated. Chronic infections, 
particularly in children, can lead to failure to thrive syndrome which includes growth stunting 
and decreased intellectual development (Buret, 2008). More recently giardiasis has been 
recognised as being associated with the development of other diseases including arthritis, post-
infectious irritable bowel syndrome and chronic fatigue syndrome (Halliez and Buret, 2013).  
There are several classes of antigiardial agents on the market, including the nitroimidazoles and 
benzimidazoles. With the emergence of drug resistance, adverse side effects of available drugs 
and sub-optimal dosing regimens, the utility of the available drugs is limited (Bendesky et al., 
2002; Jokipii and Jokipii, 1979; Watkins, 2003; Wright et al., 2003). Due to the limitations of 
the available drugs and the consequences of infection it is of high priority to develop new drugs 
for the treatment of giardiasis. The development of new drugs is dependent on robust in vitro 
tests to first identify and characterise potential candidates followed by in vivo efficacy, toxicity 
and PK/PD studies to confirm in vitro results. Although there is an unmet need for new 
antigiardial agents, there is a lack of standardised systems for the development of potential drug 
candidates in vitro and in vivo which, among other things, limits inter-laboratory comparisons 
(Benere et al., 2007; Gardner and Hill, 2001).  In this section of the review the current treatment 
options, efficacy screens available in vitro and in vivo to facilitate the standardisation of the 
evaluation of new antigiardial agents and allow the potential for inter-laboratory comparisons, 
as well as promising new antigiaridal compounds are discussed. 
The desired profile for new antigiardial drugs would include the inability for the selected 
compound to travel across the intestinal barrier and a slow passage through the gastrointestinal 
tract as Giardia trophozoites attach to the epithelial cells but do not invade (Thompson, 2000). 
In addition, it would be beneficial for the compounds to have high selectivity for Giardia over 
other microorganisms as, with most of the current drugs available, treatment can result in 
significant disruption to the gastrointestinal microbiota which can cause a cascade effect of 
further health problems (Adamsson et al., 1999; Jakobsson et al., 2010; Jernberg et al., 2007; 
Shreiner et al., 2015). 
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1.5.4 Current drug therapies available for the treatment of Giardia 
Several antiparasitics have been developed for the treatment of G. duodenalis infections, the 
main classes currently and historically used being acridine derivatives, nitroimidazoles, 
nitrofurans, benzimidazoles, nitrothiazolyl derivatives and aminoglycosides (Figure 1.5). Each 
class has advantages and disadvantages to use (Escobedo and Cimerman, 2007; Upcroft et al., 
1996). 
Acridine derivatives 
Quinacrine, an acridine derivative, was the first drug widely used in the treatment of giardiasis 
before the introduction of metronidazole in the 1960s. The clinical efficacy of quinacrine has 
been reported as high as 90% when administered over 5-10 days, with the recommended 
treatment lasting for 5 days (Miyamoto and Eckmann, 2015). Side effects of the drug include 
nausea and vomiting and the compound is reported to have a bitter taste which contributes to 
poor compliance amongst patients. More severe side effects have included toxic psychosis and 
other psychiatric disturbances. Discolouration of the skin and nails has also been reported. In 
addition, this drug is contra-indicated in patients with glucose-6-phosphate dehydrogenase 
deficiency due to haemolysis and in pregnancy due to cross-placental transfer and a possible 
link to spina bifida and renal agenesis in the foetus. There is also a disulfiram like effect (which 
includes headaches, nausea, vomiting, chest pain, blurred vision and difficulty breathing) when 
taken in conjunction with alcohol (Escobedo and Cimerman, 2007; Gardner and Hill, 2001; 
Upcroft et al., 1996). The mechanism of action of this class of antigiardials is not fully 
understood, it was originally thought to interfere with DNA synthesis, as this was observed in 
vitro, and it has been understood to inhibit the cytoplasmic NADH oxidase enzyme. However, 
studies involving the natural fluorescence of the molecule did not locate it to the nucleus of the 
parasite where DNA is located or in the cytoplasm with the oxidase enzyme, instead it appears 
to localise at the cell membrane which continues to deteriorate over time after exposure to the 
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Figure 1.6 Drug structures of currently and historically used antigiardials. 1 – quinacrine, 2 – metronidazole, 3 – tinidazole, 





5- nitroimidazoles  
Antigiardial activity of the 5-nitroimidazoles was first discovered in the 1950s with the 
identification of metronidazole, which is the current ‘gold-standard’ treatment for giardiasis, 
and has been a mainstay in treatment for the last 50 years. Other 5-nitroimidazoles that can be 
used in therapy include tinidazole, ornidazole and secindazole but these are not available in all 
countries. The mean efficacy of metronidazole is around 88% when taken for 5-10 days 
(Gardner and Hill, 2001). Longer durations of dosing as well as shorter higher doses have been 
tested but both result in a drop in efficacy, due to poor compliance and side effects in the former 
case. Mild side effects can include a metallic taste, nausea and headaches, which in addition to 
long dosing periods, can contribute to poor compliance amongst patients. More significant side 
effects include central nervous system toxicity, particularly with higher doses. Studies in 
bacteria and animals suggest that metronidazole is mutagenic and carcinogenic however at 
therapeutic doses there is no evidence to suggest that metronidazole is a significant risk for the 
development of cancer in humans (Gardner and Hill, 2001). Studies into the use of 
metronidazole during all stages of pregnancy do not show any increase in congenital 
abnormalities in relation to metronidazole use (Koss et al., 2012). Metronidazole is 
contraindicated with the ingestion of alcohol due to a disulfiram like effect (Escobedo and 
Cimerman, 2007). Development of resistance to metronidazole has been induced in the 
laboratory as well as documented in the clinic (Gardner and Hill, 2001; Tejman-Yarden et al., 
2013; Upcroft and Upcroft, 2001b; Wright et al., 2003).  
The mechanism of action of nitroimidazoles requires activation of the drug by reduction of the 
nitrogroup via anaerobic metabolic pathways in Giardia. In vitro this can be done by 
pyruvate:ferredoxin oxidoreductase (PFOR) or ferredoxin and metronidazole resistant 
organisms show a down regulation of PFOR and ferredoxin enzymes (Upcroft and Upcroft, 
2001b). Once active the drug damages important biomolecules such as lipids, proteins and DNA 
and is also thought to inhibit oxygen consumption of the parasite by acting as an alternate 
electron acceptor (Ansell et al., 2016; Escobedo and Cimerman, 2007). 
Tinidazole has a similar cure rate to metronidazole however it has one significant advantage – 
only a single dose is required with a mean efficacy of 92% (Gardner and Hill, 2001). As with 
metronidazole there are still side effects such as a bitter taste or a rash and tests in bacteria 
suggest it has a similar mutagenic profile to metronidazole. In addition, as a precaution it is not 
recommended for use in pregnant patients although studies in pregnant animals did not identify 
any developmental delays in offspring of exposed mothers (Escobedo and Cimerman, 2007).  
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Ornidazole is also usually given as a single dose in the treatment of giardiasis and is generally 
better tolerated than metronidazole and tinidazole however there have been rare reports of the 
development of hepatitis and cholangitis, which improved after discontinuation of the drug 
(Escobedo and Cimerman, 2007; Gardner and Hill, 2001). 
Nitrofuran derivatives 
Furazolidone, the representative antigiardial from this family, is slightly less effective than 
quinacrine and metronidazole, with a reported clinical efficacy rate of 80%. The major 
advantage of furazolidone over the examples from previous classes described is the ease of 
administration to young children with a liquid formulation available (Gardner and Hill, 2001). 
Treatment is required over 5 to 10 days and common side effects include diarrhoea, nausea and 
vomiting which all contribute to patient non-compliance. Furazolidine is contraindicated in 
glucose-6-phosphate D deficiency (due to haemolysis), in patients already taking monoamine 
oxidase inhibitors (as furazolidone has a monoamine oxidase inhibitory effect) or breast-
feeding mothers and neonates, as infants can develop haemolytic anaemia. In addition, as with 
acridine derivatives and nitroimidazoles, alcohol should be avoided due to a disulfiram like 
effect. Although furazolidone is carcinogenic in animals a similar effect has not been observed 
in humans but this could be due to a lack of surveillance in exposed populations rather than a 
lack of risk (Gardner and Hill, 2001). 
Similarily to nitroimidazoles, nitrofuran derivatives are reduced by the NADH oxidase enzyme 
to nitro radicals which damage essential cellular components such as DNA (Escobedo and 
Cimerman, 2007). 
Benzimidazoles 
The benzimidazoles, including albendazole and mebendazole, are relatively new additions to 
the antigiardial arsenal. Although these drugs are more effective than metronidazole and 
quinacrine in vitro this is not translated to clinical efficacy (as the benzimidazoles have clinical 
efficacy reportedly between 35 and 96% depending on the dosing schedule). Side effects are 
uncommon but can include abdominal pain, vomiting, nausea and diarrhoea. In addition, 
benzimidazoles (i.e. albendazole) are not recommended in pregnancy due to a teratogenic effect 
observed in rats, which is yet to be observed in humans (Escobedo and Cimerman, 2007; 
Gardner and Hill, 2001). The mechanism of action of albendazole has been extensively studied 
and it is known to target β-tubulin resulting in impaired glucose uptake and inhibition of 




Nitazoxanide and its metabolite tizoxanide have demonstrated in vivo efficacy much greater 
than metronidazole and even albendazole. In the clinical environment nitazoxanide has 
relatively good efficacy ranging between 64 and 94% and is recommended once per day for 3 
days. The mechanism of action is thought to affect the plasma membrane of the parasite 
resulting in the formation of large empty vacuoles in the cytoplasm and general cell swelling. 
The mechanism of action is thought to be reliant on the nitro group, as with the other nitro 
containing classes of antigiardials, however the action of this class is not dependant on same 
reduction pathways as the nitroimidazoles. Therefore, this class of drug is still an effective 
choice for treating parasites resistant to nitroimidazoles, such as metronidazole. In addition, 
there are few side effects observed with the most significant being abdominal discomfort. Other 
side effects are similar to previous drug classes mentioned including diarrhoea, vomiting and 
nausea. Furthermore, studies in animals have not demonstrated any adverse side effects on 
fertility or identified any mutagenic effect however, use in pregnancy is not recommended as 
no human clinical studies have been performed in pregnant patients with this drug (Escobedo 
and Cimerman, 2007). 
Aminoglycosides 
Paromomycin is the currently used aminoglycoside in the treatment of giardiasis and has a very 
broad spectrum ranging from complex parasites such as helminths to single celled prokaryotes. 
It is considered a much safer drug than others available and is recommended for the treatment 
of pregnant women however it can accumulate in patients with impaired renal function resulting 
in renal toxicity. Although side effects are rare they can include nausea and diarrhoea. Clinically 
paromomycin has shown less efficacy when compared to metronidazole, is required to be taken 
for 10 days and can disrupt the normal gut microflora (Escobedo and Cimerman, 2007; Gardner 
and Hill, 2001). This group of antigiardials is thought to inhibit protein synthesis by binding to 
giardial ribosomes. 
1.5.5 Potential antigiardial candidates identified in assays to date 
Numerous studies in recent years have involved the high throughput screening (HTS) of 
thousands of drug-like chemicals for activity against G. duodenalis. Of these studies many end 
after in vitro testing. In the last five years only a handful of compounds that have been identified 
as antigiardial in vitro have had in vivo activity confirmed, all of which are already approved 
for use in humans for other diseases. The three drugs presented here, while promising 
antigiardial agents, still have several limitations which, ideally, need to be overcome 
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(Figure1.6). These limitations include little selectivity for the parasite in question, with activity 










Figure 1.6 Structures of experimental drugs for treatment of giardiasis. 1 – miltefosine, 2 – auranofin, 3- disulfiram. 
Miltefosine  
Miltefosine is an alkylphosphocholine that is used as a treatment for breast cancer skin 
metastases and as an oral treatment for leishmaniasis. In addition, it has demonstrated 
antibacterial, antifungal and anthelmintic activity in addition to antigiardial activity. Possible 
side effects can include nausea, diarrhoea and vomiting and there is potential for teratogenicity, 
which would exclude pregnant women from treatment. In vitro it has superior activity to 
metronidazole with an 100% inhibitory effect at 40 µM after just 1 hour. In addition, it has been 
tested in a mouse model with three days of a single oral dose of 20 mg/kg able to cure an 
infection. As with most antigiardial drugs the mechanism of action appears to be complex and 
is not fully understood. Based on electron microscopy studies, miltefosine is thought to interact 
with the cell membrane causing cell lysis and possibly also disintergrating the microtubules of 
the parasite, which affects its ability to attach to the host’s intestinal surface (Eissa and Amer, 
2012). In addition, it is thought that miltefosine causes a buildup of ceramide in the cell by 
interfering with sphingomyelin biosynthesis resulting in an apoptosis like response (Eissa and 




A HTS of 910 chemical entities, 603 FDA approved and 143 approved for human use in at least 
one country, were tested for efficacy against G. duodenalis in vitro using an image based assay 
for detection of trophozoite adherence (Gut et al., 2011). From this screen, ~20 promising 
antigiardial agents were discovered and auranofin, currently used in the treatment of rheumatoid 
arthritis, was considered the most promising candidate to continue with as it has a well-
established toxicity profile and is considered safe for use in humans. Auranofin, is composed 
of a gold molecule with attached thiol and phosphate groups, with the potential to treat a wide 
range of diseases from cancer to bacterial infections (Roder and Thomson, 2015). In has been 
shown to be a potent inhibitor of the Giardia flavoenzyme thioredoxin oxidoreductase isolated 
from the parasite and this is assumed to be the mechanism of action by which the drug affects 
the parasite. In addition, in vivo efficacy in two animal models has been demonstrated, mice 
and gerbils, when treated once/day for 5 days. It is able to kill metronidazole resistant parasites 
and causes cellular blebbing similar to other thioredoxin oxidoreductase inhibitors (Tejman-
Yarden et al., 2013; Watkins, 2003). 
Disulfiram 
Disulfiram is an FDA approved disulphide drug that has traditionally been used in the treatment 
of alcoholism as it causes unpleasant side effects, similar to a hangover, upon the consumption 
of alcohol. Use in the treatment of alcoholism has declined due to poor patient compliance and 
other possible uses of the drug are being explored, one of which is as an antigiaridal. Disulfirum 
and its metabolite, which is more potent, thiram are able to inhibit metronidazole resistant 
Giardia in vitro. The in vivo activity of both compounds has also been confirmed in an adult 
mouse model with 5 mg/kg per day for 3 days, significantly reducing the number of intestinal 
trophozoites. Disulfiram is thought to inhibit Giardia trophozoites by inhibiting the carbamate 
kinase enzyme that catalyses the final step in the arginine dihydrolase pathway, which is 
essential for energy metabolism and survival of the parasite (this enzyme is not present in higher 
eukaryotes such as humans) (Galkin et al., 2014). 
1.5.6 Approach to antigiardial screening 
With the array of negative side effects, limited availability of drugs in some countries, extended 
dosing schedules leading to patient non-compliance and the increasing development of 
resistance, it is important to develop novel therapeutic options. In addition, the new candidate 
antigiardial drugs identified in the last five years that have demonstrated in vivo efficacy also 
have limitations in treating Giardia. These limitations include a low specificity for Giardia, a 
range of potential side-effects in the host. All of these factors necessitate the development of 
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novel antigiardial agents that have a high specificity for Giardia over host cells and beneficial 
microorganisms reducing the potential for negative side-effects very low. 
Currently there are a wide variety of in vitro assays to assess the antigiardial activity of various 
chemicals, which makes comparison between different drugs difficult. In this section of the 
review the available techniques are highlighted and a potential screening effort for streamlining 
screening projects is suggested.   
1.5.7 Current in vitro screening of potential antigiardials 
The in vitro characterisation of new drugs requires an initial screen to identify any ‘hits’ and 
ideally this screen would be high through-put, to increase the likelihood of identifying any new 
antigiardials. This initial screen should be simple, cost effective, reliable, reproducible, 
accessible and amenable to automation (Benere et al., 2007). Following the initial screen, it is 
important to confirm any ‘hits’ identified with a secondary screen. Preferably this second screen 
would target an alternative measurement of antigiardial activity and as with the first assay, 
simplicity, cost effectiveness, reliability, reproducibility and accessibility would all be 
important characteristics of the chosen assay. Although automation of the second assay could 
be achievable, it is probably not that essential as the number of molecules progressing to this 
stage would be markedly less than in the original identification assays (Bonilla-Santiago et al., 
2008). Several methods for the identification of active drugs have been developed including 
assays that target inhibition of adherence, cell viability or metabolic activity, each lending itself 
differently to HTS, however there is currently no standardised method for the identification of 
potential antigiardial drug candidates and, as far as is known, a thorough review of the methods 
available has not been completed. The current assays available can be roughly divided into three 
categories based on the screening parameter being used i.e. metabolism, trophozoite adherence 
or proliferation. There are also a few other assays which do not fall into these categories. 
Various detection methods for these screening parameters have been identified, with their own 
advantages and disadvantages.  
Measurement of cell adherence and proliferation  
The adherence of Giardia trophozoites to the surface of intestinal epithelial cells is crucial for 
disease progression and this characteristic of the parasite has been exploited in vitro to test the 
antigiardial activity of various compounds, since the beginning of assessment of antigiardial 
agents. Assays that measure cell proliferation have also been developed and both are included 
here as many of them use similar detection techniques. Original drug testing assays involved 
treating the Giardia trophozoites with the compound of interest and then counting the number 
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of remaining cells using a haemocytometer and this method has become the gold standard of 
antigiardial testing to which all other methods are compared to (Bell et al., 1991; Busatti and 
Gomes, 2007; Chen et al., 2011). This method is extremely simple, uses minimal equipment 
and is universally accessible, however it is time consuming and has a possibility for human bias 
(Chen et al., 2011). The identification of false positives due to the electrostatic interaction 
between certain drugs and the culture flask has been reported, but this can be overcome by 
providing a layer of mammalian cells for the trophozoites to attach to, which adds a level of 
complexity to the assay and is not commonly used (Favennec et al., 1992). Due to the time 
consuming nature of cell counting these methods requiring a haemocytometer are not amenable 
to automation or HTS.  
To overcome the time consuming nature of counting cells as described above, several assays 
have been developed which measure trophozoite proliferation by using a fluorescent stain and 
computer software to count the number of trophozoites (Bonilla-Santiago et al., 2008; Gut et 
al., 2011). These assays reduce the time involved and increase the number of potential drug 
candidates that can be screened. Both of these assays involving a fluorescent stain, either 
propidium iodide or DAPI, are set-up for automation and use computer software to count the 
number of cells (Bonilla-Santiago et al., 2008; Gut et al., 2011). Both of the assays include the 
adherent and non-adherent fractions of the sample, are relatively simple, reliable, have been 
validated as HTS, are automated (though they can be completed without automation if desired) 
and are significantly less time consuming than traditional adherence assays (Bonilla-Santiago 
et al., 2008; Gut et al., 2011). The protocol using a DAPI stain has the advantage over the 
propidium iodide stain as it does not require any wash steps (Gut et al., 2011). Although these 
assays have advantages over the traditional adherence assay, they require expensive equipment 
and produce a large number of electronic files which have to be stored. In addition, they cannot 
discriminate between live and dead cells (Gut et al., 2011).  
Alternative methods to measure cell proliferation have been developed, the earliest of which 
involved the incorporation of radioactive thymidine. This assay introduced the problem of 
radioactive waste disposal and was not amenable to HTS (Bell et al., 1991). A more recent 
assay has been developed that measures cell proliferation of adherent trophozoites using a 
methylene blue dye (Busatti and Gomes, 2007). After exposure to experimental drugs, the cells 
are fixed, treated with methylene blue, lysed and the OD recorded (Busatti and Gomes, 2007). 
This assay is amenable to HTS, does not require any specialist equipment and is cheap, reliable 




Measurement of metabolism assays 
Probably equal in popularity to adherence and proliferation assays is the measurement of 
metabolic activity to determine the antigiardial activity of potential drugs. The metabolic 
detection assays developed for antigiardial screening rely on a substrate that is altered by 
metabolically active cells to give a recordable signal e.g. absorbance. Kang et al developed a 
colourimetric assay using enzymes from the purine salvage pathways. Although this assay is 
sensitive and simple the required substrates do not seem to be readily available and the assay 
has not been utilised outside of this group for screening of antigiardials (Kang et al., 1998; 
Upcroft and Upcroft, 2001a). Several other colourimetric assays have been developed using 
substrates that are metabolised to the formazin dye, including MTT and XTT, where XTT has 
the obvious advantage of being water soluble, while MTT requires extra steps to solubilise the 
product. In addition, XTT is not considered toxic to the cells and therefore the cells can be 
reused (Benere et al., 2007; Wright et al., 1992). More recently an assay using resazurin which 
is reduced to resofurin (both a colourimetric indicator as well as a fluorescent indicator) has 
been published (Benere et al., 2007). This method has an advantage over all the other metabolic 
assays previously described as the dye is non-toxic and it is much more sensitive than the MTT 
and XTT substrates, requiring less dye to measure a result. However, as with other assays 
relying on the reduction of chemicals to gain a signal, resazurin is readily reduced by the culture 
media, therefore a wash with PBS is required before addition of the dye (Benere et al., 2007). 
Other assays  
The only additional assay to be reviewed in this paper is the measurement of ATP which is an 
important marker of functional integrity of living cells and which quickly decreases during and 
after cell death. This assay uses a commercially available kit which measures ATP content using 
luminescence. This assay is highly sensitive, simple and requires no wash steps, however a 
luminescence reader would be required. In addition, this assay measures both the adherent and 
non-adherent cells (Kulakova et al., 2014). 
1.5.8 Current in vivo screening of antigiardial compounds 
After identification of in vitro activity and selection of promising candidates it is essential to 
assess in vivo efficacy. Several models of Giardia infection have been developed in various 
animal hosts from ruminants to mice. As an effective model for drug efficacy studies, an 
infection model needs to be easily accessible by researchers, be reliable and give results that 
are translational to the final target host (Sande, 1999). Although several large animal models 
are available in cattle, sheep and dogs they will not be reviewed here as due to the size and cost 
of the animals they are considered impractical for initial drug screening efficacy assays, as 
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drugs used in efficacy studies are usually only available in small quantities and initial drug 
screening costs need to be kept low. In addition, the environment of these animals and housing 
is not always available and would have many variations/variables between different areas. 
Instead this review will focus on small animal models. There are two main models that are 
reportedly used for Giardia infection, mice and gerbils (Sande, 1999). While some papers 
mention a rat model this is not described in detail (Sande, 1999). Gerbils are known to be easily 
infected with human strains of Giardia and have similar symptoms to humans however the 
availability of gerbils is limited in certain areas due to import/quarantine restrictions (Sande, 
1999). The second and more prolifically described model in the literature is a mouse model of 
infection. Mice have the advantage over gerbils because they are universally available and they 
have been the mammal of choice in recent antigiardial discovery projects (Eissa and Amer, 
2012; Reynoldson et al., 1991; Tejman-Yarden et al., 2013). In addition, mice are commonly 
used in research of human diseases and information on drug behaviour in humans can be 
inferred based on previous experiences in mice. There are a range of mouse models described 
to varying degrees that have been used in the assessment of in vivo antigiardial activity of 
several drugs including albendazole, miltefosine and auranofin (Eissa and Amer, 2012; 
Reynoldson et al., 1991; Tejman-Yarden et al., 2013). It has been shown that the strain, age, 
immunocompetency and gut microbiota of the mouse and the isolate of Giardia being used all 
play a role in the establishment of a reliable model (Byrd et al., 1994; Hill et al., 1983; Singer 
and Nash, 2000). It appears that no model has been used routinely however streamlining of the 
animal model would be much more difficult than in vitro studies due to the reasons mentioned 
above. Several of the models have been developed to study the progression of infection and the 
effects of infection, not specifically for drug development. 
Neonatal models of infection 
Models of infection using neonatal mice usually infect the pups by oral gavage with trophozites 
or cysts around 6-9 days of age (Hill et al., 1983). It is thought that due to the immature immune 
system, infection is established in a high number of animals and lasts for a relatively long period 
before the maturation of the neonatal immune system clears the infection (Hill et al., 1983). 
Establishment of infection is determined via one of two methods. The first method relies on the 
shedding of cysts to determine the course of infection and animals are treated shortly after cyst 
shedding is first identified, while the second method establishes the model, sacrificing pups at 
various time points to determine when the trophozoites have begun to proliferate in the gut 
(Reynoldson et al., 1991; Singer and Nash, 2000; Tejman-Yarden et al., 2013). Based on this 
information the animals in future studies will be treated with a drug a few days after the 
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infection would have been expected to be established (Reynoldson et al., 1991; Tejman-Yarden 
et al., 2013).  
A description of the first method is given by Reynoldson et al using a cat strain to test the 
efficacy of albendazole while the second method has been described by Tejman-Yarden. 
Reynoldson used strains from their personal collection while Tejmen-Yarden described a model 
with 3 different strains, two assemblage A including the widely used WB strain and one 
assemblage B strain, therefore it appears this model could be used universally with whatever 
strains are available (Tejman-Yarden et al., 2013). 
Although the neonatal pup model is a simple and reliable model which can be established with 
a range of Giardia isolates and mice strains, and has proven useful in the past for the 
development of various antigiardial agents, it is possible the translatability of the information 
from animals to humans would not be a direct scale-up as was demonstrated with albendazole, 
where a much larger dose was required to clear the infection in mice than is required in humans 
(Reynoldson et al., 1991). 
Weaned mouse models of infection 
More recently several weaned models of infection have been developed to further study the 
pathogensis of Giardia infection in both immunocompromised and immunocompetent mice 
(Eissa and Amer, 2012; Singer and Nash, 2000). One study has reported infection of Swiss 
adult mice with uncharacterised cysts from human patients to determine the efficacy of 
miltefosine (Eissa and Amer, 2012). Other models include malnourishment of mice to induce 
immunocompromise or the use of genetically immunocompromised or immunolimited strains 
of mice (Bartelt et al., 2013; Byrd et al., 1994; Kulakova et al., 2014; Singer and Nash, 2000). 
In addition, models which alter the gut microbiota using antibiotics may be a viable method for 
establishment of infection but would not be ideal for use in drug discovery as the interaction 
between different drugs cannot be predicted. In addition, immunocompromised mice require 
special housing to limit exposure to unwanted pathogens. 
It would seem that the suckling mouse model would be the ideal model for initial in vivo 
efficacy trials and could be further validated with an adult model of infection as described by 
Tejman-Yarden (Tejman-Yarden et al., 2013).  
1.5.9 Suggested experimental screening flow for antigiardial discovery 
Based on the methods outlined above, the following model of screening potential antigiardial 
compounds which incorporates the need for the initial assay to have (a) the potential for high-
through put screening, (b) require minimal specialised equipment, (c) be sensitive and (d) be 
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low cost is suggested. In addition, it would be beneficial to have an assay that can be used to 
both screen the antigiardial activity of a compound and the potential toxicity of the compound 
against mammalian cells. Having an assay with a dual purpose simplifies the drug discovery 
process and ensures that the same parameters of effect are being measured e.g. metabolic 
activity or ATP content rather than metabolic activity for Giardia and ATP content for 
mammalian cells. This will also ensure comparison between antigiardial activity and toxicity. 
With these requirements in mind it is suggested that the initial screen involve a colourimetric 
assay based on the use of a resazurin dye (Benere et al., 2007). Although this assay does require 
the media to be removed prior to the addition of the dye (due to the reduction potential of the 
media), this assay can be used for measuring antigiardial activity of potential drug candidates 
as well as potential toxicity towards mammalian cells. As with most of the assays developed 
the resazurin assay only measures the metabolic activity of the adherent parasites, therefore 
would not be able to distinguish between metabolic inhibitors and adherence inhibitors unless 
cells were collected from the supernatant (Benere et al., 2007). Equally it does not distinguish 
between metabolic inhibitors, drugs that cause cell death and proliferation inhibitors but would 
be able to pick-up any drugs that affect any of these pathways.  
Following initial identification of any compounds with activity against Giardia in the resazurin 
assay, a secondary assay to confirm antigiardial activity would be ideal. The ideal assay for the 
secondary screen would target another measure of efficacy and in this case we recommend an 
adherence assay, as adherence is crucial in disease progression. Traditional adherence assays 
are time consuming and have a high possibility for error therefore we recommend the methylene 
blue assay described above as it is simple, easily accessible and a direct measure of adherent 
trophozoites (Busatti and Gomes, 2007).  
Following confirmation of antigiardial activity, each potential drug candidate should undergo 
selectivity assays using mammalian cells for potential host toxicity and bacteria for specificity 
studies towards Giardia. It is considered important that the compounds have limited if any 
activity towards bacteria as these microorganisms comprise the beneficial gut bacteria 
necessary for normal gastrointestinal function (Adamsson et al., 1999; Jakobsson et al., 2010; 
Jernberg et al., 2007; Shreiner et al., 2015).  
Ideally, a treatment for Giardia would remove the parasite without upsetting the gastrointestinal 
microbiota, allowing the host to make a swift recovery and possibly prevent against future 
infection. In addition, compounds should be screened against a range of representative strains 
of Giardia including various assemblages. The process of in vitro screening would ideally take 
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the minimum amount of time to ensure maximum efficiency. Validation of in vivo efficacy 
should be of high priority, as it has been well established that in vitro efficacy does not always 
translate to in vivo efficacy (Sande, 1999). Following in vitro screening, drugs would progress 
to in vivo models using a neonatal mouse model as this is the most cost effective, accessible 
and reliable model available.  
Following verification of in vivo efficacy, preliminary toxicology, PKPD and lead optimisation 
can occur if desired. This will lead to the selection of the most promising candidate to progress 
































1.6 Aims and outline of thesis 
As reviewed above there is a need for the development of novel antimicrobial agents to treat a 
wide range of infectious diseases. This thesis focussed on the continued development of 
robenidine and an extensive library of structurally related analogues as potential treatments for 
bacterial and protistanl infections. Initially the spectrum of activity of the library against a range 
of pathogenic organisms was determined. These organisms included various species of bacteria, 
the kinetoplasts T. brucei and L. donovani as well as G. duodenalis. Although the initial 
antibacterial activity of several analogues had already been investigated (as reviewed above) 
this thesis examined the method of bacterial killing and Gram-negative antimicrobial potential 
of the lead candidates. In addition, several new analogues were developed during the course of 
candidature, which require antibacterial testing. The antiprotozoal activity of the structural 
analogues against T. brucei, L. donovani and G. duodenalis has not been previously described. 
Based on the information from initial screening results completed in this study and the resources 
and expertise available, further characterisation of the library against G. duodenalis was 
completed. This included initial screening of a large number of compounds using a resazurin 
assay followed by mechanism of action studies involving electron microscopy. To determine 
the in vivo efficacy of the library establishing animal models was in both pigs and mice. 
Although a model was not established in pigs, a model was established in mice using the same 
strain of Giardia utilised in in vitro experiments.  
Specific aims of the study were to: 
1. Determine the in vitro efficacy of novel structural analogues against bacteria (both 
representative Gram-positive and Gram-negative organisms), including time-kill 
experiments  
2. Determine if the target of this library of compounds is present within Gram-negative 
organisms, such as E. coli and P. aeruginosa, through the use of membrane 
permeabilising agents and development of cell-wall deficient cells 
3. Determine the in vitro efficacy of a sample of structural analogues against the 
kinetoplasts T. brucei and L. donovani, including selectivity profiles over host cells 
4. Determine the in vitro efficacy of a sample of analogues against G. duodenalis followed 
by mechanism of action studies and further in vitro characterisation 
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Screening confirmed the antibiotic activity of Robenidine, 1 (2,2'-bis[(4-
chlorophenyl)methylene]carbonimidic dihydrazide hydrochloride), against both MRSA and 
VRE with MIC values of 8.1 and 4.7 M respectively (Figure 2.2).  SAR analysis revealed 
tolerance for 4-Cl isosteres with the 4-F (8), 3-F (9), 3-CH3 (22), 4-C(CH3)3 (28) returning 
moderate (23.7-71 M) and the 3-Cl (3), 4-CH3 (21), 4-CH(CH3)2 (27) good potency (8.1-13.0 
M).  Imine carbon alkylation revealed the presence of a methyl/ethyl binding pocket which 
also accommodated a CH2OH moiety (75). Analogues 1, 27 and 69, had rapid and potent 
bactericidal activity against 24 clinical MRSA and MSSA isolates, with 69 retaining activity 
with 2% serum. Analogues 1, 27 and 69 displayed no dose limiting cytotoxicity at ≥ 2x the MIC 
or haemolysis at ≥ 8x the MIC. Addition of polymyxin B engendered Gram-negative activity 
with E. coli and P. aeruginosa MIC values of 4.2-21.6 M. Analogues 1 and 75 displayed 
excellent human and mouse microsomal stability, intrinsic clearance and hepatic extraction 
ratios with T1/2 > 247 min, CLint <7 L/min/mg protein and EH <0.22 in both human and mouse 
liposomes for 1, and human liposomes with 75. 
 
 









The management of bacterial infections has become increasingly difficult with the 
emergence of antimicrobial resistance. In particular the ESKAPE pathogens (Enterococcus 
faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, 
Pseudomonas aeruginosa, and Enterobacter species), are causing significant problems 
worldwide (Pendleton et al., 2013). Methicillin-resistant S. aureus (MRSA) is a major pathogen 
causing both hospital and community-acquired infections. In addition to methicillin resistance, 
S. aureus isolates resistant to the last line antimicrobials vancomycin, linezolid, daptomycin, 
anti-MRSA cephalosporins (ceftobiprole and ceftaroline) and mupirocin have been isolated 
from clinical cases (Antonov et al., 2015; Chan et al., 2015; Endimiani et al., 2011; Hiramatsu, 
2001; Marty et al., 2006).  
Concurrent with the increasing prevalence of antimicrobial resistance, there has been a large 
gap in the development of new antimicrobials to treat these pathogens and as time from initial 
identification to release of a product onto the market can take ten years, alternatives for 
treatment need to be rapidly identified to alleviate the problem in the short term. One attractive 
approach is the repurposing of food and drug administration (FDA) approved drugs in clinical 
use as potential antimicrobials.  Another under evaluated area is re-examination of compounds 
previously developed for use to support animal health for antimicrobial activity as candidates 
for further structural modification for possible use in human medicine.  These approaches offer 
known safety and development pathways with associated time and cost savings (Chong and 
Sullivan, 2007).  
Within the animal medicine sphere, robenidine (1, 2,2'-bis[(4-chlorophenyl)methylene]-
carbonimidic dihydrazide hydrochloride; Figure 2.2) is a well-known anti-coccidial agent 
which has been used worldwide since the early 1970s in the prevention of coccidian infections 




Figure 2.2  Chemical structure of robenidine (1). 
Robenidine 1 belongs to the aminoguanidine compound class, a diverse group of bioactive 
compounds used in the treatment of a broad range of diseases from bacterial infections through 
to cancer and diabetes and many are already approved for human use (Saczewski and Balewski, 
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2009, 2013). Excellent activity against Babesia microti infection has been reported in mouse 
models with 100% inhibition noted at 25 and 50 mg/kg (Yao et al., 2015). 
Despite 1 having a long history of use in animals there have been no in-depth evaluations as 
a potential antibacterial agent, although early work demonstrated robenidine had activity 
against unidentified Gram-positive soil bacteria (Hansen et al., 2009).  Herein we report on the 
in vitro antibacterial activity of 1 and the development of preliminary structure activity 
relationship (SAR) data around this scaffold.  The efficacy of selected analogues against clinical 
isolates of MRSA is also examined. 
2.4 Results and Discussion 
Access to a focused library of robenidine analogues was realized by the condensation of 
selected mono-substituted benzaldehydes with 1,3-diaminoguanidine hydrochloride [14].  
Under ethanol reflux conditions low (18%) to excellent (93%) yields of the desired analogues 
(1 – 31) were obtained (Scheme 2.1).  The minimum inhibitory concentration (MIC) of these 
analogues was determined against two strains of MRSA and VRE, and one strain each of E. 
coli and P. aeruginosa and the data presented in Table 2.1. 
 
Scheme 2.1  Reagents and conditions: (i) 1,3-diaminoguanidine hydrochloride, EtOH, reflux, 16 h. 
Ampicillin was used as an internal control and showed both Gram-negative (E. coli, 45.8 
M; P. aeruginosa, 366 M) and Gram-positive (MRSA, 183 M; VRE 11.5 M) activity.  
However none of the robenidine analogues, 1 – 31, showed Gram-negative activity (Table 2.1).  
Robenidine, 1 inhibited the growth of MRSA and VRE with MIC values of 8.1 and 4.7 M 
respectively.  Removal of the 4-Cl moiety with the synthesis of 2 resulted in a complete loss of 
activity. A halogen scan revealed a preference for the 4-Cl moiety, with a two-fold loss in VRE 
activity with the 3-Cl (3) and no activity with 2-Cl (4) analogues.  Other halogen substituents 
were poorly tolerated with only 3-Br (6), 4-F (8) and 3-F (9) displaying modest levels of activity 
(MIC < 75 M).  The 3-Br (6) displayed a near 10-fold VRE vs. MRSA selectivity. Of the 
additional electron withdrawing groups examined: CN, NO2 and CF3, only the 4-CF3 (11) 
displayed moderate levels of activity with MIC values of 36.5 and 11.4 M against MRSA and 
VRE respectively (Table 2.1 and supplementary data). These data suggest that an electron-
withdrawing group is poorly tolerated and that the effect of the 4-Cl moieties in 1 may be steric. 
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Hydrogen bond donors, e.g. 12-14, were poorly tolerated with the 4-OH (12) analogue ~25-
fold less MRSA and ~60-fold less VRE active than 1. Methylation saw a modest activity 
improvement, but only with the 3-OMe (16). The more electronegative 4-OCF3 (18) retained 
VRE activity but was two-fold less active against MRSA.  The corresponding 4-SCH3 (19) was 
more active, particularly against VRE with a MIC of 12.7 M.  The 4-SCF3 (20) showed 
reduced activity, again suggesting a poor tolerance for electronegative substituents (Table 2.1). 
In general, alkyl substituents were well tolerated with the 4-CH3 (21) displaying comparable 
MRSA (MIC 9.1 M) activity to 1.  The equivalent 3- and 2-CH3 (22 and 23) were an order of 
magnitude less active, as were the 4-propyl and butyl analogues (24 and 25). The 4-iso-propyl 
(26) with MIC values of 9.1 and 13.0 M against MRSA and VRE respectively, displayed 
activity comparable with 21 and 1.  However, the iso-propyl moiety is known to be metabolized 
via highly reactive intermediates, which resulted in our examination of replacement with both 
4-tert-butyl (27) and 4-NMe2 (28), but both were less active than 26 (Aprile et al., 2011; 
Hansen et al., 2009).  A 2- or 4- Ph moiety (29 and 30) was poorly tolerated, but the 4-ethynyl 
(31) showed moderate (MIC 17.2 M) and selective activity against VRE.  Polar substituents 
such as 4-CH=CHCOOH, 4-NHCOCH3 and 3-COOH were inactive (MIC > 128 g.mL
-1; 
supplementary data). 
With an understanding of the SAR of the simple phenyl rings, the effects of multiple moieties 
were next explored.  These analogues were synthesized as described in Scheme 2.1 from the 
corresponding aldehydes and the outcome of screening is presented in Table 2.2. 
The inclusion of two halogens was initially investigated.  Interestingly, despite the parent 2-
F (10) and the 2,5-di-F (32) analogues being inactive, combination with 4-Cl (33) gave MRSA 
and VRE activity comparable to 1. The 3,4-di-F (34) saw a reduction in MRSA activity but 
retention of VRE activity.  A 4-Cl moiety in combination with a 2-NH2 (38), 2-NHCH(OH)CH3 
(39), and 2-OH (42) afforded good to modest MRSA and VRE activity.  These data suggest 
that the 2-F of 33 may be acting as a hydrogen bond isostere.  In an attempt to improve aqueous 
solubility, the 4-Cl was replaced with 4-NMe2 with 2-OH retention with the synthesis of 43, 
but this resulted in a loss of activity. Combining the 2-OH with 3-CH3 (41), both individually 
active substituents (Table 2.1, 14 and 22), resulted in no activity, possibly due to the proximity 
of the substituents interfering with their respective interactions. Of the catechol bearing 
analogues (44 – 46), only modest activity was noted with 44. The introduction of a third OH 
moiety (50 – 52) saw both the reintroduction of low levels of activity against MRSA and VRE, 
and with 52 also a low level of activity against P. aeruginosa (MIC 322 M).  These catechol 
analogues were not investigated further, nor were the variations that saw methylation or OH to 
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Br exchange or introduction of pentafluoro moiety examined as these analogues, 53 – 57, were 
inactive across all bacterial strains examined. 
 
 
Table 2.1 The inhibition of MRSA, VRE, E. coli and P. aeruginosa growth by 1,3-aminoguanidine Schiff base analogues 
possessing mono-substituted aromatic rings (1 – 31). 
 
   MIC (µM) 
Compound R MRSA VRE E. coli P. aeruginosa 
Ampicillin - 183 11.5 45.8 366 
1 4-Cl 8.1 4.7 -a - 
2 H - - - - 
3 3-Cl 8.1 10.8 - - 
4 2-Cl - - - - 
5 4-Br - - - - 
6 3-Br - 15.4 - - 
7 2-Br - - - - 
8 4-F 47 23.7 - - 
9 3-F 47 71 - - 
10 2-F - - - - 
11 4-CF3 36.5 11.4 - - 
12 4-OH 192 288 - - 
13 3-OH 192 288 - - 
14 2-OH 36.0 240 - - 
15 4-OCH3 - - - - 
16 3-OCH3 88 88 - - 
17 2-OCH3 - 358 - - 
18 4-OCF3 187 85 - - 
19 4-SCH3 61 12.7 - - 
20 4-SCF3 96 135 - - 
21 4-CH3 9.1 12.1 - - 
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22 3-CH3 24.4 24.4 - - 
23 2-CH3 121 61 - - 
24 4-(CH2)2CH3 83 73 - - 
25 4-(CH2)3CH3 232 193 - - 
26 4-CH(CH3)2 9.1 13.0 - - 
27 4-C(CH3)3 24.2 29.0 - - 
28 4-N(CH3)2 30.9 30.9   
29 4-Ph 282 106 - - 
30 2-Ph - - - - 
31 4-CCH - 17.2 - - 





Table 2.2 The inhibition of MRSA, VRE, E. coli and P. aeruginosa growth by 1,3-diaminoguanidine Schiff base analogues 




MRSA VRE E. coli P. aeruginosa 
32 2,5-F -a - - - 
33 2-F, 4-Cl 6.1 7.4 - - 
34  3,4-F 40.1 10.7 - - 
35 2,4-Cl - - - - 
36 2,6-Cl - - - - 
37  3,5-Cl - - - - 
38  2-NH2, 4-Cl 5.0 6.3 - - 
39 2-NHCH(OH)CH3, 4-Cl 66 98 - - 
40 2-NHCOCH3, 4-Cl - - - - 
41 2-OH, 3-CH3 - - - - 
42 2-OH, 4-Cl 80 45 - - 
43 2-OH, 4-N(CH3)2 229 76b - - 
44 2,3-OH 88 262 - - 
45 2,4-OH - - - - 
46 3,4-OH - - - - 
47 3-OH, 4-OCH3 - - - - 
48 3-OCH3, 4-OH 244 163 - - 
49 3,4-OCH3 - - - - 
50 2,3,4-OH 161b 161b - - 
51  2,4,5-OH 161 322 - - 
52 3,4,5-OH 161 - - 322 
53 3-OCH3, 4,5-OH - - - - 
54 3-NO2, 4-OH - - - - 
55 2,3,4,5,6-F - - - - 
56 2-Br, 4,5-OCH3 - - - - 
57 3-Br, 4,5-OCH3 - - - - 
a “-” = No inhibitory activity observed at 128 μg.mL-1; b active against only one of the two strains examined within 
either MRSA or VRE. 
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The introduction of phenyl ring isosteres, fused aromatics, heterocyclic and methylene spaced 
analogues (58-67) was accomplished as per Scheme 2.1 (Meanwell, 2011).  These analogues 
were screened for MRSA and VRE activity (Table 2.3).  In virtually all instances the phenyl 
ring isosteric modification resulted in a significant loss of both MRSA and VRE activity relative 
to 1.  In multiple instances selectivity towards MRSA (63, 64) and VRE (67) was observed.  
With the pyridyl analogues only the 4-Cl (60) was active, suggesting again a key role for a 4-
Cl substituent in this class of compounds. Other fused aromatics, 2-hydroxynaphthyl, 3-





Table 2.3 Inhibition of MRSA and VRE by 1,3-diaminoguanidine Schiff bases bearing extended linkers, non-aromatic and 
isosteric phenyl ring replacements (58 – 67). 
 
MIC50 (µM) 































a “-” = No inhibitory activity observed at 128 μg.mL-1; b active against only one of the two strains examined within either MRSA or VRE. 
Installation of a range of isocyanates and chloroformates to afford the respective carbamate and 




Scheme 2.2 Reagents and conditions: (i) N-substituted isocyanate or O-substituted chloroformate, i-PrNEt2, CH3CN, reflux, 




Potential imine carbon based modifications were explored through coupling of phenones with 
1,3-diaminoguanidine hydrochloride to afford alkyl substituted analogues (68-80) (Scheme 2.3; 
Table 2.4). While the compounds were evaluated against the Gram-negative pathogens, no 
activity was observed (data not shown). 
 
 
Scheme 2.3 Reagents and conditions: (i) 1,3-diaminoguanidine hydrochloride, EtOH, reflux, 16 h.  
 
Introduction of a methyl substituent at the imine carbon imparted activity to compounds whose 
methine counterpart bore no activity, such as 68 and 70 whereas their desmethylated analogues 
2 and 5, respectively were MRSA and VRE inactive (Table 2.1). In a similar manner ‘C-
methylation’ of 1 to afford 69 provided a marginal improvement in activity (Table 2.4). 
However, this ‘C-alkylation’ strategy was not universally applicable, as it appears to be 
incompatible with the CF3 substitution of 71, abolishing MRSA activity with retention of VRE 
inhibition. 
Sequential probing of this space with straight chain aliphatics (72 - 74) suggested the 
presence of a C-methyl/ethyl binding pocket with the C-ethyl (72); the largest C-alkyl 
substituent to retain antibacterial activity. Further probing of this region with hydrogen bond 
donor/acceptor atoms, bearing either neutral or ionic qualities, showed that the pocket would 
tolerate a neutral hydrogen bond donor/acceptor (CH2OH; 75), however introduction of ionic 
species in 76 (CH2NH2) and 77 (COOH) resulted in abolition of potency (Table 2.4). 
Coupling of the favorable aromatic substituents, the 4-methyl (21) and 4-tert-butyl (27), 
moieties from the parent phenyl analogues with the C-methyl substituents from this series of 
analogues gave rise to 78 and 79, which were amongst the most potent analogues developed 
herein with MIC values in 4.5 – 36.2 M.  Attempts to enhance compound solubility through 
the introduction of a 4-piperazin-1-yl moiety (80) were unsuccessful with a significant loss in 
potency noted (Table 2.4). 
Having established the antibacterial activity of this class of compounds, we examined the 
activity of 1, 27 and 69 against twenty clinically obtained isolates of MRSA and four 
methicillin-sensitive S. aureus (MSSA) isolates obtained from the ATCC.  All three analogues 
(1, 27 and 69) were bactericidal against all the S. aureus strains tested with MBC:MIC ratios of 





Table 2.4 Inhibition of MRSA and VRE by 1,3-diaminoguanidine Schiff base analogues (68 – 80) bearing imine substitution. 
 
Compound R R′ 
MIC50 (µM) 
MRSA VRE 
68 CH3 H 18.2 49 
69 CH3 Cl 7.5 3.8 
70 CH3 Br 16.4 24.6 
71 CH3 CF3 -a 17.2 
72 CH2CH3 Cl 56 18.7 
73 (CH2)2CH3 Cl - - 
74 (CH2)3CH3 Cl - - 
75 CH2OH Cl 20.3 15.2 
76 CH2NH2 H - - 
77 COOH H - - 
78 CH3 CH3 11.2 8.4 
79 CH3 C(CH3)3 4.5 36.2 
80 CH3 piperazin-1-yl 243 278 




Table 2.5 MIC and MBC concentrations for 1, 27, 69 and ampicillin against 20 clinically isolated MRSA and 4 ATCC 
MSSA bacterial strains. 
S. aureus (n = 24) 




1 5.4 43.1 >250 5.4 – 10.8 1 (96%) 
27 4.8 – 38.6 38.6 >250 4.8 – 38.6 1 (87.5%) 
69 1.3 – 5.0 10.0 >250 2.5 – 5.0 1 (87.5%) 
Ampicillin 0.3 – 143 -b -b 2.0 – 143 - 
a MIC in serum determined using S. aureus ATCC 29213 only; b ‘-‘ = not determined 
 
The lead, 1, was uniformly active across all clinical isolates with a 5.4 M MIC value, 27 
displayed a broader range of activity from 4.8 – 38.6 M and 69 from 1.3 – 5.0 M.  A profound 
and negative impact on the MIC values with a 4-fold decrease with 1 and 27 at 2% and no 
activity at 50% serum was observed.  The effect with 69 was less stark with the MIC values 
dropping to 10 M at 2% serum.  This suggests a high level of protein binding of these 
analogues, but does not necessarily render these analogues ineffective in vivo (Lee et al., 1991). 
As anticipated none of these analogues displayed any Gram-negative activity against E. coli or 
P. aeruginosa (Table 2.6).  However in the presence of polymyxin B nonapeptide (PMBN; 4.1 
M), a peptide which disrupts the outer membrane, 1 and 69 showed at least a 10-fold MIC 
improvement suggesting that the lack of Gram-negative antibacterial activity for this compound 
was a consequence of lack of compound penetration of the bacterial outer membrane (Randall 
et al., 2013). With 1 and 69, MIC values were comparable with those observed with 





Table 2.6 MIC for 1, 27 69 and clofazimine against E. coli ATCC 25922 and P. aeruginosa ATCC 27853. 
 E. coli 25922 P. aeruginosa 27853 
 MIC +PMBNb MIC +PMBN 
M 
1 >250 21.6 >250 21.6 
27 >250 >250 >250 >250 
69 >250 10.0 >250 5.0 
Clofazimine >250 4.2-8.4 >250 8.4 
a PMBN – polymyxin B nonapeptide 
Time kill curve evaluation of 1, 27 and 69 at 1, 2, 4 and 8 times their MIC against one 
susceptible S. aureus isolate (ATCC 29213) and one clinical MRSA isolate (USA300) 
confirmed their bactericidal activity resulting in a ≥ 4-log reduction in bacterial cell numbers 
over an 8 hour period across all the analogue doses evaluated (Figure 2.3).  After 24 hours some 
bacteria regrowth was observed with all compounds at all concentrations tested (data not 
shown). 
Of the analogues evaluated, only 1 showed statistically significant activity against S. aureus 
biofilms (based on a one-way ANOVA analysis).  Significant biofilm retardation was only 
noted at concentrations > 43.2 M, and resulted in a ≤3-log reduction in cells irrespective of 
analogue concentration. 
Hemolysis was evident with 1 at ≥ 173 M while no hemolysis was observed with 27 or 
69 at concentrations as high as 600 M.  Low to moderate levels of cytotoxicity against a normal 
human lung fibroblast cell line (HEL 299) with 1, 27 and 69 were observed with growth 
inhibition (GI50) values of 17.7, 28.8 and 6.7 M respectively; and against a human 
hepatocellular carcinoma cell line (Hep G2) returned GI50 values of 25.4, 26.3 and 13.8 M 
respectively.  These values are at least twice the observed MIC50 values for these three 
analogues.  It is important to note that an in vitro cytotoxicity screening assay does not provide 
a “go/no-go” step in the drug development process. Indeed, when used in a prospective manner, 
they have not been highly predictive of in vivo toxicity (Halder et al., 2015). A single in vitro 
screening platform is unlikely to provide the data required to evaluate risk and predict human 
toxicity. In this regard, it is widely accepted that additional models using a tiered toxicity 
screening approach are required in order to define and predict clinical toxicity. In addition 
extensive in vivo studies have been performed previously with 1 which determined the oral 
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LD50 to be ~3000 mg/kg in rats and 1500 mg/kg and 2900 mg/kg per day in male and female 
rabbits respectively (Aquilina et al., 2011). Robenidine, 1 has been used safely since the early 
1970’s as an oral anti-coccidial agent in poultry and rabbits (Kantor et al., 1970). Furthermore, 
no adverse effects were reported after dosing mice with 50 mg/kg p.o. of 69 (Sondhi et al., 
2009). 
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Figure 2.3 Time-kill assay of (A) 1 (robenidine), (B) 27 and (C) 69; against methicillin-sensitive (left) and methicillin-
resistant (right) strains of S. aureus. Cultures were inoculated with 106 CFU/mL bacteria and exposed to increasing 
concentrations of compounds for 8 hours. Samples were taken at 4 and 8 hours to determine viable cell numbers. Key: closed 
circles () – control, open circles (○) - MIC, closed diamonds () – 2x MIC, open diamonds () – 4x MIC, closed triangles 




Analogues 1, 27 and 69 were considered for preliminary in vivo stability and degradation 
studies, however we were concerned that the C-methyl imine moiety might be highly 
susceptible to oxidation, and as such examined the stability and degradation of the related 
CH2OH substituted 75, which also afforded the possibility of enhanced solubility as a 
consequence of the additional polar moiety (cf. 69).  We examined the physicochemical and 
metabolism parameters of 1, 27 and 75 in human and mouse liposomes and this data is presented 
in Table 2.7.  As anticipated these analogues broadly conformed with Lipinski’s rules and 
presented moderately favorable LogD values at both pH 3.0 and 7.4, although the solubility 
was modest, but highest with 1 and 75 (Lipinski et al., 1997).  Of the three analogues evaluated, 
27 displayed the lowest T1/2 and correspondingly higher intrinsic elimination and hepatic 
extraction ratios, CLint and EH respectively (Table 2.7).  Both CLint and EH with 1 and 75 were 
considerably more favorable with T1/2 > 247 min, CLint <7 L/min/mg protein and EH <0.22 in 
both human and mouse liposomes for 1, and human liposomes with 75.  The metabolic 
parameters were slightly poorer with 75 in mouse liposomes, but still acceptable at 131 min, 13 
L/min/mg protein and 0.22 for T1/2, CLint and EH respectively (Obach, 1999; Ring et al., 2011).
 
 
Table 2.7 physiochemical and Metabolism Results for 1, 27, and 75. 
 
a<15% compound loss in 60 min. bBelow sensitivity limit of 7 µL/min/mg protein based on 0.4 mg/L 
microsomal protein concentration. cBelow sensitivity limit based on 0.4 mg/mL microsomal protein 
concentration. dThe microsome-predicted hepatic extraction ratios (EH), obtained based on relative 
rates of test compound degradation in vitro, were used to classify compounds as low (<0.3), 
intermediate (0.3-0.7), high (0.7-0.95), or very high (>0.95) extraction compounds. 
 
2.5 Conclusions 
Our screening confirmed robenidine, 1; a widely used poultry industry anti-coccidial agent 
was active against both MRSA and VRE.  Removal of the 4-Cl moiety resulted in loss of 
activity, however a wide array of isosteric and other mono-substituents were moderately (4-F 
(8), 3-F (9), 3-CH3 (22), 4-C(CH3)3 (27)) to well tolerated (3-Cl (3), 4-CH3 (21), 4-CH(CH3)2 
(26).  Bulky substituents were poorly tolerated.  The introduction of di-substituted phenyl 
moieties was well tolerated with 2-F,4-Cl (33) and 2-NH2,4-Cl (38).  No noteworthy potency 
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was observed with only the indole (66) and benzothiophene (67) showing modest levels of 
activity.  Similarly, no activity was noted with the development of carbamate and urea 
analogues.  Modifications at the imine carbon revealed the presence of a methyl/ethyl binding 
pocket with good activity with 69-70 and the CH2OH analogue 75. 
Analogues 1, 27 and 69, had rapid and potent bactericidal activity against MRSA in vitro. 
Robenidine 1 displayed promising activity against S. aureus biofilms in vitro.  These promising 
results were further validated with excellent in vitro antibacterial profiles against clinical S. 
aureus (MRSA and MSSA) isolates.  Of particular note was the limited effect of 2% serum on 
the MIC values of 69, where both 1 and 27 were rendered essentially inactive.  Moreover, none 
of these analogues displayed dose limiting cytotoxicity against the two cell lines examined, 
returning GI50 values at least two-fold higher than the compound MIC50, no significant 
hemolysis was observed until compound concentrations reached at least 8-times the MIC value.  
Efficacy against Gram-negative E. coli and P. aeruginosa was only observed in the presence of 
polymixin B, with activities comparable with Clofazimine (Vaara, 1992). 
Preliminary evaluation of physicochemical and metabolic parameters in human and mouse 
liposomes further supports the development of these analogues as potential clinical antibiotic 
leads with both 1 and 75 displaying excellent stability, intrinsic clearance rates (CLint) and 
hepatic extraction (EH) ratios. Both CLint and EH with 1 and 75 were highly promising for future 
development with T1/2 > 247 min, CLint <7 L/min/mg protein and EH <0.22 in both human 
and mouse liposomes for 1, and human liposomes with 75 (Obach, 1999; Ring et al., 2011). 
2.6 Experimental 
2.6.1 Chemistry - General Methods 
All reactions were performed using standard laboratory equipment and glassware.  Solvents 
and reagents were purchased from Sigma Aldrich, Lancaster International or TCI and used as 
received.  Organic solvents were bulk quality, and were distilled from glass prior to use.  
Organic solvent extracts were dried with magnesium sulfate (MgSO4), and dried under reduced 
pressure with either Büchi or Heidolph rotary evaporators.  Melting points were recorded in 
open capillaries on a Stuart SMP11 Melting Point Apparatus.  Temperatures are expressed in 
degrees Celsius (°C).  Where available, literature values are provided and appropriately 
referenced.  Electrospray mass spectra were recorded using 10% DMSO/H2O or HPLC-grade 
methanol or acetonitrile as carrier solvents on a Shimadzu LC-MS spectrometer. 
Nuclear magnetic resonance (NMR) spectroscopy was performed on a Bruker Avance 300 MHz 
spectrometer, where proton NMR (1H-NMR) spectra and carbon NMR (13C-NMR) spectra 
were acquired at 300 and 75 MHz respectively, or a Bruker Avance III 400 MHz spectrometer, 
where 1H-NMR and 13C-NMR were acquired at 400 and 100 MHz respectively.  All spectra 
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were recorded in deuterated dimethyl sulfoxide (DMSO-d6), obtained from Sigma Aldrich or 
Cambridge Isotope Laboratories Inc., unless otherwise stated, with the residual solvent peaks 
used as the internal reference (δ 2.49 (quintet) and δ 39.7 (septet) for 1H-NMR and 13C-NMR 
respectively).  Chemical shifts (δ) were measured in parts per million (ppm) and referenced 
against the internal reference peaks.  Coupling constants (J) were measured in Hertz (Hz). 
NMR assignments were determined through the interpretation of one- and two-dimensional 
spectra, specifically gradient heteronuclear single quantum correlation (gHSQC), gradient 
heteronuclear multiple bond correlation (gHMBC) and distortionless enhancement by 
polarization transfer quaternary (DEPTQ) spectroscopy.  Multiplicities are denoted as singlet 
(s), broad singlet (br s), doublet (d), doublet of doublets (dd), doublet of doublet of doublets 
(ddd), triplet (t), triplet of doublets (td), doublet of triplets (dt), quartet (q), quintet (quin) and 
multiplet (m).  Peaks are listed in increasing chemical shift in the following format: chemical 
shift (integration (1H), multiplicity (1H), coupling constant (1H), ascribed assignment). 
2.6.2 Microbiology 
Antimicrobial agents 
Robenidine (1, NCL812) was provided by Neoculi Pty. Ltd. Ampicillin and clofazimine used 
in this study were sourced from Sigma Aldrich. 
Bacterial isolates 
A total of 20 MRSA clinical isolates were kindly provided by Associate Professor Geoffrey 
Coombs (Department of Microbiology, Pathwest Laboratory Medicine WA). MSSA strains 
ATCC 25923, 6538, 49775 and 29213 were obtained from the American Type Culture 
Collection together with E. coli ATCC 25922 and P. aeruginosa ATCC 27853. Isolates used in 
initial screening assay were sourced as follows: SCCmec type IV MRSA, VRE, multidrug-
resistant E. coli and P. aeruginosa clinical isolates were kindly provided by Prof Mary Barton, 
University of South Australia. 
Susceptibility testing 
The MIC of all analogues was determined according to CLSI guidelines in cation-adjusted 
Mueller-Hinton broth (CAMHB) at a total volume of 100 L with test concentration increasing 
2-fold from 0.25 g.mL-1 to 128 g.mL-1 (CLSI, 2008). All analogues were dissolved in 100% 
DMSO to a concentration of 12.8 mg.mL-1 prior to dilution in broth. 
The MIC50 and MIC90 for 1, 27 and 69 was determined using a modified MIC assay based on 
CLSI guidelines (CLSI, 2008). Luria Bertani (LB) broth was used instead of CAMHB as it has 
been previously shown that 1 can chelate calcium ions (Rozengart and Saakov, 2002). In 
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addition, the antimicrobial dilutions of 1, 27 and 69 were completed in 100% DMSO, with 2 
L added to each well, as the compounds are hydrophobic. The assay was performed in a total 
volume of 200 L in 96 well plates.  Antimicrobials were tested in final concentrations as 
follows; 1: 0.7 – 345.3 M, 27: 0.6 – 309.2 M and 69: 0.6 – 321 M. MIC tests involving 
ampicillin were performed according to CLSI guidelines in CAMHB. Plates were incubated for 
20 - 24 hours at 37°C before determination of the MIC. For Gram-negative organisms the MIC 
was determined as above with and without supplementation of media with polymyxin B 
nonapeptide (PMBN) (4.1 M). Clofazimine was used as control in PMBN studies and prepared 
as the test compounds (Vaara, 1992). 
The effect of serum on the MIC of the compounds was also determined. MIC assays were 
performed as described above, however the media was supplemented with 2, 10 or 50% heat 
inactivated adult bovine serum. 
Minimum bactericidal concentration 
The minimum bactericidal concentration (MBC) was determined according to the CLSI 
guidelines.26 Briefly, the MIC assay was extended and after determination of the MIC 10 L 
aliquots were taken from all wells above the MIC and spotted onto sheep blood agar. The plates 
were incubated for 24 and 48 hours before determination of the MBC as the lowest 
concentration where 99.9% of the final inoculum is killed. 
Time kill assays 
Time kill assays were performed in 20 L samples at 1x, 2x, 4x and 8x the MIC of each 
compound in glass flasks according to CLSI guidelines with LB broth replacing the CAMHB 
(NCCLS, 1999).  The compounds were serially diluted in 100% DMSO at 100x the final desired 
concentration and 200 μL of appropriate concentrations added to each flask. Cultures were 
incubated at 37 °C with samples taken at 0, 4, 8 and 24 hours. 
Biofilm Assays 
Biofilm activity was determined using the MBEC assay system as previously outlined (Ceri et 
al., 2001). Briefly, biofilms were allowed to grow for 24 hours on MBEC pegs before exposure 
to the compounds for a further 24 hours. After exposure the biofilms were dispersed by 
sonication and the CFU.mL-1 determined via spot plating. Again all compounds were serially 





Sheep erythrocytes were exposed to various concentrations of 1, 27 and 69 as described 
previously (Leejae et al., 2013).  Briefly, erythrocytes were washed three times in saline, re-
suspended to a final concentration of ~1010 cells.mL-1 and 5 L of compound dissolved in 
DMSO was added. Erythrocytes were incubated at 37 °C for 30 minutes with gentle shaking 
before being put on ice for 5 minutes and centrifuged to pellet cells. The positive control was 
erythrocytes exposed to water resulting in 100% lysis. After centrifugation the absorbance of 
the supernatant was recorded at 550 nm. 
Tissue culture cytotoxicity 
HEL 299 (ATCC CCL-137) and Hep G2 (ATCC HB-8065) human cell lines were maintained 
in Dulbecco’s Modified Eagle’s Medium (DMEM; Gibco Cat No: 12430) supplemented with 
10% (vol/vol) foetal bovine serum and 1% PenStrep (100 U/mL Penicillin and 100 g/mL 
Streptomycin) and passaged ~ every 3 days. Assays were performed in duplicate in 96 well 
plates seeded with ~50 000 cells per well. Twenty-four hours after seeding the plates, media 
was removed, washed once with medium without antibiotics and fresh media was added. Two 
hours later, 1, 27 and 69 were diluted in DMSO and added to each well at a concentration of 
1% in doubling dilutions starting at the same concentrations used for MIC testing. After 24 
hours exposure WST-1 reagent was added to each well at a final concentration of 10%. 
Absorbance at 450 nm was recorded after 1 hour of incubation with WST-1 reagent. The GI50 
values were determined via non-linear regression using GraphPad Prism v6 software. 
Synthetic Chemistry (See Appendix 1 for specific synthesis methods.) 
Compounds 3, 4, 8, 9-11, 15-17, 21-23, 69, 71, S1, S3, and S5-S7, S36, S37 were synthesized 
by an external contractor, EpiChem Pty Ltd (Melbourne Australia).  
General Method A 
A suspension of the appropriate aldehyde (2.2 eq.) and N,N-diaminoguanidine hydrochloride 
(1.0 eq.) in EtOH was heated at reflux for 16 h. The mixture was cooled and diluted with Et2O 
to effect crystallization. The resulting precipitate was collected and washed with Et2O to afford 
the carbonimidic dihydrazide. 
General Method B 
A suspension of aldehyde (2.2 eq.) and N,N-diaminoguanidine hydrochloride (1.0 eq.) in EtOH 
(5 mL) was subjected to microwave irradiation (150 W) at 100 °C for 10 minutes. Most of the 
solvent was then removed in vacuo, Et2O (5 mL) was added and the flask was chilled to effect 
crystallization. The resulting precipitate was collected and washed with Et2O (5 mL) to afford 
the carbonimidic dihydrazide. 
78 
 
Chapter 3: Potential of Novel Robenidine Analogues as Antibacterial 
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Recently 79 structural analogues of robenidine were developed to explore antibacterial structure 
activity relationships (SAR). Several of these analogues were active against the Gram-positive 
pathogens S. aureus and E. faecalis, however no activity against Gram-negative pathogens was 
observed. Although no inherent Gram-negative activity was observed among the 79 analogues, 
the MIC decreased 10 fold in the presence of a membrane permeabilising agent. In this study 
spheroplasts of E. coli were developed to better understand the Gram-negative activity of 
robenidine. In addition, the SAR was further explored with the intention to induce native Gram-
negative activity. As expected, studies with spheroplasts confirmed that the target of robenidine 
is present in Gram-negative organisms and demonstrated a bactericidal mechanism of action. 
In addition, novel analogues were developed with activity against Gram-negative bacteria, with 
minimum inhibitory concentrations (MICs) against E. coli and P. aeruginosa ranging between 
16 and 128 µg/ml.  
 
3.3 Article 
The development of MDR pathogenic bacteria is an emerging concern for the global healthcare 
system. In particular, the ‘ESKAPE’ pathogens (Enterococcus faecium, Staphylococcus aureus, 
Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa and Enterobacter 
species) cause the majority of nosocomial infections and can readily share resistance genes 
(Rice, 2008). Of greatest concern are the Gram-negative bacteria resistant to critically important 
antimicrobials. To further add to the issue, there is limited development of novel antimicrobials 
to combat MDR Gram-negative bacteria. A recent review of drugs under development for 
treatment of MDR Gram-negative pathogens by the Infectious Diseases Society of America 
stated that progress in this area remains alarmingly slow. Of the 7 drugs reported in clinical 
development none were active against the entire range of Gram-negative bacilli (Boucher et al., 
2013; WHO, 2017). In this study, we examined the potential of a new class of antimicrobials, 
based on the structure of the coccidostat robenidine, to be developed for use as Gram-negative 
antibacterial agents.  
The antibacterial activity of robenidine (2,2’ – bis[(4-chlorophenyl) methylene]-carbonimidic 
dihydrazide hydrochloride) and 79 structural analogues has been recently reported. In the 
reported study, none of the analogues had intrinsic activity against Gram-negative bacteria. 
However, a small subset was able to inhibit Gram-negative bacteria in the presence of polymxin 
B nonapeptide (PMBN), a membrane permeabilising agent (Abraham et al., 2016). 
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In this study, the activity of robenidine against Gram-negative bacteria was explored further by 
producing spheroplasts (cells lacking a cell wall) of E. coli to investigate the kill profile of 
robenidine. In addition, a further 32 novel analogues were screened for antibacterial activity. 
Methicillin susceptible S. aureus strains ATCC 25923, 6538 and 29213 were obtained from the 
American type tissue culture collection along with Escherichia coli ATCC 25922, Escherichia 
coli ATCC 25923 and Pseudomonas aeruginosa ATCC 27853. E. faecalis, Pseudomonas spp., 
MRSA 1, MRSA 2, VRE 1 and VRE 2 were obtained from The University of Adelaide School 
of Animal and Veterinary Science (SAVS) bacterial collection. All robenidine analogues were 
supplied by Prof. Adam McClusky (University of Newcastle). All other antimicrobials were 
sourced from Sigma Aldrich.  
The induction of E. coli (ATCC 25922) spheroplasts was performed with ampicillin. An 
overnight broth culture was diluted to approximately 1 x 109 cells/ml in Cation-adjusted 
Mueller-Hinton broth (CAMHB) supplemented with 50 μg/ml ampicillin, 0.4 M sucrose and 8 
mM MgSO4 (Lederberg, 1956; Randall et al., 2013). The culture was incubated for ~ 2hrs, until 
the majority of cells had become spherical, as observed under phase contrast microscope. The 
regeneration of spheroplast cells, necessary to determine spheroplast formation efficiency and 
activity of robenidine, was determined using brain heart infusion agar. Assays to determine the 
effect of robenidine against E. coli spheroplasts were performed in test tubes. An aliquot (3 ml) 
of spheroplast culture was added to each test tube with 50 μl of robenidine at an appropriate 
concentration (8, 16, 32, 64 or 128 µg/ml) and gently inverted to mix. DMSO (compound 
solvent) only was used as a positive control. Spheroplasts were incubated at 37°C for 24 hrs, 
with samples taken at 0, 2, 4, 6, 8 and 24 hours. At each sampling, the tubes were gently inverted 
to mix the culture. Samples were serially diluted 1:10 and 10 μl of each dilution spotted onto 
brain heart infusion agar (in triplicate). Samples were incubated at 37°C for 48 hrs and colonies 
counted at 24 and 48 hrs post incubation. At 24 hrs post robenidine exposure, a sample was 
taken from each concentration, stained with Trypan blue and imaged at 100X magnification. 
Each assay was repeated in duplicate, in duplicate. 
Susceptibility testing of the analogues was completed according to Clinical Laboratory 
Standards Institute (CLSI) guidelines for testing antimicrobial agents (CLSI, 2008). Initially, 
CAMHB was used but was replaced with Luria Bertanini broth (LBB) due to interactions 
observed with the test compounds and CAMHB (Rozengart and Saakov, 2002) (Appendix 3). 
Antimicrobial stocks and bacterial suspensions were prepared according to CLSI guidelines. 
Modifications were made to the standard protocol due to the insoluble nature of the novel 
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analogues. All analogues were serially diluted in DMSO at 100 X the final desired 
concentration and 2 µl of dilution added to individual wells of the assay plate. CAMHB or LBB 
was added to a final volume of 180 μl and finally 20 μl of diluted bacterial suspension was 
added to give an assay concentration of ~ 5 X 105 cells/ml per well. The assay was incubated 
for 20-24 hrs at 37°C before interpretation of the results. All assays were repeated in duplicate. 
In this study, the potential for robenidine to target Gram-negative bacteria was explored through 
the development of E. coli spheroplasts. Spheroplasts are viable bacterial cells in which the cell 
wall is almost completely lacking, causing the cells to take on a spherical shape (Poole, 1993). 
In this case, the cell wall was removed by the addition of sub-inhibitory concentrations of 
ampicillin. Although the cells are still viable, they are unable to reproduce (Appendix 3). Once 
the ampicillin has been removed, cells are able to regenerate and continue normal growth. The 
spheroplast formation frequency in this study was >99% with a regeneration frequency of 
>70%. Time-kill curve evaluation of robenidine against E. coli spheroplasts indicated 
bactericidal activity of the compound resulting in a > 4 log reduction of cells at the 2 highest 
concentrations of robenidine after 24 hr exposure (Figure 3.1).  
In addition, all concentrations tested resulted in some inhibition of spheroplast regeneration 
after 24 hrs. These results confirm the previous findings (Abraham et al., 2016) where 
robenidine and a second structural analogue were able to inhibit bacterial growth in the presence 
of PMBN, a membrane permeabilizing agent, with a ≥ 10-fold reduction in minimum inhibitory 
concentration (MIC). The results in the present study demonstrated that the bactericidal activity 
of robenidine in Gram-negative organisms is similar to that seen in Gram-positive organisms 
(Abraham et al., 2016). Furthermore, it is possible to hypothesise from this information that 
robenidine may have a potential target site that doesn’t involve the cell wall as robenidine still 
had an inhibitory effect despite removal of the cell wall.  Cell samples from each concentration 
were taken at 24 hours for microscopic observation (Figure 3.2). At concentrations of 16 µg/ml, 
spheroplasts appeared swollen in size compared to untreated cells and were no longer clearly 
defined. As the concentration of robenidine increased, the cells became increasingly 
pleomorphic in shape.  
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Figure 3.1 The activity of robenidine against E. coli spheroplasts. E. coli spheroplasts were induced with sub-lethal 
concentrations of ampicillin before exposure to robenidine at concentrations ranging from 0 – 128 μg/ml. The experiment was 
repeated in triplicate and a representative result has been portrayed here. Error is ± SD. Key: triangles 0 μg/ml robenidine; 
circles 8 μg/ml robenidine; squares 16 μg/ml robenidine; triangles 32 μg/ml robenidine, diamonds 64 μg/ml robenidine and 
hexagons 128 μg/ml robenidine. Broken line indicates the detection limit. A log3 reduction in cell number signifies statistical 
significance as described by CLSI guidelines. 
 
In this study, a novel subset of robendine analogues were also screened against representative 
bacterial pathogens (Table 3.1 and 3.2). Of this group of compounds, 18 showed antibacterial 
activity against at least one Gram-positive pathogen with MICs ranging from 4 – 128 µg/ml 
further confirming the Gram-positive spectrum of this series of compounds (Abraham et al., 
2016). More interestingly, seven of the novel analogues demonstrated inhibitory activity 
towards Gram-negative pathogens with MICs ranging from 16 – 128 µg/ml. All the Gram-
negative active agents were effective in inhibiting the growth of E. coli while three were active 
against both E. coli and P. aeruginosa. All of the compounds that were active against the Gram-
negative organisms were smaller in size (mw <310 g/mol) and had an exposed guanidine 
terminus. Although the smaller size of the Gram-negative active agents could be important to 
the Gram-negative activity (presumably through the ability to traverse outer membrane porins), 
it is also possible that the guanidine terminus, a moiety that induces cell membrane 
permeability, is a more important attribute assisting in transfer of the compound across the 
bacterial membrane, as permeabilisation of the Gram-negative outer-membrane has been shown 
to extend the spectrum of activity of the lead to Gram-negative organisms (Abraham et al., 





Figure 3.2 Morphological effect of robenidine on E. coli spheroplasts after 24-hour exposure. E. coli spheroplasts were treated 
with A: 0 ug/ml, B: 16 ug/ml, C: 32 ug/ml or D 64 ug/ml of robenidine before staining with trypan blue and imaging. As the 
concentration of robenidine increased the cells became more pleomorphic in shape which corresponded to relative bactericidal 
activity at the various drug concentrations. Cells imaged at 100 X magnification. 
 
In conclusion we confirmed the target of robenidine is present in Gram-negative bacteria and 
that the compound has bactericidal activity. In addition, several novel analogues were identified 
with antibacterial activity, and these were also demonstrated to have activity against Gram-
negative pathogens including P. aeruginosa. The extension of the spectrum of activity could be 
in part due to the small molecular weight of the active analogues as well as the guanidine 
terminus increasing the membrane permeability potential of the analogues. Based on this study, 






Table 3.1 Selection of analogues chosen to be tested for antibacterial activity against both Gram-positive and Gram-negative 
bacteria. Analogues were tested according to CLSI guidelines in cation adjusted Mueller Hinton broth. Each analogue was 
tested in duplicate and ampicillin was used as a control drug. 
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- - - - 
aE.coli ATCC 25922, bIsolates from The University of Adelaide SAVS collection (Pseudomonas #8, E. faecalis 





Table 3.2 Selection of robenidine analogues screened for antibacterial activity. The compounds were screened according to 
CLSI guidelines with LB broth replacing CAMHB and prior dilution of analogues in DMSO. Assays were repeated in duplicate. 
 MIC (µM) 
ID 
Structure 






137.7 104.7 – 
137.7 




146.6 73.3 - 
146.6 













































































- 299.5 - - - 
a S. aureus ATCC 29213, bIsolates from The University of Adelaide SAVS collection (MRSA 1, MRSA2, VRE 1, 
VRE 2, Pseudomonas #8, E. faecalis #32), c E.coli ATCC 25922, d = no inhibition at 128 µg/ml. e = no inhibition 
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Trypanosomatids cause significant human morbidity and mortality, with an estimated 1.3 
million new cases per year resulting in ~ 30 000 deaths occurring due to Leishmania sp. alone. 
In addition to this, trypanosomatids, such as Trypanosoma brucei (endemic to Africa), cause 
significant morbidity and mortality to humans, as well as significant losses in the livestock 
industry. Currently the chemotherapy available for these organisms is limited and has unwanted 
toxic side effects. In this study we investigated the antitrypanosomatid activity of several novel 
chemical entities, based on the structure of the well characterised coccidiostat robenidine, 
against promastigote stages of the L. donovani and T. brucei parasites. The sensitivity of the 
parasite towards the compounds was measured using the metabolic dye resazurin and toxicity 
towards mammalian cells, was determined with a WST-1 dye. Several of the drugs were highly 
effective against both parasites in primary screens. The drugs were not selective for T. brucei 
over mammalian cells. However, several of the compounds had very promising results against 
L. donovani with selectivity indices > 20. Based on the results of this study, several novel 






Trypanosomatids, including Trypanosoma spp. and Leishmania spp., cause significant 
morbidity and mortality in tropical regions of the world. These parasites are included as a part 
of the WHO neglected diseases initiative and, combined, are estimated to infect 20 million 
people globally with at least a further 300 million at risk (Lopes et al., 2010; Santos et al., 2008). 
Two of the most devastating disease agents from this family are Trypanosoma brucei and 
Leishmania donovani, both of which can result in fatal consequences if not treated (Barrett and 
Croft, 2012; Lopes et al., 2010; No, 2016). 
T. brucei is endemic to Africa and is responsible for the disease commonly known as sleeping 
sickness, which is 100% fatal if left untreated. In the year 2000, there are an estimated 70 000 
new infections with T. brucei each year with 60 million people at risk, mostly in rural villages 
(Burri et al., 2000). However the estimated cases had dropped to less than 15 000 in 2014 
(WHO, Global Health Observatory data repository). T. brucei is spread via the insect vector, 
the tsetse fly, and, depending on the subspecies of parasite, can result in an acute disease that 
lasts for months or a chronic disease that can last for years. The first stage of the disease, where 
the parasite is found in the lymphatic system and blood stream, includes symptoms such as 
fever, chills, headache and lymphadenopathy. As the disease progresses, the parasite moves 
into the central nervous system (CNS) with symptoms including severe headache, psychiatric 
manifestations and mental deterioration which progresses to seizures, coma and eventually, 
death (Barrett and Croft, 2012; Buscher et al., 2017; Field et al., 2017; Lopes et al., 2010; Lutje 
et al., 2013). 
L. donovani is more widespread than T. brucei, found in Africa, Asia and Europe. As seen with 
Trypanosoma spp., Leishmania is also transmitted by an insect vector; the phlebotomine 
sandfly. Several disease manifestations of Leishmania occur, including visceral and various 
severities of cutaneous leishmaniasis. Visceral leishmaniasis, caused by L. donovani, is fatal if 
left untreated and is characterised by fever, weight loss and swelling of the liver and spleen, 
while cutaneous leishmaniasis is characterised by severe skin lesions that can leave disfiguring 
scars (Barrett and Croft, 2012). Unlike Trypanosoma spp., Leishmania spp. have an 
intracellular stage in the human host, residing and multiplying in the macrophages eventually 
leading to macrophage lysis, release of the parasite and progression of the disease (Santos et 
al., 2008). 
Although the disease burden caused by trypanosomatids is high, there is a significant lack of 
effective and safe treatment options (Field et al., 2017). For the treatment of T. brucei 
pentamidine and suramin are used during the early stages of the disease (before migration to 
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the CNS) and melarsoprol and eflornithine are used in the late stages of the disease (after CNS 
migration). While eflornitine seems to be relatively safe it is significantly more expensive than 
melarsoprol (Brun et al., 2001a; Brun et al., 2001b; Burri et al., 2000; Kennedy, 2013). The 
other 3 drugs mentioned have severe side effects including nephrotoxicity and renal 
complications, severe allergic reactions in some individuals and reactive encephalopathy which 
can result in death in up to 70% of afflicted patients (Burri et al., 2000; Kennedy, 2013; Lopes 
et al., 2010). 
The drugs available for the treatment of leishmaniasis have similar limitations to those used in 
the treatment of T. brucei. Currently pentavalent antimonials are used which are highly toxic. 
More recently, amphotericin B, paromomycin and miltefosine have been used in treatment in 
various countries (Richard and Werbovetz, 2010). 
In addition to the side effects of the drugs, there have also been reports of treatment failures due 
to the development of drug resistance within the parasite population (Lira et al., 1999; Matovu 
et al., 2001). 
With the severe side effects and treatment failures, which are increasing as drug resistance 
increases, it is crucial to continue the discovery and development of novel antitrypanosomatids 
(Santos et al., 2008). This has proven difficult in the past, with several promising candidates 
being rejected due to toxic side effects or the inability to treat late stages of disease in animal 
models (Brun et al., 2001a). With the prohibitive cost and time consuming nature of drug 
development in mind and the need for new treatments as soon as possible, the repurposing of 
chemically characterised biologically active compounds has become popular, as it is a relatively 
cheaper and quicker method of drug development than starting with completely novel chemical 
entities or plant extracts (Chong and Sullivan, 2007; Field et al., 2017). 
We performed a preliminary study into the potential efficacy of robenidine (812) and several 
novel analogues against both T. brucei and L. donovani in vitro. Robenidine is a coccidostat 
that has been used in the poultry and commercial rabbit industries since the 1970s to control  
Eimeria (Kantor et al., 1970). Safety and toxicity studies have shown it to have no genotoxic, 
carcinogenic or reproductive toxicity in vitro or in animal models, making it a good choice for 
other antiparasitic applications. In this study, 19 analogues of 812, in addition to 812 itself, 
were tested against the procyclic and promastigote stages of the respective parasites as these 
stages are easily grown in vitro and are a good preliminary indicator for activity against the 













ID R R’ ID R ID R R’ 
812 4-Cl H 195 4-CH3C6H4 041 H 4-CF3 
024 4-CN H 197 5-OHC6H4 042 H 2-CF3 
026 3-CN H 201 4-N(CH3)2C6H4 052 H 3-Cl 
028 2-OCH3 H 245 C10H8 191 CH3 4-Cl 
062 4-Cl CH3 246 C(C6H5) 231 CH3 4-C(CH3)3 
099 4-C(CH3)3 H  
113 4-N(CH3)2 H     
166 4-SCF3 H 
171 2-OH, 4-N(CH3)2 H 





4.4 Materials and methods 
4.4.1 Antimicrobial agents 
Compounds were synthesised at the University of Newcastle and are all considered structural 
analogues of robenidine. The compounds were all dissolved in DMSO to a final concentration 
of 10 mM. Pentamidine (Sigma) was used as a positive control and dissolved in DMSO to a 
final concentration of 10 mM. 
4.4.2 Leishmania donovani screening 
Procyclic promastigotes from exponentially growing cultures maintained in DME-L+ Bob 
additions in a humidified incubator at 28°C with 5 % CO2 were used for all assays. To determine 
the antitrypanosomatidial activity, compounds were diluted in culture media to a final volume 
of 10 μM in 96 well plates. Promastigotes were diluted to a density of ~8 x105 cells/ml then 
added to the assay plate resulting in a final cell density of 4 x 105 cells/ml. Cells were incubated 
for 96 hrs at 28°C before the addition of resazurin dye (Sigma). Fluorescence was read at 
excitation 530 nm and Emission 590 nm (Synergy H4 hybrid reader, BioTek). To determine 
IC50’s, compounds that showed inhibitory activity at 10 μM were further investigated. 
Compounds were serially diluted in thirds, in a 96 well plate, in cell growth media so that 
concentrations ranged from 0.005 to 10 μM and promastigotes were added to a final 
concentration of 1 x 106 cells/ml. Cells were incubated at 27°C for 72 hrs before the addition of 
resazurin dye (Sigma). Fluorescence was measured as above. Results were analysed using a t-
test in Graphpad Prism v7 software. 
4.4.3 Trypanosoma brucei screening 
Procyclic promastigotes from exponentially growing cells maintained in SDM-79 medium in a 
humidified incubator at 28°C with 5 % CO2 were used in all assays. Compounds were initially 
screened at 10 μM for activity, diluted in culture media before the addition of promastigotes 
(final concentration 4 x 105 cells/ml). Cells were incubated for 48 hrs at 27°C before the 
addition of resazurin dye. Fluorescence was measured as for L. donovani activity assays. 
Compounds that showed inhibition at 10 μM were further characterised to determine IC50 
values. Compounds were serially diluted in thirds in culture media resulting in final 
concentrations ranging from 0.005 – 10 μM. Promastigotes were added at a final concentration 
of 4 x 105 cells/ml. Cells were incubated at 27°C for 48 hrs before the addition of resazurin dye. 
In addition, promastigotes, at a concentration of 8 x105 cells/ml were exposed to 10 μM of 026 
for 1.5 hours before removal of the drug via centrifugation at 5000 rpm for 7 minutes and 
resuspension of cells in culture media. Following this, cells were incubated for 96 hours at 27°C 
and observed daily for metabolic activity (resazurin dye) and morphological changes. A DMSO 
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treated culture was used as a negative control. Results were analysed using a t-test in Graphpad 
Prism v7 software. 
4.4.4 Cell toxicity assays 
RAW 264.7 cells, a mouse macrophage line, were grown in RPMI1640 media supplemented 
with L-glutamine and either 10 % FCS (general maintenance of cell line) or 5 % FCS 
(cytotoxicity assays) and were routinely subcultured when 80 % confluent, approximately every 
3-4 days. To determine in vitro cytotoxicity, cells were diluted to a final concentration of 1 x 
105 cells/ml and assays were performed in a final volume of 200 μl in 96 well plate (nunc; 
Thermo Fisher Scientific). After inoculation of plates, cells were incubated in a humidified 
incubator for 2 hrs at 37°C with 5% CO2 before the addition of analogues diluted in DMSO (2 
μl / well) or DMSO only for the growth control. Cells were incubated for a further 24 hrs at 
37°C with 5% CO2. After incubation the metabolic activity of the cells was determined using 
the WST-1 assay system according to manufacturer’s instructions (Roche Australia). Briefly, 
cells were washed with PBS and incubated with a final concentration of 10 % WST-1 reagent 
in PBS for 1 hour (humidified 37°C, 5% CO2). Absorbance was measured at 450 nm (iMark 
Microplate Reader S/N 12510, Bio-Rad Laboratories). The IC50 was determined via graphpad 
prism software using the nonlinear regression function with a normalised response. The 
selectivity index of the compounds was determined by dividing the IC50 of the compound 
against macrophages by the IC50 against the respective parasite. 
4.5 Results 
Robenidine and 19 structural analogues were screened for activity against the promastigote 
stage of L. donovani and T. brucei at 10 μM. Of the compounds tested 70% showed a ≥90% 
reduction of metabolic activity in L. donovani, while only 10% showed a similar reduction of 
metabolic activity in T. brucei (Figure 4.1). Only one of the analogues (197) showed no activity 
against L. donovani at the concentration tested and only minimal activity towards T. brucei and 
is considered the least active of the analogues tested. Analogues 026, 062 and 246 were very 
effective against both species of parasites. The majority of compounds showed activity against 
L. donovani with 026, 028, 041, 042, 062, 099, 195, 201, 219 and 246 being the most active. 
The activity of the analogues against T. brucei was more varied with 026, 062, and 246 having 
the greatest activity while 041, 042, 191 and 231 were the least effective. Further investigation 
of a selection of compounds that had the greatest activity against the parasites was completed 
to determine the IC50 values. Against L. donovani the IC50 value was determined for 028, 099, 
166, 201, 245, 246 and 812. The IC50 range was 0.37 μM (028) to 6.48 μM (245 and 246). The 
IC50 value was determined against T. brucei with the 6 most effective analogues; 024, 026, 062, 
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171, 195 and 246. Of these analogues 026, 171 and 195 were the most effective with IC50 values 










































































































































































Figure 4.1 Antitrypanosomatid activity of robenidine and 19 structural analogues. The activity of the potential drug 
candidates was assessed using the promastigote stages of the Trypanosoma brucei (black) or Leishmania donovani (grey) 
parasites and measured with a fluorescent dye. The analogues were divided into three groups based on core scaffolds: A - 
scaffold 1, B -scaffold 2 and C - scaffold 3. Refer to Table 4.1 for detailed structural information. All novel analogues were 
significantly different than the control, except NCL197 against Leishmania, as analysed by a t-test. p < 0.001. 
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In vitro toxicity of the most active antiprotozoal analogues investigated in this study was 
determined using RAW 264.7 cells (Table 4.2). Fifty percent Growth inhibition (GI50) 
concentrations ranged from 3.7 ± 0.7 μM to 19.3 ± 3.8 μM and were used to calculate the 
selectivity index (SI) of the analogues for the parasite over mammalian cells.  
An assay to determine the ability of T. brucei to recover after a short exposure to 026 was 
performed. After 1.5 hrs of exposure to the 026 compound, promastigotes were pleomorphic in 
appearance. Metabolic activity of the culture was determined at 48 and 96 hours post exposure 
and no activity was observed.  
Table 4.2 The selectivity of active analogues for trypanosomatid parasites over mammalian cells. Cells were exposed to 
increasing concentrations of the compounds for select periods of time to determine the GI50 or IC50. The selectivity index (SI) 
was determined by dividing the GI50 of macrophages by the IC50 of parasites. An SI ≥10 was considered selective for the 











812 14.8 ± 1.3 - - 2.9 ± 0.2 5.1 
024 12.7 ± 2.8 3.4 ± 0.1 3.8 - - 
026 9.6 ± 1.0 1.7 ± 0.6 5.7 2.5 ± 0.1 3.8 
028 8.1 ± 2.8 - - 0.3 ± 0.1 27.9 
062 7.2 ± 1.3 4.0 ± 0.8 1.8 - - 
099 7.7 ± 0.6 - - 0.4 ± 0.1 20.7 
113 12.9 ± 3.5 - - 0.9 ± 0.1 14 
166 9.5 ± 0.1 - - 3.2 ± 1.0 2.8 
171 12.5 ± 3.6 1.4 ± 0.1 9.1 - - 
195 5.8 ± 0.3 1.5 ± 0.8 3.8 - - 
201 12.3 ± 2.1 - - 2.9 ± 0.2 4.2 
219 19.3 ± 3.8 - - 0.8 ± 0.1 24.1 
245 3.7 ± 0.7 - - 7.2 ± 2.1 0.6 
246 13.8 ± 0.1 4.2 ± 0.4 3.3 6.7 ± 3.0 2.1 
 
4.6 Discussion 
Nineteen structural analogues of 812, in addition to 812 were tested for activity against the 
promastigote stages of representative Leishmania and Trypanosoma parasites in vitro. The 
Leishmania parasite was, overall, more sensitive towards the drug library than the Trypanosoma 
parasite. This could be due to the longer exposure time tested with L. donovani (96 hrs) 
compared to T. brucei (48 hrs), which was due to the different growth conditions of each 
parasite. Nevertheless, several of the agents were effective in inhibiting T. brucei, with 026 
being the most active. In addition, T. brucei parasites were unable to recover from a short 
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exposure to 026 instead becoming pleomorphic in structure and undetectable using metabolic 
indicator dye. The drugs tested against the parasites were characterised into 3 structural groups 
based on the core scaffold of each compound (Table 4.1). Although only a small number of 
analogues were used in this study, some comparison between structures can be made. 812 was 
very effective against L. donovani (100% inhibition) and inhibited T. brucei ~70 % in 
comparison to non-treated cells. When the aromatic chloride moieties were replaced with 
cyanide (024) activity against L. donovani decreased from 100% parasite inhibition to 65% 
inhibition, while T. brucei inhibition increased to > 80%. Similar inhibition to 812 of both 
parasites was observed when the Cl’s were replaced with 4-C(CH3)3 (099) while activity 
towards T. brucei decreased significantly when the same moieties were replaced with 4-
N(CH3)2 (113). Activity towards both parasites decreased when a 4-SCF3 (166) change was 
made. Imine substitution of 812 with a methyl group improved activity towards T. brucei (062). 
Imine substitution of 099 also improved activity towards T. brucei (219). Addition of an alcohol 
group to the aromatic rings (171) of 113 resulted in a large decrease in activity against both 
parasites. The compounds from scaffold 3, non-symmetrical adjuncts of scaffold 1, showed no 
significant activity towards T. brucei under the current assay conditions, but the majority had 
activity against L. donovani. Tri-fluoride groups on the aromatic ring (041 and 042) of scaffold 
3 in different positions appear to be equally effective in inhibiting L. donovani in the screening 
assay. Removal of one aromatic imine portion of 062 (191) resulted in a complete loss of 
activity towards T. brucei suggesting that the symmetry of 062 is related to activity, at least in 
T. brucei. Some analogues belonging to scaffold 2 had relatively good activity towards both 
parasites. The only exception was 197 which was moderately active towards T. brucei but 
inactive against L. donovani. The activity of the analogues towards T. brucei does not appear 
to be selective over activity towards mammalian cells as investigated in this paper, with 171 
being the most selective but still with a SI below 10. On the other hand, 4 of the analogues 
active against L. donovani were considered selective for the parasite over mammalian cells. 028 
was the most selective with an SI of 27.9. 099 (SI 20.7) was also very selective for L. donovani 
and both 028 and 099 also showed selectivity for L. donovani over T. brucei.  
Despite promising results in promastigote stages of the parasites it is crucial to test these drugs 
against amastigotes, especially the intracellular amastigotes of L. donovani. Although results 
with promastigotes can be predictive of results with amastigotes, it has been shown that some 
compounds can be selective for different stages of the parasite (De Muylder et al., 2011; 
Vermeersch et al., 2009). In addition, potential for the analogues to transfer across the blood 
brain barrier in treating T. brucei is also important as in late stages of the disease, when most 
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treatment cases present, the parasite has crossed the blood brain barrier, resulting in treatment 
failure with drugs that are excluded by this barrier (Brun et al., 2001a). 
In this study we investigated the potential of several novel analogues of the anti-parasitic drug 
robenidine to kill the kinetoplast parasites L. donovani and T. brucei. The activity of the 
analogues was varied between the parasite species with L. donovani being more susceptible 
than T. brucei to the chemical entities investigated. 
 In this study an SI ≥10 was considered selective for the parasite. Based on this classification 
none of the active analogues were selective for T. brucei over mammalian cells while 4 (028, 
099, 113 and 219) were considered highly selective for L. donovani with SI’s ≥ 14. In addition, 
these 4 analogues showed less activity towards T. brucei in original screening assays suggesting 
they have a greater selectivity for the Leishmania parasite over other parasites and would make 
good candidates for future experiments, firstly in amastigote stages of the L. donovani parasite 
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Giardia duodenalis is a ubiquitous parasitic pathogen that causes significant morbidity and 
mortality worldwide. Failures in drug therapy are common due to poor patient compliance as a 
result of the need for repeated administration, off target drug effects and increasing drug 
resistance in parasite populations. In this study, the efficacy and selectivity of robenidine (812) 
and 119 structural analogues against Giardia in vitro was determined. In addition, electron 
microscopy (SEM and TEM) studies were carried out. A total of forty-six analogues, in addition 
to robenidine, had antigiardial activity. After 5 hours, compound exposure IC50’s as low as 0.2 
µM were observed with corresponding MICs of 2.8 µM. This is in contrast to metronidazole 
(the standard treatment for giardiasis), which required 24 hrs to exhibit inhibitory activity, with 
an MIC 3-fold higher and an IC50 19-fold higher than the best analogues in this study. 
Elimination of activity against bacteria and mammalian cells while maintaining antigiardial 
activity was also observed with 14 analogues, a significant advantage over already registered 
drugs. Electron microscopy studies showed that a Giardia selective analogues had a 
multifaceted effect on Giardia trophozoites, which differed from the parent compound. In 
addition, no in vivo toxicity in mice was observed for selected analogues at 100 mg/kg delivered 
orally once per day for 3 days. In conclusion several new chemical entities were identified that 
were selective for Giardia over other cells. Two analogues in particular met all selection criteria 
with rapid giardicidal activity and a multifaceted phenotypic response involving cell 






Giardia duodenalis (syn. Giardia lamblia, Giardia intestinalis) is a bi-nucleate parasitic protist 
causing between 200 million and 1 billion human infections annually, making it the most 
common enteric parasitic pathogen worldwide (Halliez and Buret, 2013; Upcroft and Upcroft, 
1998; Upcroft and Upcroft, 2001b). Although infections are common in developed nations they 
are more prevalent in developing nations. Giardia has been recognised by the World Health 
Organisation as an important pathogen by its addition to the neglected diseases initiative 
(Savioli et al., 2006). Giardia infection is established via ingestion of cysts directly through a 
faecal-oral route or via contaminated food or water (Savioli et al., 2006; Thompson, 2000). 
Giardia causes a malabsorptive gastrointestinal disease with symptoms including diarrhoea, 
bloating and abdominal cramping (Buret, 2008).  Symptoms may be acute or chronic and re-
occurring.  Persistent infection, especially in children and immunocompromised hosts, results 
in long term effects including malnutrition, developmental delay and failure to thrive syndrome 
(Wright et al., 2003).  
Globally there are several classes of antigiardial drugs used to treat giardiasis. The most 
common include the nitroimidazoles, nitrothiazole, nitrofuran, acridine, benzimidazole, 
quinolone and aminoglycoside compound classes (Wright et al., 2003).  The most frequently 
used nitroimidazoles, metronidazole and tinidazole, have a treatment success rate of 80 – 90%; 
while albendazole, a benzimidazole, has a reported efficacy of 62 – 95% (Wright et al., 2003).  
Treatment failures with these drugs are commonly reported and many exhibit unwanted side 
effects including but not limited to genotoxicity, nausea, fatigue and malaise (Wright et al., 
2003).  Metronidazole, is known to cause vomiting, weakness and headaches and is potentially 
carcinogenic (Bendesky et al., 2002; Jokipii and Jokipii, 1979). Furthermore, treatment failure 
due to the development of resistant organisms has been reported for all the commonly used 
drugs (Bendesky et al., 2002; Jokipii and Jokipii, 1979). 
The combination of ineffective treatments resulting from adverse side effects and emerging 
resistance to all classes of antigiardial drugs provides an imperative to identify and develop low 
side effect, low toxicity antigiardial compounds that ideally are selective for Giardia over other 
microorganisms to minimise dysbiosis and ensure maintenance of optimal gut bacteria 
(Jernberg et al., 2007). To potentially expedite discovery and reduce development costs, others 
and we are actively examining the re-purposing of existing clinical and veterinary medicines. 
One such agent is robenidine, a symmetrical chloroaromatic compound linked via a guanidinal 
core (Table 5.1). It has been in use in the commercial poultry and rabbit industries as an 
anticoccidial agent since the early 1970s (Kantor et al., 1970). In this study we evaluated the 
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antigiardial activity of robenidine and 119 structural analogues and performed preliminary site 
and mechanism of action studies using electron microscopy. 
5.4 Materials and methods 
5.4.1 Chemicals 
Robenidine used in this study was provided by Neoculi Pty Ltd (Burwood, Vic, Australia). All 
analogues of robenidine used in the study were previously developed at The University of 
Newcastle for use in another drug discovery program, grant reference number LP110200770 
(Abraham et al., 2016). The remaining drugs used in this study were sourced from Sigma 
Chemical Company (St Louis, Missouri). 
Chemicals used for the culture of Giardia in vitro were sourced as follows: glucose and L-
cysteine (ACROS organics, Thermo Fisher Scientific, Scoresby, Vic), ammonium iron (III) 
citrate, ascorbic acid (Sigma-Aldrich, Castle Hill, NSW), potassium dihydrogen 
orthophosphate (UNIVAR, Ingleburn, NSW), bovine bile (Fluka analytical (BD)), di-potassium 
hydrogen orthophosphate (Fronine laboratory supplies, Riverstone, NSW). 
5.4.2 Cell culture 
G. duodenalis (BAH2c2 strain) was cultivated according to the method of Clark and Diamond 
in Keister’s modified TYI-S-33 medium, supplemented with heat inactivated foetal bovine 
serum (Hyclone™, Thermo Fisher Scientific, Scoresby, Vic) at 37°C in plastic 9 mL screw-
capped test tubes (nunc). Subcultures were performed once a confluent monolayer was 
observed, approximately 2 – 3 times per week (Clark and Diamond, 2002). 
CaCo-2 cells, a human cell line derived from a primary colonic tumour, were sourced from 
Cellbank Australia and were maintained in MEM supplemented with 2 mM glutamine, 1% non-
essential amino acids and 10% FCS (Thermo Fisher Scientific). Cells were passaged when 
confluent, approximately 1-2 times per week. 
5.4.3 In vitro drug efficacy assays 
Resazurin Reduction Assay 
To evaluate the in vitro efficacy of the compounds, a resazurin reduction assay was used as 
previously described (Benere et al., 2007).  The compounds were initially screened at 50 and 
25 μM and any compound with > 50% inhibitory activity at 25 μM was further tested to identify 
the IC50 and minimum inhibitory concentration (MIC). For all assays the media of confluent 
cultures was replaced with fresh media and the cultures were placed on ice for 40 minutes to 
detach trophozoites. Trophozoites were enumerated using a haemocytometer and 50 000 
trophozoites were added to each test well of a 96 well plate. Either single concentrations (final 
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concentration 25 or 50 μM) for the screening assay or tripling dilutions of the test compounds 
(highest concentration 25 μM) for IC50 and MIC determinations in DMSO were added to wells. 
The assays were repeated in triplicate with three individual biological replicates per compound. 
Metronidazole and a DMSO vehicle only used as controls. Plates were incubated under 
anaerobic conditions (anaerogen sachet, Thermo Fisher Scientific) for 5 or 24 hours at 37°C, 
following which, the viability of treated cells was determined using the resazurin reduction 
assay (Benere et al., 2007). The media was removed and replaced with an equal volume of 
warm PBS. Resazurin (Sigma) was then added at 10% of the total volume of the wells. Plates 
were further incubated for colour development and absorbance read at 570 nm and 630 nm. 
Resazurin reduction was then calculated according to the following formula:  
((Eoxi630 x A570) – (Eoxi570 x A630))/((Ered570 x C630)-(Ered  x C570)) x 100  
Where: Eoxi630 = 34798, Eoxi570 = 80586, A570 = absorbance at 570nm, A630 = absorbance at 
630 nm, Ered570 = 155677, Ered630 = 5494, C630 = absorbance of negative control well at 630 
nm and C570 = absorbance of negative control well at 570 nm. 
Modified adherence assay 
A second screening method, based on counting adherent trophozoites, was developed and used 
to validate the primary screen with a select number of analogues. The assay was prepared in 24 
well plates with plastic coverslips placed in the bottom. Trophozoites were prepared as above 
by placing on ice and ~5 x 105 cells/ml were added to each well. Drugs prepared in DMSO 
were added at the required concentration, with the DMSO concentration never exceeding 1%. 
Assays were incubated for 5 hrs at 37°C under anaerobic conditions before the media was 
removed and cells were fixed with glutaraldehyde or methanol. Once the coverslips were dry, 
cells were stained with a Romanowsky stain variant (Rapid stain), fixed to a glass slide and 
imaged at 10 X magnification. Images were processed with dotcount v1.2 software (obtained 
from http://reuter.mit.edu/, 2008 – 2012 copyright by Martin Reuter) to count the number of 
cells present and data analysed using GraphPad Prism version 6.00 for Windows, GraphPad 
Software, La Jolla California USA, www.graphpad.com paired t-test function. Assays were 
repeated in duplicate.  
5.4.4 Recovery assay 
G. duodenalis trophozoites were harvested on ice as outlined above and 5x105 cells/ml were 
added to 1.5 ml centrifuge tubes. Cells were exposed to 5 μM of select analogues, metronidazole 
or DMSO (1%) only for 5 hrs under anaerobic conditions at 37°C. After exposure cells were 
collected by placing tubes on ice for 40 minutes followed by centrifugation at 900 X g for 5 
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minutes. The supernatant was removed and cells were resuspended in 8 ml of fresh media (in 9 
ml culture tube). The number of trophozites were counted using a haemocytometer and cells 
were incubated for 48 hrs with cell numbers being determined at 24 and 48 hrs. Assays were 
repeated in duplicate. data was analysed using a t-test. 
5.4.5 Antibacterial activity 
The antibacterial activity was determined using S. aureus ATCC 29213 and E. coli ATCC 
25922 in Luria Bertanini broth (LBB). Compounds were diluted in DMSO to 100 X the final 
desired (25 or 50 μM) concentration and 2 μl added to 178 μl of broth. Bacterial cells were 
suspended in 0.9 % saline to a concentration equivalent to a 0.5 McFarland standard, diluted 
1:20 in saline and 20 μl of diluted suspension added to the assay plate to give a final cell 
concentration of ~ 5 x 105 CFU/ml. Cells were incubated for 18-24 hrs before interpretation of 
results. Assays were repeated in duplicate. 
5.4.6 Mechanism of Action Studies 
Transmission Electron Microscopy 
To determine any effects robenidine (812) has on the ultrastructure of Giardia trophozoites and 
to further elucidate the mechanism of action, transmission electron microscopy was performed. 
Giardia BAH2c2 trophozoites were exposed to 6 μg/mL robenidine for 30 minutes, 1 or 4 hrs, 
placed on ice for 40 minutes to detach trophozoites then washed twice with PBS (900 X g, 10 
min 4°C) and fixed with a combination of glutaraldehyde and formaldehyde overnight. Cells 
were washed with PBS + 4% sucrose before fixation with osmium tetroxide for 1 hour. Samples 
were dehydrated through a graded ethanol series (70 – 100%) followed by suspension in 
propylene oxide for ten minutes. Samples were centrifuged and suspended in 1:1 mixture of 
propylene oxide and epoxy resin for an hour before centrifugation. Following overnight 
suspension in 100% epoxy resin samples were resuspended in fresh resin and polymerized at 
70°C for 24 hours. After sectioning samples were stained with uranyl acetate and lead citrate. 
Sections were imaged with a FEI tecnai G2 Spirit Transmission Electron microscope (CMCA 
University of Adelaide). Three individual replicates of each treatment were prepared and pooled 
for TEM processing. 
Scanning Electron Microscopy 
To determine the effect that robenidine, 139 and 135 has on the cell surface of the Giardia 
trophozoites and potentially elucidate a mechanism of action, scanning electron microscopy 
was performed as follows. Giardia BAH2c2 trophozoites were prepared as for TEM, however 
109 
 
they were exposed to compounds for 2 hours. After fixation with glutaraldehyde cells were 
attached to plastic coverslips (pre-treated with poly-L-Lysine for 10 minutes) and washed with 
PBS + 4% sucrose before dehydration through a graded ethanol series (70 – 100%). Following 
ethanol dehydration coverslips were dried using a critical point drier, coated with platinum and 
observed using a ZIESS SEM (CMCA University of Western Australia) Two individual 
replicates were prepared and observed for morphological changes. 
5.4.7 Cytotoxicity 
CaCo-2 cells, maintained as outlined above, were collected via trypsinisation and enumerated 
using trypan blue and a haemocytometer. Select analogues were prepared in DMSO so that the 
final concentration in the assay would be either 25 or 50 μM. 1 X 105 cells/ml were added to 
each assay with the appropriate drug dilution. Assays were completed in 96 well plates and 
incubated for 24 hours at 37°C, 5% CO2 in a humidified incubator. After incubation cells were 
washed with warm PBS before the addition of 10% resazurin in PBS. Assays were incubated 
to allow colour development and absorbance read at 630 and 570nm. Activity of the analogues 
against mammalian cells was calculated according to the formulation stated above. Each 
compound was tested in triplicate. 
5.4.8 In-vivo Toxicity of Select Analogues  
Suckling mice (Arc:arc(s) – Swiss origin mice) were obtained from the animal resource center 
at Murdoch (WA) and were 3-4 weeks old at the time of the trial. Each litter had 10 mice and 
was housed independently. Mice were given 100 mg/kg of robenidine (812), 135, 139 or 
metronidazole orally once per day in a volume of 0.1 ml for 3 days. Control groups were 
given an equivalent volume of saline or the formulation used to deliver the compounds. Post 
exposure mice were sacrificed via cervical dislocation and organs were observed for gross 
pathological changes. Animal ethics granted through Murdoch University (permit number: 
R2855/16). 
Compound preparation for in vivo toxicity 
All analogues were provided by Prof. Adam McClusky at The University of Newcastle. 
Metronidazole was sourced from Sigma Aldrich. All drugs, including metronidazole, were 
suspended in an aqueous formulation and saline was used as the no treatment control. Drugs 
were delivered in a final volume of 0.1 ml via oral gavage. Mice were treated with ~100 mg/kg, 
once a day, p.o. for 3 days. 
110 
 
5.4.9 Statistical analysis 
The results for the in vitro drug efficacy studies were analysed using GraphPad Prism version 
6.00 for Windows, GraphPad Software, La Jolla California USA, www.graphpad.com. For the 
resazurin reduction assay the mean and standard error of the mean was determined with each 
assay completed in triplicate. The IC50 was calculated using the log (inhibitor) vs. normalised 
response – variable slope function in Graphpad Prism. For the adherence assay mean and 
standard error of the mean were calculated and data analysed using an unpaired t-test, 
comparing each treated sample to the growth control. 
5.5 Results and discussion 
5.5.1 Antigiardial activity 
This study investigated the potential antigiardial activity of robenidine and related structural 
analogues. In total, 119 analogues from the library, were screened which have been divided into 
9 groups based on similar core structures, were screened (Tables 5.1 – 5.9). The in vitro 
antigiardial activity of the parent compound robenidine has previously been demonstrated as 
described by the patent US4310541A, where robenidine was found to be 4 times more active 
than metronidazole with an IC50 of 1.5 ppm. In the current study robenidine had relatively good 
inhibitory activity towards G. duodenalis with an IC50 of 0.2 μM and an MIC of 2.8 μM after 
just 5 hours, while metronidazole, the current gold-standard drug had an IC50 of >25 and MIC 
of >25 at 5 hours in the same assay (IC50 of 2.8 μM after 24 hrs). Removal of the Cl moiety on 
the benzene ring (100) resulted in a 50% decrease in activity when compared to robenidine 
while replacement of the Cl with a Br group resulted in only a two-fold decrease in activity 
(134) when compared to robenidine, with an IC50 of 1.7 μM and an MIC of 8.3 μM after 24 hrs 
(Table 5.1).  











IC50 MIC (µM) 
5 hr 24 hr 5 hr 24 hr 
812 4-Cl 0±0 0.2 0.9 2.8 2.8 40.7±22.6 Y 
134 4-Br 0±0 0.5 1.7 8.3 8.3 97.1±1.6 N 
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109 3-NO2 0±0 1.4 17.3 8.3 8.3 85.9±6.7 N 
129 2-Br 0±0 3.4 0.8 25 25 79.1±2.3 N 
116 2-Ph 0±0 52.8 2.8 >25 >25 75.4±3.4 N 
160 4-OCF3 0±0 0.3 0.2 8.3 2.8 -
 a Y 
166 4-SCF3 3.7±6.4 0.7 0.2 8.3 2.8 - Y 
112 4-Ph 0±0 0.4 0.4 8.3 2.8 - Y 
140 4-SCH3 0±0 0.2 0.9 25 8.3 - Y 
136 4-
(CH2)3CH3 
0±0 0.3 1.9 25 8.3 - Y 
099 4-C(CH3)3 0±0 2.9 3.2 25 8.3 - Y 
121 4-
(CH2)2CH3 
0±0 5.9 0.8 >25 8.3 - Y 
120 4-
CH(CH3)2 
0±0 9.3 1.9 >25 8.3 - Y 
131 3-Br 0±0 1.1 2.9 25 25 - Y 
126 4-CCH 0±0 27.1 1.2 >25 25 - Y 
100 H 55.8±10.6 - - - - - N 
102 2-NO2 82.3±3.2 - - - - - N 
110 4-NO2 86.8±36.7 - - - - - N 
151 4-OH 172.9±4.9 - - - - - Y 
098 3-COOH 113.1±10.6 - - - - - N 
108 3-OH 147.4±25.5 - - - - - Y 
119 4-
NHCOCH3 
130.6±16.9 - - - - - N 
107 2-OH 112.8±10.4 - - - - - Y 
026^ 3-CN - - - - - - N 
024^ 4-CN - - - - - - N 
028^ 2-OCH3 - - - - - - Y 
a not progressed due to non-selective activity or unsatisfactory screening results, ^ only screened at 50 µM. * concentration of 
compound used in this assay is 25 μM. 
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In addition, this 4-Br substitution eliminated antibacterial activity and reduced the in vitro 
toxicity significantly. While the 4-Br substitution appears to be the most effective for 
maintenance of antigiardial activity, 2-Br and 3-Br substitutions (129, 131) also exhibit similar 
antigiaridal activity with IC50’s of 0.8 and 2.9 μM respectively after 24 hours. However, the 
MIC for each of these compounds is 3 fold higher than the 4 Br substitution at 25 μM after 24 
hours. Like the 4-Br substitution, the 2-Br substitution did not display antibacterial activity. Of 
the additional electron withdrawing groups investigated in this group (110, 109, 026, 024 and 
102), only 3-NO2 substitution retained antigiardial activity with a MIC of 8.3 μM at 5 hrs. In 
addition, this analogue (109) was selective for Giardia trophozoites over both bacterial and 
mammalian cells. Hydrogen bond donors (107, 108 and 151) were all inactive and methylation 
(028) did not improve activity. 4-OCF3 and 4-SCH3 substitutions (160 and 140) had similar 
activity to the parent molecule with IC50’s of 0.2 and 0.9 μM respectively after 24 hours while 
4-SCF3 (166) substitution also demonstrated improved activity over the parent molecule (0.2 
μM at 24 hrs). All the alkyl substituents tested (126, 121, 120, 136, 099) demonstrated activity 
no more than two-fold higher than the parent molecule. The propyl group was the most active 
(121) with an IC50 of 0.8 μM after 24 hrs. The alkyl moieties were slower acting than the parent 
molecule and required a full 24 hrs to reach MICs similar to the parent molecule. Compound 
126 was the slowest acting with no activity observed at 5 hrs and a MIC of 25 μM reached only 
after 24 hrs (compared to 8.3 μM for all other alkyl substituents tested.) Substitution with polar 
groups at the 3 or 4 position (119, 148 and 098) resulted in a loss of antigiardial activity. A 2- 
or 4- phenyl moiety (112, 116) demonstrated good activity with IC50’s at 24 hrs of 2.8 and 0.4 
μM, respectively. The 4-Ph substitution resulted in more rapid and complete activity than the 
2- Ph substitution, with an IC50 of 0.4 μM reached at 5 hrs and an MIC of 2.8 μM. In contrast, 
the 2-Ph substitution was unable to completely inhibit the metabolic activity of Giardia at the 
concentration tested and no antigiardial activity was observed at the 5 hr time point. 
More complex substitution of the phenyl rings resulted in few improvements in activity (Table 
5.2). No single F substitution of the phenyl ring was investigated in this study (due to 
availability of compounds from the library) but 2,5 –F and 2,3,4,5,6 –F substitution resulted in 
no observable antigiardial activity (128, 118). On the other hand, 3,4 di-substitution with F 
resulted in good activity (123) with an IC50 of 1.2 μM and an MIC of 8.3 μM after 24 hrs. 
Addition of a 2-NHCOCH3 (170) molecule onto the parent structure did not noticeably change 
the IC50 at 24 hrs however the MIC at 24 hrs was increased 12 –fold while the toxicity towards 
CaCo-2 cells was decreased 2-fold. 2-Br (129) substitution, described above, gave comparable 
activity to robenidine and the addition of 4, 5- OCH3 (135) further improved the potency and 
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speed of action of the molecule while improving the safety profile and retaining specificity 
towards Giardia over bacteria. 135 had a 4-fold improvement in the IC50 and a 12-fold 
improvement in the MIC and maximum activity was reached much sooner, at 5 hrs instead of 
24 hrs when compared to the parent drug. In addition, no significant toxicity was observed in 
the mammalian cell assay. The remaining analogues in this group all bearing catechol analogues 
were mostly poorly tolerated. Only the 3-NO2, 4-OH and the 3-OCH3, 4-OH analogues (122 
and 117) demonstrated any inhibitory activity towards Giardia. An IC50 was not calculated for 
117 as, in the second assay, no dose response was observed. This could possibly be a result of 
instability of the compound in the solvent or storage conditions used. 
The next group of molecules probed for activity were 1,3-diaminoguanidine Schiff base 
analogues with imine substitutions (Table 5.3). Imine substitution of robenidine with various 
carbon chains (153, 154, 062 and 156) resulted in similar IC50’s at 24 hrs compared to the parent 
drug. The MIC at 24 hrs for the ethyl, propyl and butyl substitutions were increased at least 12 
fold. In contrast, the MIC for the methyl substitution improved 3-fold, however the improved 
MIC was in conjunction with ≥ 40% increase in toxicity toward mammalian cells (062). While 
the methyl and ethyl imine substitutions maintained antibacterial activity the longer propyl and 
butyl chains eliminated antibacterial activity. Di-halogen substitution, 2-F, 4-Cl, with a methyl 
imine substituent decreased activity compared to the parent molecule with a 12-fold decline in 
MIC at 24 hrs (215). Methyl imine substitution of 100, an inactive analogue, imparted moderate 
antigiardial activity with an IC50 of 7.6 μM after 24 hrs (143). However, imine substation of 
COOH or CH2NClH3 (167, 165) did not improve activity of 100. Methyl substitution of 134 
did not improve activity while a similar substitution of 099 resulted in a 5-fold improvement in 
the 24 hr IC50 (155, 219). 
The next group of analogues tested focussed on the same core structure as the previous 3 groups 
but involved substitution with extended linkers and nonaromatic and isosteric phenyl ring 
replacements, in addition to an imine substitution (172) (Table 5.4). All of the analogues tested 
from this group had a H at the imine position, except 172, which had a methyl moiety. Furyl 
substituents (095, 144, 133, 145) did not exhibit any antigiardial activity, in fact a 4-bromofuryl 
moiety increased the metabolic activity of Giardia greater than 5 X the growth control. 
Similarly, pyridyl substituents (172,149,175) were not inhibitory towards Giardia. The 
substitution of a benzyl group (096) resulted in a 60% decrease in metabolic activity at 25 μM 
and when replaced with an anisyl group, activity improved to 100% inhibition at 25 μM, with 
an IC50 of 0.3 μM and an MIC of 2.8 μM at 24 hrs (150). 138 also had moderately good activity. 
Of the fused aromatic substituents only 146, 139, 132, 141 and 124 had antigiardial activity. 
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Both 139 and 132 were selective for Giardia over both mammalian and bacterial cells, however 
139 was more lethal toward Giardia than 132 with an MIC of 2.8 μM. 
A small number of the analogues with asymmetrical substitution of the molecule core were 
tested but none had antigiardial activity potent enough to pursue in this study (Table 5.5). 
A larger number of phenylmethylidene guanidines were probed for activity. Of these, only one 
(237) had antigiardial activity with an IC50 of 10.9 μM. All of the remaining analogues tested 
from this group were considered inactive (<50% inhibitory activity at 25 μM) for this study, 
suggesting that larger molecules are required to instigate antigiardial activity; or perhaps 
symmetry in the molecule is important (Table 5.6). 
A selection of 1,4-bis-pyrimidine analogues from the library with various aromatic ring and 
imine substitutions were tested (Table 5.7). Several of these analogues have similar aromatic 
and imine substitutions as those from the first 3 structural groups and the majority of these 
displayed similar activity profiles, suggesting the substituents are the instigators of activity 
rather than the core structure. There were several analogues that either gained or lost activity 
compared to the corresponding Schiff base, which may be due to a loss of flexibility within the 
molecule. 
Single Cl substitution on the aromatic ring of the bis-pyrimidine core, as seen with the parent 
molecule robenidine, had a large loss in activity when compared to robenidine with < 50% 
reduction in metabolic activity for 187. However, replacement of the Cl for a F or Br group 
restored activity similar to that seen with robenidine, as did a 3,4-F substitution. Methyl imine 
substitution with a 4-Cl moiety on the aromatic ring (204) afforded activity, however this was 
many fold higher than the corresponding Schiff base, 062, and a further decrease in activity was 
seen when the NH2 was removed from the central pyrimidine ring (185). As seen in previous 
structural classes, substitution with catechol moieties, whether mono-, di- or tri-, did not provide 
antigiardial activity. 4-CH3 substitution (195) did not result in activity, while the slightly larger 
4-C(CH3)3 alkyl group (198) significantly improved the IC50 when compared to robenidine but 
resulted in an unfavourable MIC. A 4-OCH3 (230) substitution also resulted in similar activity 
to the parent compound. While H-replacement of all aromatic or imine substituents with 
structure 1 (100) resulted in a loss of activity, the same substitution with structure 5 had 
antigiardial activity, although slightly higher than robenidine (199). Further imine substitution, 
either with O or CH3, significantly decreased antigiardial activity (Table 5.7). 
Substitution of the bis-pyrimidine structure with extended linkers, non-aromatic or isosteric 
ring replacements resulted in two analogues with IC50’s equal to or better than robenidine (245, 
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246) (Table 5.8). Although 096 has the same extended aromatic linker as 246, the antigiardial 
activity of 096 was limited. The remaining analogues in this group were not pursued further as 
the inhibition of Giardia at the screening concentration of 25 µM was not considered high 
enough. 
The final structural group investigated in this study had a triazine core (Table 5.9). Phenyl 
substitution with a 4-Cl in combination with an imine methyl group (as seen in 062 and 204) 
(208) resulted in a loss of activity, which is in contrast to the corresponding analogues 062 and 
204, both of which had similar substitutions but different core structures and the best 
antigiardial activity observed, however unselective. As seen with other analogues previously, 
catechol substitution of the aromatic rings resulted in no antigiardial activity (211, 207). While 
substitution with 4-Br was the only change to show activity from the limited molecules of this 
group that were investigated. 
After initial screening was completed and IC50 determined for active analogues select results of 
the screening assay were validated with a secondary activity assay looking at cell adherence. In 
this assay 812, 099 and 062 were chosen as representative compounds due to good antigiardial 
activity and availability of large enough quantities of compound. Adherence assays supported 
the original resazurin assay with a significant reduction in adherent trophozoites after treatment 







Figure 5.1 Inhibition of adherence of Giardia duodenalis by robenidine (812) and two structural analogues, 062 and 099. 
Cells were exposed to the compounds for 5 hours before staining. Stained cells were imaged at 10 X magnification and counted 
using DotCount™ software. Each assay was completed in triplicate. A – Adherence of control cells (each blue dot represents 
1 cell), B- adherence of cells exposed to robenidine (3 μg/ml) for 5 hours, C – graph of number of adherent trophozoites after 
exposure to each compound for 5 hours. Data expressed as mean number of trophozoites ± SEM.  * p-value 0.0448, ** p-value 
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Antibacterial IC50 MIC (µM) 










10.3±11.8 8.3 0.8 >25 25 83.1±4.4 N 




















110.7±5.3 - - - - - N 
118 2, 5-F 99.8±14.9 - - - - - N 






- - - - - N 












93.3±18.1 - - - - - N 
105 2,3,4-OH 108.6±8.2 - - - - - Y 
a not progressed due to non-selective activity or unsatisfactory screening results at 25 µM. * concentration of 




Table 5.3 Antigiardial activity of 1,3-Diaminoguanidine Schiff base analogues with imine substitutions 
 
 










IC50 MIC (µM) 








0±0 1.8 0.5 >25 25 79.1±5.5 N 





CH3 0±0 0.2 0.6 2.8 2.8 -
a Y 








CH3 0±0 0.4 4.3 >25 25 - Y 






- - - - - N 
a not progressed due to non-selective activity or unsatisfactory screening results at 25 µM. * concentration of 





Table 5.4 Antigiardial activity of 1,3-Diaminoguanidine Schiff Base analogues with extended linkers and nonaromatic and 
isosteric phenyl ring replacements 
 
























H 0±0 0.1 0.4 
>2
5 
2.8 87.4±3.7 N 
132 
 
H 0±0 0.7 1.6 
>5
0 
25 97.1±0.7 N 
124 
 








H 0±0 0.3 0.3 2.8 2.8 -a Y 
146 
 
H 0±0 1.6 1.4 25 8.3 - Y 
141 
 
H 0±0 0.3 1.5 25 8.3 - Y 
138 
 
H 0±0 0.4 3.7 
>2
5 
25 - Y 
096 
 





H 96.3±6.6 - - - - - N 
144 
 
H 96.9±41.8 - - - - - N 
147 
 


















- - - - - N 
175 
 












- - - - - N 
a not progressed due to non-selective activity or unsatisfactory screening results at 25 µM. * concentration of 

















control)* Antibacterial  IC50 
MIC 
(µM) 
226 CONHCH2CH3 96.0±2.7 -
a - - N 
224 COOCH2CH3 72.5±8.3 - - - N 
229 
 
57.5±2.0 - - - N 
227 
 
100.6±0.8 - - - N 
225 COOCH2CH(CH3)2 87.1±2.6 - - - N 
a not progressed due to non-selective activity or unsatisfactory screening results at 25 µM. * concentration of 







Table 5.6 Antigiardial activity of substituted phenylmethylidene guanidines. 
 
ID R R’ 
Inhibition 








IC50 MIC (µM) 







0±0 0 10.9 >25 25 -a Y 
235 2-F, 4-Cl H 89.2±13.3 - - - - - Y 




H 83.6±5.7 - - - - - Y 








90.5±4.7 - - - - - Y 
042^ 2-CF3 H - - - - - - N 
041^ 4-CF3 H - - - - - - Y 
052^ 3-Cl H - - - - - - Y 




CH3 - - - - - - Y 
a not progressed due to non-selective activity or unsatisfactory screening results at 25 µM, ^ only screened at 50 




Table 5.7 Antigiardial activity of 1,4-bis pyrimidine analogues with mono-, di-, tri- and poly-substituted aromatic rings, 
imine substitution. 
 












IC50 MIC (µM) 
5 hr 
24 
hr 5 hr 
24 
hr 




H 0±0 2.5 0.04 25 25 - N 
222 3,4-F H 0±0 0.5 0.7 25 2.8 - N 
193 4-Br H 0±0 4.0 1.2 25 2.8 - Y 
220 4-F H 0±0 0.6 0.7 25 8.3 - Y 
199 H H 0±0 0.9 7.3 25 25 - Y 
204 4-Cl CH3 0±0 2.4 3.2 >25 25 - Y 
197 3-OH H - - - - - - Y 
125 
 
195^ 4-CH3 H - - - - - - Y 





H 65.7±4.5 - - - - - N 
194 H O 69.5±20.1 - - - - - N 
184 H CH3 88.8±6.8 - - - - - Y 
242 2,5-OH H 106.6±5.3 - - - - - N 
244 2,3-OH H 117.2±34.4 - - - - - Y 
243 3,4-OH H 81.1±3.3 - - - - - N 




68.0±16.0 - - - - - N 
185 4-Cl CH3 30.1±11.1 - - - - - N 
187 4-Cl H 57.1±1.5 - - - - - N 
a not progressed due to non-selective activity or unsatisfactory screening results at 25 µM, ^ only screened at 50 




Table 5.8 Antigiardial activity of 1,4-bis pyrimidine analogues with extended linkers and nonaromatic and isosteric phenyl 














IC50 MIC (µM) 
5 hr 
24 





0±0 5.5 0.7 25 2.8 -a Y 
246 
 
0±0 7.7 0.04 >25 25 - Y 
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45.0±18.2 - - - - - Y 
239 
 
78.3±13.1 - - - - - Y 
238 
 
99.6±9.3 - - - - - N 
241 
 
76.9±1.9 - - - - - Y 
a not progressed due to non-selective activity or unsatisfactory screening results at 25 µM. * concentration of 




Table 5.9 Antigiardial activity of robenidine analogues with a triazine core 
 
 



















H 0±0 0.3 2.7 25 25 - Y 




H 65.2±14.9 - - - - - N 




H 77.8±5.0 - - - - - Y 
a not progressed due to non-selective activity or unsatisfactory screening results at 25 µM. * concentration of 




5.5.2 Recovery assay 
To determine the long-term effect on Giardia of short term exposure to robenidine and 13 novel 
analogues, cells were exposed to the analogues for 5 hours before drug withdrawal. Of the 14 
compounds tested 4, including robenidine, resulted in the inability of Giardia to recover 48 hrs 
post compound removal (Figure 5.2). The remaining 10 compounds had growth patterns similar 
to the no-treatment control. Metronidazole exposed cells were also able to recover after 5 hrs 
exposure. The ability of 139, 135 and 109 to prevent the growth of Giardia cells after short 
exposure times is an advantage over compounds that require longer exposure periods to have a 
long lasting effect. Another advantage of these compounds, over the lead robenidine and 
commercially available drugs, is the selectivity for Giardia over bacterial and mammalian cells. 
In addition, 139 and 135 both had improved efficacy against Giardia when compared to 
robenidine, at least halving the IC50, Based on the aforementioned in vitro results, 135 and 139 
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Figure 5.2: Recovery assay of Giardia duodenalis exposed to robenidine and selected robenidine analogues. Giardia 
trophozoites were exposed to the analogues for 5 hours before centrifugation to remove the compounds. Cell numbers were 
determined at 24 and 48 hrs post exposure. Error ± SD. Metronidazole (Mz) and growth control included on all figures as a 
comparison. 812, 135, 139, 198, 109, 124 were all significantly different than the growth control at 24 and 48 hrs according 
to a t-test, p<0.001. 
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5.5.3 Mechanism of action 
Despite robenidine being used for the past 40 years the mechanism of action is not known. 
Previous studies of the mechanism of action of robenidine have been inconclusive with some 
suggesting that ATPase is the primary target while others have identified no obvious 
morphological effect in E. tenella on mitochondria or the nucleus, with chiefly the golgi body 
and endoplasmic reticulum being affected (Lee and Millard, 1972; Wong et al., 1972). In the 
same study, swelling of the perinuclear space was noted by the authors who suggested this 
could be due to the overproduction of proteins potentially indicating an increase in metabolism 
causing the cells to self-destruct (Lee and Millard, 1972). In this study, we performed electron 
microscopy studies to try to elucidate a possible mechanism of action of robenidine and the two 
most promising analogues 135 and 139.   
Electron microscopy showed gross morphological changes in the trophozoites after 1 hour of 
exposure to robenidine (Figure 5.3). TEM studies revealed that the treated trophozoites 
developed extreme membrane blebbing, most significantly affecting the adhesive disc, 
scattered with electron dense material. In addition, unusual vacuolar membranous structures 
appeared within the cytoplasm. Several trophozoites also exhibited rupturing of the dorsal 
cytoplasmic membrane and all observed trophozoites had various degrees of disintegration of 
the cytoplasmic space. SEM studies also showed extreme membrane blebbing, as seen in TEM, 
after 2 hour of exposure. Furthermore, these images showed that there was severe damage to 
the cell wall of the engorged adhesive disk with distinct lesions observed on the surface. Based 
on the electron microscopy results of this study it appears that robenidine exposure results in a 





Figure 5.3 Transmission electron microscopy of Giardia duodenalis trophozoites exposed to 6 ug/ml robenidine for 1 hour. 
Image A - demonstrating extreme membrane blebbing at the adhesive disk and development of membranous structures within 
the cytoplasm, Image B – magnification of the membranous structures observed in Image A, Image C –membrane blebbing and 








SEM studies with cells exposed to 135 and 139 at 3 X the MIC for two hours also demonstrated 
significant morphological changes. While 135 and 139 are structurally related to robenidine the 
terminal moieties are quite distinct. While there were similarities between all three compounds 
in destruction of the adhesive disc (Figure 5.4-5.7), the membrane disintegration caused by 
robenidine was not as distinct with 135 and 139. In addition to membrane degradation both 135 
and 139 caused severe cell swelling, with cells taking on a spherical conformation, a feature 
which was not observed after exposure to robenidine (Figure 5.6 -5.7). After exposure the 135 
aggregates of trophozoites were observed suggesting that 135 may have an additional 
mechanism of action (Figure 5.6). 
 
Figure 5.4 Scanning electron microscopy of Giardia duodenalis TOP: unexposed trophozoites, BOTTOM: exposed to 
metronidazole (3 X IC50) for 2 hours, both dorsal and ventral views. 
 
 It is possible that robenidine causes the plasma membrane of the protistann to become 
destabilized, altering membrane properties leading to cell swelling and modifications of the 
cytoplasmic space. Another possible theory is that robenidine has a similar mechanism of action 
as the thiazolides which demonstrate a disintegration of the cytoplasmic space as observed by 
TEM and development of membrane ruptures on the adhesive disc resulting in a loss of osmotic 
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potential (Muller et al., 2006).  In addition, research into the mechanism of action of CGP 
40215A, effectively a structural analogue of robenidine where the chlorides have been 
substituted with amine groups, identified a strong bond with the AT region of DNA (Nguyen 
et al., 2002). The strong bond was facilitated by the guanidine backbone which is conserved in 
robenidine and both 135 and 139, potentially providing another alternative mechanism of action 
for this series of compounds. The binding of robenidine analogues with appropriate structural, 
spatial and hydrogen bond characteristics to the AT region of DNA could result in a cascade of 
events resulting in a disruption of normal cellular process and eventually, cell death. Although 
135 and 139 also damage the cell membrane this damage is not to the extent of that induced by 
robenidine in the same period of time, therefore, it appears to be a secondary mechanism of 
action. The most distinct difference observed in 139 treated cells compared to non-treated cells, 
and also present in the populations of 135 treated cells, was extensive cell swelling resulting in 
a loss of distinctive cell features. Finally, 135 appeared to cause conglomeration of trophozoites, 





Figure 5.5 Scanning electron microscopy of Giardia duodenalis exposed to robenidine (812) (3 X IC50) for 2 hours. Images 





Figure 5.6 Scanning electron microscopy images of Giardia duodenalis exposed to 135 (3 X IC50) for 2 hours. Image A-B 









Figure 5.7 Scanning electron microscopy of Giardia duodenalis after exposure to 139 (3 X IC50) for 2 hours. Image A-B 







5.5.4 In vivo toxicity of select analogues 
Of the 13 most promising analogues (those with irreversible antigiardial activity, no 
antibacterial activity or mammalian cell toxicity) 2 were chosen for preliminary in vivo toxicity 
testing, based on in vitro toxicity, MIC, recovery assays, and structural diversity of the 
analogues, namely 135 and 139. Metronidazole and 812 were also included. Neonatal mice 
were treated orally for 3 days with 100 mg/kg of the compounds or saline or formulation only 
and no behavioural signs of toxicity were observed. 
5.6 Conclusion 
In this study we demonstrate that robenidine and several analogues at the concentrations tested 
have potent rapid activity against G. duodenalis in vitro with no observed in vivo toxicity. In 
conclusion the analogues investigated in this study show excellent potential as future 
antigiardial agents as they are potent, relatively quick acting and have the potential to 
concentrate at the target site due to aqueous insolubility. This study also moved a step closer to 
determining the mechanism of action of robenidine and two promising analogues, 
demonstrating that severe cell damage is acquired after only 1 – 2 hours of drug exposure. 
However, further study is required to elucidate the exact mechanism of action. In addition, both 
135 and 139 displayed no toxic effects in neonatal mice following oral administration of doses 





Chapter 6: Development of Animal Models of Giardiasis
139 
 
Chapter 6.1: Cross-Species Transmission of Giardia duodenalis in Livestock 
Introduction: 
Background: Current models of human giardiasis infection usually involve the use of rodents, 
either gerbils or more commonly mice. While these models have their advantages including 
small size and animal availability, there are several disadvantages of using rodent models in the 
evaluation of drugs for human disease. Infection and disease progression is highly dependent 
on mouse strain and trophozoite infection number as well as mouse age (Byrd 1994). Other 
models using neonatal mice are limited by the development of the mouse immune system, 
which clears the infection.  
Although infection models in mice are improving significantly, accurately portraying 
symptoms seen in human disease, it has been reported that mice can behave very differently to 
humans when treated with experimental compounds. While a compound may be effective in a 
mouse model it could still be ineffective in human trials. It has been reported that pig models 
are much more likely to be predictive of therapeutic outcome in humans than rodent models. In 
addition, pigs are much more similar to humans in relation to the immune system (>80% 
analysed features similar, <10% in mice), anatomy including the gastrointestinal tract, genetics 
and physiology than mice are to humans (Kararli, 1995; Meurens et al., 2012; Miller and E., 
1987; Zhang et al., 2013). 
A giardiasis model in pigs would have several advantages over mice due to the similarities 
mentioned above (Meurens et al., 2012; Zhang et al., 2013). Pigs are becoming a favoured large 
animal model for many areas of medical research including toxiciology as it is believed that 
pigs will respond to novel agents in a way that is more predictive of human reactions than 
rodents (Kararli, 1995). 
Therefore, in this study we attempted to establish an infection model in post-weaned piglets in 
an effort to mimic human giardiasis infection and provide a model for the development of 
human antigiardial agents. 
Pigs have been reported to be infected with assemblage A (a strain infectious to humans) and 
assemblage E (a livestock specific strain, though recent reports have documented infection in 
humans with this assemblage) based on PCR analysis of faeces (Armson et al., 2009). In 
addition, a heavy infection in pigs caused by an assemblage E isolate was confirmed by the 
isolation of trophozoites from the GIT (Koudela et al., 1991). As an initial step in the 
establishment of a pig giardiasis model for the development of anitgiardial agents, cysts isolated 
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from infected calves (chosen because they will provide the number of cysts needed and should 
contain cysts of assemblages infectious to pigs) were used to infect pigs, in the hope that a 
reliable model of giardiasis could be established in swine. 
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Giardia duodenalis is a ubiquitous enteric parasite that infects a wide range of mammals 
including humans. Molecular characterisation of G. duodenalis has identified eight 
Assemblages (A-H) with different host specificities, livestock are predominantly infected with 
assemblage E. An understanding of the transmission dynamics of assemblage E between 
different livestock hosts is lacking, but is important to better understand the spread of infection 
on farms. In the present study, we attempted to infect pigs with a calf derived Assemblage E 
isolate of G. duodenalis. No infection was observed in the pigs and further research is required 
to determine the degree of host-specificity within livestock species. 
Keywords: Giardia transmission livestock 
6.1.3 Article: 
Giardia duodenalis (syn. intestinalis, lamblia) is a ubiquitous enteric parasitic protist that can 
infect a broad range of mammalian hosts. The parasite is capable of causing significant 
pathological changes to the intestine, resulting in a malabsorption syndrome (Buret, 2007), but 
clinical signs can range from asymptomatic infections to short term bouts of severe diarrhoea 
to chronic infections that can cause malnutrition and developmental delays (Berkman et al., 
2002; Homan and Mank, 2001; Lengerich et al., 1994). Recent research has linked Giardia 
infection in humans with the development of secondary diseases such as irritable bowel 
syndrome and chronic fatigue (Hanevik et al., 2014; Wensaas et al., 2012) and in production 
animals, infections in livestock may adversely affect weight gain resulting in production losses 
(Olson et al., 1995). 
Despite the impact G. duodenalis has on human and animal hosts, cross-species transmission 
of G. duodenalis remains poorly understood. There is extensive debate into the potential host 
specificity of various G. duodenalis isolates and the likelihood of transmission of G. duodenalis 
between various host species. In particular, the zoonotic potential of G. duodenalis has resulted 
in several studies evaluating the cross-species infectivity, but few studies have directly 
demonstrated transmission of Giardia from an animal source to humans. Giardia derived from 
gerbils was found to infect a human volunteer (Majewska, 1994), however the genotypic 
characterisation of the isolate was lacking. The majority of cross-transmission studies have 
investigated the zooanthroponotic potential of human derived isolates of G. duodenalis to infect 
various animal hosts. The results of these studies were mixed, with some isolates able to cause 
infection between hosts, while others could not cause infection between hosts. These studies, 
while shedding considerable light on cross-species transmission of G. duodenalis, lacked 
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molecular characterisation of the isolates used (Erlandsen et al., 1988; Gasser et al., 1987; 
Hewlett et al., 1982; Majewska, 1994; Visvesvara et al., 1988).  
With the development of molecular tools, recent research has focused on the molecular 
characterisation of a large number of G. duodenalis isolates derived from different hosts in the 
hope of better understanding the epidemiology of this parasite. These studies have been 
completed in various parts of the world with a range of hosts. To date, within the species G. 
duodenalis, there are eight distinct assemblages designated A-H (Ryan and Caccio, 2013). The 
host range of these assemblages has been examined based on characterisation of G. duodenalis 
isolated from the faeces of different hosts and this has led to the proposal of G. duodenalis as a 
species complex, with each assemblage representing a distinct species, due to the genetic 
variation observed between assemblages (Monis et al., 2003). It is currently accepted that 
Assemblages A and B are the main assemblages to commonly cause infection in humans, but 
these Assemblages have also been detected in the faeces of other mammals, including dogs and 
cattle. Assemblages C and D are generally limited to dogs but assemblage C has been reported 
in the faeces of humans in China and Slovakia and assemblage D in German travelers (Broglia 
et al., 2013; Liu et al., 2014; Strkolcova et al., 2015). Until recently, assemblage E was 
considered to only infect hoofed livestock, however recent studies have identified assemblage 
E in the faeces of humans in Egypt, Brazil and Australia (Abdel-Moein and Saeed, 2016; 
Fantinatti et al., 2016; Foronda et al., 2008; Helmy et al., 2014; Scalia et al., 2016; Zahedi et 
al., 2017). In one study, assemblage E was detected in the faeces of 62.5% (25/40) of children 
living in agricultural areas in Egypt (Abdel-Moein and Saeed, 2016). More recently, in 
Australia, assemblage E was detected in 6.8% (6/88) of Giardia-positive faecal samples from 
Queensland (Zahedi et al., 2017). Similarly, Assemblage F, although mainly found in cats, has 
been reported in the faeces of humans in Ethiopia (Gelanew et al., 2007). Assemblages G and 
H have only been reported in rats and marine mammals respectively to date. While molecular 
genetic typing of Giardia cysts or DNA excreted in the faeces can classify isolates into the 
appropriate assemblage and provide information on the potential host range, the cross-species 
transmission of different isolates cannot be definitively determined using these methods. In 
addition, the majority of research into G. duodenalis has focussed on humans, however G. 
duodenalis is also known to have a negative impact on production animal health. Previous 
studies in ruminant models have shown that infection with G. duodenalis causes changes in the 
intestinal microvilli of the host resulting in decreased nutrient absorption (O'Handley et al., 
2000) potentially leading to decreased weight gain and subsequent production loss (Olson et 
al., 1995). Despite the potential impact giardiasis has on production animals, the cross-species 
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transmission of G. duodenalis between livestock species is not well understood. While it is 
known that hoofed livestock are predominantly infected with assemblage E isolates, they can 
also be infected with assemblage A and assemblage B isolates.  
In this study, we attempted to establish a Giardia infection in pigs using cysts obtained from a 
dairy calf in order to better understand the pathogenesis of the infection in pigs and the response 
of the infection to chemotherapy. Here, we report the results of the infection trial in order to 
provide important information on the cross-species transmission of Giardia. 
For this study, 24 weaned piglets (large white x landrace), ~8 weeks old, weighing between 9 -
17 kg, were obtained from a commercial piggery in South Australia. The piglets were confirmed 
negative for Giardia cyst excretion via zinc sulphate faecal floatation on two separate occasions 
prior to transfer to the trial facility, once at pre-weaning and once at ~ 6 weeks old. Upon arrival 
(Day 1) pigs were weighed and randomly assigned to 4 groups. The piglets were housed in 
groups of six in adjacent concrete floored pens using a deep litter system (straw), and contact 
between groups was limited. Once allocated to groups, they were infected orally with ~6 x104 
G. duodenalis cysts obtained from a naturally infected calf. During the study, pigs were fed a 
standard non-medicated pelleted piglet food (Lienert Advantage 500, Lienert Australia) ad lib 
until day 7 when they were fed a follow on post-weaning pellet (Leinert Advantage 300, Lienert 
Australia) until the end of the trial. Pigs were monitored daily for clinical signs of infection 
including diarrhoea, lethargy and inappetence. On days 4, 7, 11, 15, 23, 25 and 30, faecal 
samples (1g per animal) were obtained from piglets via rectal stimulation and examined for the 
presence of Giardia cysts. On day 18, a randomly selected pig was sacrificed to determine 
trophozoite numbers in the small intestine. On day 36 all pigs with a positive faecal cyst count 
were sacrificed and ~ 1cm2 sections of the ileum, jejunum and duodenum were collected and 
parasite numbers enumerated. This study was approved by the University of Adelaide Animal 
Ethics Committee, permit number S-2014-064 
To prepare the Giardia inoculum, a fresh (<5 days) faecal sample from an infected calf with a 
high cyst count was suspended in water and filtered through surgical gauze. The liquid was then 
layered over sucrose (specific gravity 1.15) in 50 ml centrifuge tubes and centrifuged at 900g 
for 10 minutes. The top layer and the gradient were transferred to a clean tube and centrifuged 
at 900 g for 10 minutes. The supernatant was discarded and the pellet resuspended in water. 
The number of cysts in 10 µl of water was enumerated and the volume adjusted to give a cyst 
density of 6x104 cysts/ml. Cysts were kept at 4°C until infection of pigs (< 2weeks). The 
viability of the cysts was tested following previously described methods (Bingham and Meyer, 
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1979). Purified cysts were suspended in HCl pH 2 (in a ratio of 1:10), washed and suspended 
in TYI-S-33 medium and observed for excystation. 
A previously described method was used to determine faecal Giardia cyst number (O'Handley 
et al., 2000). Approximately 1 g of faeces was suspended in 7 ml of water then filtered through 
a gauze swab. The filtrate was layered over 5 ml of sucrose (specific density 1.15) in a 15 ml 
centrifuge tube. The samples were centrifuged at 800 x g for 5 minutes. The top layer of liquid, 
including the gradient was placed into a clean centrifuge tube and centrifuged again at 800 x g 
for 5 minutes. The supernatant was discarded and the pellet resuspended in 1 ml of water. 10 
µl was air-dried on a Poly-L lysine treated slide (Emgrid Australia), then 20 µl of anti-Giardia 
specific fluorescent antibody (Sapphire Biosciences) was layered over the top of the dried 
sample and incubated for 30 minutes before mounting a coverslip over the sample and counting 
the number of cysts under a fluorescent microscope. 
To identify trophozoites in the gastrointestinal tract (GIT) of trial animals, sections of the ileum, 
duodenum and jejunum were removed, cut to approximately 1cm lengths, then incised 
longitudinally into the lumen and placed into sterile cold PBS. The tissue was rocked for 30 
minutes at room temperature to detach trophozoites. Samples of supernatant (20 μl) were placed 
onto a glass slide and covered with a coverslip then viewed microscopically for trophozoites.  
For PCR analysis, cysts from the inoculum and positive pig faecal samples were purified as 
above then purified cysts were freeze-thawed 5 times before DNA was extracted using a Power 
Soil DNA Kit (MoBio, Carlsbad, California). Extraction blanks (no faecal sample) were used 
in each extraction group. Purified DNA was stored at -20°C prior to PCR.  
Nested PCR amplification of the triose phosphate isomerase (tpi) gene using assemblage A, B 
and E specific primers was performed as previously described (Geurden et al., 2008; Levecke 
et al., 2009; Sulaiman et al., 2003). The glutamate dehydrogenase (gdh) gene was amplified 
with a nested PCR using GDHeF and GDH2 primers in the primary reaction and the GDHiF 
and GDH4 primers in the secondary reaction following the PCR reaction protocol of Caccio et 
al (2008) with the annealing temperature changed to 55°C and 52°C for the primary and 
secondary reactions respectively (Caccio et al., 2008; Read et al., 2004). The amplified DNA 
from the secondary tpi PCR products were separated by gel electrophoresis and purified for 
sequencing using an in house filter tip method (Yang et al., 2013). Purified PCR products were 
sequenced independently using an ABI Prism™ Dye Terminator Cycle Sequencing kit 
(Applied Biosystems, Foster City, California) according to the manufacturer’s instructions at 
64°C, 62°C and 67°C annealing temperature for assemblages A, B and E tpi PCR products, 
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respectively (Geurden et al., 2008; Levecke et al., 2009; Read et al., 2004). Amplified DNA 
from the secondary gdh PCR were then directly Sanger sequenced by the Australian Genome 
Research Facility. 
All random samples taken from the original herd before transfer of the trial piglets to the 
research facility were negative for Giardia cysts via sucrose floatation or immunofluorescent 
detection. Samples collected on days 4, 7, 11 and 15 were all negative for Giardia cysts based 
on immunofluorescent detection. The pre-patent period of giardiasis varies depending on 
species and source of infection. Previously it has been reported that the pre-patent period can 
be up to 23 days in beavers given human derived cysts however a prepatent period in pigs could 
not be identified (Erlandsen et al., 1988). As no cysts were detected during the first 15 days, a 
random pig was chosen on day 18 to determine if there were any trophozoites present within 
the GIT. All sections collected (duodenum, ileum and jejunum) were negative for trophozoites, 
indicating that no infection had established to date. In order to take into account a longer 
prepatent period, faecal collection was continued for a further 15 days. One faecal sample 
collected on day 23 was positive for Giardia cysts with a faecal count of ~ 1000 cysts/gram of 
faeces. A faecal sample from the same piglet, as well as a piglet in the same pen and one in a 
separate pen, were positive for Giardia cysts on day 25 with cyst counts of between 60 and 300 
cysts/gram of faeces. On day 30, only 1 animal remained positive with Giardia cysts (~66 cysts 
per gram of faeces), all other animals were negative. On day 36, all three pigs that had 
previously shown a positive faecal cyst count were euthanized and samples were taken from 
the ileum, duodenum and jejunum. A single trophozoite was identified in the mid-jejunum of 
one pig with a positive faecal cyst count. Both of the other animals and all other intestinal 
sections were negative for trophozoites. The faecal material of the euthanized pigs was also 
negative for cysts.  
DNA sequences from the inoculum used to infect the pigs and the positive samples collected 
were compared. Collection of the trophozoite DNA was also attempted but this was 
unsuccessful. The initial inoculum and DNA from cysts excreted in a single sample from one 
of the pigs were typed as assemblage E at both the tpi and gdh loci. The tpi locus was highly 
conserved between both samples however there were 4 single nucleotide polymorphisms 
(SNPs) in the gdh region between the calf sample used as the inoculum and the pig sample. 
Each sample aligned 100% with previously described samples in Genbank over a 585 bp 
segment. The calf sequence from this study had 100% similarity to another calf sample obtained 
from the same region (Roseworthy, South Australia), while the pig gdh sequence had 100% 
similarity to a pig derived isolate, P-15 which is in axenic culture but was originally initiated 
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via trophozoites collected from the intestine of infected pigs in Europe (Genbank accession 
numbers: AY178740 and AY178741). The significance of this finding is yet to be determined 
as further study would be required to determine if the mutational changes represent natural 
genetic variation or a shift towards host adaption in a different livestock species.  
Although a small number of pigs (12%) were excreting Giardia cysts in their faeces, the number 
of cysts/gram of faeces was very low and the time until cysts were observed in the faeces was 
prolonged. Both of these factors indicate the possibility that the pigs re-ingested the original 
inoculum, which could have passed through the pigs following the initial challenge. 
Nevertheless, only a single trophozoite was observed in a single section of small intestine from 
one of the four pigs sacrificed. Thus, based on the results of this study, these pigs were not a 
suitable host for Giardia obtained from a calf. The results demonstrate a low potential for cross-
species establishment of infection with the isolate used.  
Previous molecular studies in Australia and overseas have detected G. duodenalis in pigs at a 
frequency between 0.1 and 41 %. One such study in Australia identified post-weaned piglets 
had the highest prevalence of G. duodenalis (32 %), with the majority of isolates belonging to 
assemblage E and the remaining isolates belonging to assemblage A (Armson et al., 2009). In 
addition, another study in Europe confirmed giardiasis in post-weaned pigs (8 weeks) by 
isolation of trophozoites from the GIT (Koudela et al., 1991). Further study in Europe 
demonstrated the cross-species transmission of a pig derived G. duodenalis isolate to goat kids 
suggesting low host specificity of the isolate used, however the neonatal goat kids were fed 
with cow’s milk, removing the GIT protective effect of the parent milk and the isolate used to 
infect the kids was not characterised (Koudela and Vitovec, 1998). Despite reports of G. 
duodenalis infection occurring naturally in pigs, in the present study, post-weaned piglets were 
unable to be unequivocally experimentally infected, which could be due to the possible host 
specificity of the inoculum. However, it is possible that if younger piglets were used (e.g. 
preweaned) or the pigs were immunocompromised, an infection may have established with the 
isolate used. 
This study demonstrates that using an assemblage E isolate of G. duodenalis from cattle we 
were unable to establish a reliable infection in pigs. Further work is warranted to understand 
the cross-species transmission of G. duodenalis assemblages and the role it plays in livestock 
health and production. 
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In this study we describe a neonatal mouse model of Giardia infection for the development of 
novel antigiardial compounds. Using this model, mice were consistently infected with the 
Assemblage A BAH2c2 strain which had been maintained in axenic culture, with 105 
trophozoites per animal recovered. This model proved to be robust, consistent and ideal for 
preliminary drug efficacy trials and further drug development. 
6.2.3 Article 
Giardia duodenalis (aka. G. lamblia) is one of the most common enteric pathogens worldwide 
and is especially prominent in children in developing nations, often resulting in chronic 
infections with long lasting side effects such as malnourishment, developmental delays and 
general failure to thrive (Berkman et al., 2002; Homan and Mank, 2001; Lengerich et al., 1994). 
In addition, a correlation between giardiasis and the development of other diseases such as 
irritable bowel syndrome has also been established (Hanevik et al., 2014). Although there are 
current treatments available for giardiasis, treatment failures occur often, due in part to poor 
adherence to dosing schedules, unpleasant side effects and the development of drug resistance 
in the parasite (Jokipii and Jokipii, 1979; Wright et al., 2003). An important step in the 
development of novel chemotherapeutics for the treatment of giardiasis is preliminary 
evaluation of potential antigiardials in animal models, as in vitro efficacy does not always 
translate to in vivo efficacy (Sande and Zak, 1999).  
Attempts to develop mouse models of giardiasis have been undertaken in both adult and 
neonatal mice. In immunocompetent adult mice only one characterised human derived isolate 
(GS(M)/H7 – assemblage B) was able to cause infection over several weeks. However, 
development of infection is highly dependent on mouse strain and intestinal microflora (Byrd 
et al., 1994; Singer and Nash, 2000). Other models using cysts of uncharacterised human 
derived strains (e.g. H3 – assemblage B) have been shown to cause longer infections. However, 
these models are not ideal for drug development as the strains cannot be characterised in vitro, 
they require the animals be maintained on an antibiotic cocktail (which could interfere with the 
activity of novel compounds) (Bartelt et al., 2013; Singer and Nash, 2000)In addition, not all 
isolates can cause successful infections in mice, identified by the shedding of cysts and presence 
of trophozoites in the intestine upon necropsy. The neonatal mouse model, on the other hand, 
is ideal for early antigiardial compound testing as pre-weaned pups have been shown to be 
susceptible to a wide variety of Giardia strains including those available in axenic culture 
allowing comparison between different strains and in vitro and in vivo results (Lemee et al., 
2000; Reynoldson et al., 1991). 
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In this study we describe modifications of the suckling mouse model of Giardia infection first 
described in 1983 and used in preliminary testing of albendazole efficacy in the 1990’s (Hill et 
al., 1983; Reynoldson et al., 1991). The Giardia strain used, BAH2c2, was isolated from an 
Australian human patient, maintained in axenic culture (TYI-S-33 media, passaged 2-3 times 
per week) and has not previously been reported to infect mice (Wielinga et al., 2011). The 
additional modifications made to this model include highly sensitive techniques for detection 
and monitoring of infection including fluorescent antibody staining and qPCR. These 
modifications make the identification of infection more accurate and reliable. 
All work was performed with the approval of Murdoch University Animal Ethics Committee 
(Permit #R2855/16) Animals used were arc:arc (S) Swiss origin mice sourced from the Animal 
Resource Centre, Murdoch, Perth, Western Australia. Suckling mice were obtained when 6 
days old (7-13 mice per group, number of mice in initial trial determined using a power 
calculation with a confidence of 95%, and an estimated 30% of animals becoming infected) and 
were acclimatised for 2-3 days in the PC2 facility. Mice were housed in plastic cages with wire 
lids with food and water supplied ad lib. Housing and nesting material were also provided. All 
mice were inoculated when nine days old via oral gavage using a flexible gavage needle 
(Walker Scientific, Joondalup DC WA Australia 6919). In the initial establishment model mice 
were inoculated with either 1x104 or 1x105 Giardia duodenalis trophozoites of the P1c10 strain 
(a clone of the Portland 1 strain, previously shown to cause infection in neonatal mice) or the 
BAH2c2 strain (a clone isolated from a human from Woodanilling, south-western Australia 
(Meloni et al., 1990; Wielinga et al., 2011) in a volume of 100 µL of 0.9% saline. In all 
subsequent trials animals were inoculated with 1x105 trophozoites of the BAH2c2 strain in a 
volume of 100 µL of 0.9% saline. Faecal samples were collected by removing groups to a 
separate cage without bedding. Due to the small volume of faeces produced by neonatal mice, 
faecal samples were pooled by group in order to obtain sufficient sample for testing. Faeces 
were examined for cysts via sucrose gradient centrifugation and observed via optical 
microscopy, immunofluorescent microscopy as described previously and qPCR (O'Handley et 
al., 2000). Briefly, cysts were concentrated by sucrose gradient centrifugation (prepared in-
house, specific gravity 1.13, centrifugation: 900 X g, 5 minutes) and samples taken for each 
cyst detection method. For immunofluorescent detection, 20 μl of concentrated cysts were 
placed onto a glass slide (Polysciences, Inc., Warrington, PA United States 18976) and air dried. 
An aliquot of Giardia specific fluorescein-labelled antibody (Giardi-a-Glo, Sapphire 
Bioscience, Redfern NSW Australia 2016, 20 μl) was placed over the top of the sample and 
incubated at 37°C in a humidified box for 30 minutes. Excess antibody was removed by gentle 
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washing with phosphate buffered saline (PBS) and a coverslip was mounted onto a slide using 
aquapolymount (Thermo Fisher Scientific, Scoresby VIC Australia 3179). Samples were 
viewed with an Olympus BX41 microscope and the number of Giardia cysts/mg faeces 
calculated. The qPCR for the detection of giardial glutamate dehydrogenase (gdh) DNA in 
faeces was based on the method of Yang et al 2014.  The protocol used the primers gdhF1 F1 
5′ GGGCAAGTCCGACAACGA 3′, the reverse primer gdhR1 5′ 
GCACATCTCCTCCAGGAAGTAGAC 3′, developed by Yang et al., and the probe modified 
to include FAM as the reporter dye 5′-(6FAM)-TCATGCGCTTCTGCCAG BHQ2 3’ (Yang et 
al., 2014). Concentrated cyst material from the sucrose clarification was freeze-thawed five 
times using liquid nitrogen, before total DNA was extracted using a Purelink Genomic DNA 
extraction kit (Invitrogen, Thermo Fisher Scientific, Scoresby VIC Australia 3179).  Reactions 
were preformed using TaqPath qPCR mastermix (Thermo Fisher Scientific, Scoresby VIC 
Australia 3179) on a Quantstudio6 platform. At the end of the trial period, mice were euthanized 
via cervical dislocation and the entire small intestine was removed, incised longitudinally and 
placed in ice-cold PBS. Samples were chilled for at least 30 minutes before enumeration of 
trophozoites using a haemocytometer.  
The BAH2c2 strain with an inoculum of 1 x 105 cells/mouse was found to be the most promising 
in establishing infection in pups with 100% of animals infected in the first experiment and 
observation of cysts 13 days post-inoculation. The smaller inoculum of 1 x 104 cells only caused 
infection in 22% (2/9) of animals and no cysts were observed in the faeces. The P1c10 strain 
infected 8% (1/13) of mice at the highest inoculum used but failed to infect any mice at the 




















































































Figure 6.2.1 Experimental infection of neonatal mice with Giardia duodenalis. 1A: Establishment of infection 
with various strains and inoculum densities of G. duodenalis. Neonatal mice were infected at 9 days old with either 
the P1c10 or BAH2c2 strain of G. duodenalis. 15 days p.i. trophozoites were collected from the small intestine 
and enumerated. A – inoculum BAH2c2, 1 x 104 cells/mouse, 22% of mice infected; B – BAH2c2, 1 x 105 
cells/mouse,100% of mice infected (only subset had trophozoites counted); C  -P1c10, 1 x 104 cells/mouse, 0% of 
mice infected and D – P1c10, 1 x 105 cells/mouse, 8% of mice infected. 1B:  Reproducibility of infection of 
neonatal mice with the BAH2c2 strain of G. duodenalis. Mice were inoculated at ~9 days old with 1 x 105 
trophozoites/mouse of the BAH2c2 strain. Once cyst shedding had been observed, trophozoites were harvested 
from the small intestine and enumerated. Infection was established in 100% of animals based on the presence or 
absence of trophozoites in the small intestine. Error ± SD. Individual points represent single animals. 
 
Based on the initial experiment the BAH2c2 strain at the inoculum of 1 x 105 cells/mouse was 
chosen for future experiments. To ensure reproducibility between litters, infection with the 
BAH2c2 strain was repeated on two separate occasions. In both cases an infection was 
established in 100% of the exposed mice with faecal cysts observed 7-8 days post inoculum. 
Across all three replicates of the trial, a similar number of trophozoites was observed in 
intestinal samples (Figure 6.2.1). 
Three cyst detection methods were evaluated with immunofluorescence microscopy being the 
most sensitive, detecting the presence of cyst material in the faeces a day earlier than qPCR and 
traditional microscopy, and is easily used to quantify the number of cysts in a sample when the 
initial faecal weight of the sample is known. qPCR was the second most effective detection 
method giving a positive or negative answer while traditional microscopy was least effective 
(Table 6.2.1). In addition, qPCR and immunofluorescence do not require the specialist training 
and experience that is required for light microscopy. However, qPCR should be used in 
conjunction with microscopy detection, rather than as a stand-alone detection method, to ensure 
infection has been established, as the presence of gdh DNA does not necessarily indicate the 
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presence of viable cysts. Concentration of the cysts via sucrose gradient centrifugation was an 





(+/-) qPCR (+/-) 
Immunofluorescent microscopy 
(cysts/mg faeces) 
7 - + Positive but not quantified 
8 + + 97 
9 - + 60 
10 + + 59 
11 NT + 139 
Table 6.2.1 Comparison of three methods to detect Giardia infection in mice via faeces. Faecal samples from 
individual animals were pooled and subjected to sucrose gradient centrifugation techniques to concentrate cysts 
before preparation for microscopy or qPCR. Representative data from pooled samples collected in one experiment 
with 7 mice per group are shown (the final trial). NT – not tested. 
In this study we demonstrate that the neonatal suckling model is useful in the pre-clinical 
development of antigiardial agents as it is reproducible, predictable and easy to perform. It has 
demonstrated an improvement on previous models by utilising immunofluorescence to increase 
specificity and ease of cyst identification and qPCR for rapid identification of infection and 
confirmation of immunofluorescence results. This model has been developed specifically for 








The discovery and development of antimicrobials was one of the biggest advancements in 
medical history, providing an effective defence against the devastating consequences of 
infectious diseases. Although antimicrobials have played an important role in the advancement 
of medical, and veterinary, practise, infectious diseases still remain one of the leading causes 
of morbidity and mortality worldwide, in part due to infectious disease for which there are 
limited or no effective antimicrobials, including those included in the neglected diseases 
initiative. 
Antimicrobial resistance is also becoming a problem, with an increase in the detection, 
development and dissemination of antimicrobial resistance among populations of infectious 
disease causing organisms, reducing current treatment options. Simultaneously, a decrease in 
the investment into research and development is occurring, as investment returns are not as 
lucrative in comparison to pharmaceuticals for alternative applications (Cohen, 2000; French, 
2010; Norrby et al., 2005; Spellberg et al., 2004; Ventola, 2015). 
The development of novel antimicrobial agents is time consuming and costly, with one study 
suggesting 8-15 years from identification of novel agents to market entry, requiring > $2 billion 
(Gwynn et al., 2010; Tufts, 2014). With the current arsenal of antimicrobials rapidly becoming 
obsolete, other alternatives for traditional antimicrobial development are being sort, including 
the repurposing and redevelopment of currently know compounds (Oprea et al., 2011). 
In this thesis, the repurposing of robendine (an anticoccidial agent used in the poultry industry) 
was explored. This included the examination of a library of chemical analogues of robenidine, 
in addition to robenidine itself, for inhibitory activity against pathogenic bacterial species as 
well as the neglected protistann diseases, Leishmania donovani¸Trypanosoma brucei and 
Giardia duodenalis (syn. Giardia lamblia, Giardia intestinalis). 
7.2 General aims and chapter summaries 
This thesis explored the potential repurposing of robenidine and the antimicrobial efficacy of a 
library of robenidine analogues. It was found that robenidine and several analogues had 
antibacterial activity (chapter 2) that was targeted towards Gram-positive organisms. It was 
then identified, through the use of membrane permeabilising agents and the production of 
spheroplasts, that the target of the Gram-positive active analogues was present in Gram-
negative organisms (chapter 2 and 3). Furthermore, intrinsic activity towards Gram-negative 
bacteria was also identified with a small subset of analogues (chapter 3).  
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The potential for the use of robenidine and related analogues for the treatment of parasitic 
infections (other than coccidian infections) was also investigated. Subsets of the analogue 
library were screened for activity against Trypanosome brucei, Leishmania donovani (chapter 
4) and Giardia duodenalis (chapter 5).  
Several analogues were found to have potent activity against T. brucei. However, this activity 
was unselective, with toxicity to mammalian cells observed at similar concentrations (chapter 
4). Four (out of 19) analogues had potent and selective activity for L. donovani over mammalian 
cells with selectivity indices as high as 27 (chapter 4). Forty-six analogues were active against 
Giardia with greater than 50% inhibitory activity at 25 μM (chapter 5). Importantly 13 of these 
analogues were selective for Giardia over bacterial cells, limiting the potential for off target 
effects to beneficial microorganisms. Furthermore, 12 also had excellent in vitro toxicity 
profiles with little to no in vitro mammalian cell toxicity (chapter 5).  
In this thesis, analogues were identified with potent activity against each organism screened. 
With the exception of some antigiardial analogues, this activity was generally unselective, 
either exhibiting mammalian cell toxicity or also affecting other microbial cell types. As 
mentioned previously, there were several analogues identified that had selective antigiardial 
activity, not affecting bacterial organisms or mammalian cells, therefore, the remainder of this 
thesis focussed on the continued exploration of antigiardial activity. In vitro analysis of 119 
analogues available from the robenidine library, identified 13 with potent antigiardial activity 
that lacked antibacterial activity and mammalian cell toxicity (chapter 5). The long-term effect 
on Giardia of exposure to these analogues was determined (chapter 5). Three Giardia specific 
analogues were found to inhibit recovery of Giardia after only 5 hr exposure times. The effect 
of two of these lethal analogues, along with the lead compound, robenidine, was explored using 
electron microscopy to understand the site and mechanism of action (chapter 5). Scanning 
electron microscopy (SEM) demonstrated significant morphological changes to trophozoites 
including cell swelling and disruption of the cell membrane (chapter 5). SEM also highlighted 
the rapid action of these analogues with significant cell changes seen after only 2 hrs of 
exposure to these analogues. The in vivo toxicity of two of the most promising analogues, in 
addition to robenidine, was determined in suckling mice (chapter 5). Three week old mice were 
exposed orally to 100 mg/kg of each analogue, administered once per day for three days, with 
no behavioural or gross pathological signs of toxicity observed (chapter 5).  
The promising in vitro efficacy and selectivity in addition to no observable in vivo toxicity led 
to the development of an animal model of giardiasis for in vivo efficacy testing (chapter 6). 
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Initially, pigs were chosen as an appropriate model animal due to similarities in gut structure 
and function to humans (chapter 6.1). However, a satisfactory infection was unable to be 
established and the model was developed in the mice (chapter 6.2). As a part of this thesis a 
reliable suckling mouse model of giardiasis was successfully established using a human isolate 
of Giardia (chapter 6.2) which will be useful for future in vivo evaluation of the Giardia 
selective analogues identified in this thesis.  
7.3 Major findings, implications and future work arising from this thesis 
1. Antibacterial activity of robenidine and several analogues.  
The level of resistance to antimicrobials within the bacterial population is critical, with 
extremely limited treatment options for some infections and in some cases 50% risk of 
mortality due to a lack of effective treatments (Doi et al., 2017). The increasing inefficiency 
of antibacterials has far reaching implications for human health. Without reliable means to 
treat infections, the current advances of modern medicine, routinely performed, such as 
chemotherapy, transplantation and other complex surgeries, will carry greater risk due to 
the inevitability of untreatable bacterial complications (Brown and Wright, 2016; Doi et al., 
2017).  
Due to the urgent need for new antibacterial agents, this thesis identified the antibacterial 
potential of robenidine and 111 structural analogues for the first time. All of the analogues 
with efficacy in this study were intrinsically active against the Gram-positive organisms S. 
aureus and Enterococcus sp. including MRSA and VRE, with MICs and MBCs as low as 
2 µg/ml. Time-kill profiles demonstrated a bactericidal mechanism of action. This study 
included analysis of preliminary structure activity relationship data which facilitated a better 
understanding of chemical moieties enlisting antibacterial activity (chapter 2). In addition, 
it was shown that the target for several of the compounds was present in the Gram-negative 
pathogens E. coli and P. aeruginosa, when the outer membrane of the bacterium was 
compromised either partially using PMBN or almost entirely using sub-inhibitory 
concentrations of ampicillin (chapter 2 and 3). Further manipulation of the chemical 
structure led to the development of analogues with intrinsic Gram-negative activity (chapter 
3).  
Given the safety profile of robenidine (EFSA, 2004), the active analogues, identified here 
for the first time, have the potential to be developed as either narrow spectrum (those limited 
to Gram-positive activity) or broad spectrum (those with Gram-positive and Gram-negative 
activity) antibacterial agents. Future work in this area would involve toxicity and in vivo 
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evaluation of the most promising agents using animal models. It is suggested that the 
analogues with Gram-negative efficacy be the focus of future development as there is a dire 
need for new Gram-negative active agents, with limited options and upcoming potential 
drugs being identified and pursued (Boucher et al., 2013; Rice, 2008; WHO, 2017). 
There is also potential for the continued chemical development of the Gram-negative active 
analogues to improve efficacy and druggability and evaluate in vivo efficacy.  
 
2. Antitrypanosomal activity of robenidine and select analogues.  
Trypanosoma brucei is a flagellated extracellular parasitic protist that is endemic to 
Africa, transmitted by the Tsetse fly and infectious to humans and animals. There is 
currently a lack of safe and efficacious drugs to cure the disease, and with millions of 
people at risk of contracting the fatal (if left untreated) disease, there is a need to develop 
new treatments (Steverding et al., 2016). Although there is a need for the development 
of new agents, only a handful of papers describing potential new agents have been 
published in recent years (Buscher et al., 2017). As a part of this thesis, 19 analogues in 
addition to robenidine from the available library were tested for in vitro efficacy against 
the amastigote stage of the parasite. For the first time, 16 analogues of robeindine were 
found to have inhibitory properties against T. brucei at µM concentrations. 
Unfortunately, the inhibition was not selective for T. brucei with SI <10. However, there 
was evidence of a ‘non-flat’ SAR with variations in efficacy of different analogues and 
corresponding mammalian cell toxicity, providing a starting point for the chemical 
development of more specific T. brucei analogues and the potential for development of 
a new class of antitrypanosomal drugs. 
3. Antileishmanial activity of robenidine and select analogues. 
Leishmania donovani is one of the main causes of leishmaniasis, a disease that varies in 
clinical presentation from self-curing cutaneous leishmaniasis, which can leave 
devastating disfigurement, to potentially lethal visceral leishmaniasis (Tegazzini et al., 
2017). There are limited treatment options available for L. donovani, which all have 
significant drawbacks. The most recently developed antileishmanial treatment is 
miltefosine, which has a huge advantage over other available drugs as it is delivered 
orally. However, treatment with miltefosine requires almost 1 month of repeated 
administration, making patient compliance difficult. Furthermore, it has been associated 
with teratogenicity (Tegazzini et al., 2017). In addition, as is common with infectious 
diseases, development of resistance to antileishmanials has been reported and for some 
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drugs is widespread. With the limited compounds available, it is important to develop 
new agents as highlighted by the inclusion of L. donovani in the drugs for neglected 
diseases initiative. With this in mind, a small subset of robenidine analogues (n=19) 
were screened for antileishmanial activity in vitro. For the first time, as a part of this 
thesis, antileishmanial inhibitory activity of this library was identified. Four out of the 
twenty compounds screened had potent selective inhibitory activity towards L. donovani 
with IC50’s as low as 0.3 µM and SI’s ≥ 20.  
 
4. The antigiardial potential of novel analogues of robenidine.  
G. duodenalis is a ubiquitous intestinal parasite that can cause long-lasting adverse 
consequences including failure to thrive syndrome in children and has also been linked 
to chronic diseases such as irritable bowel syndrome (Buret, 2008; Halliez and Buret, 
2013). There are limited treatment options available which are continuing to decrease 
as drug resistance increases (Upcroft and Upcroft, 2001b; Wright et al., 2003).  
 
In vitro efficacy: In this study it was demonstrated that several structural analogues 
(n=46), in addition to robenidine itself, had antigiardial activity in vitro. Furthermore 
13 of the novel analogues demonstrated distinct advantages over robenidine including 
better in vitro safety profiles and selectivity for Giardia over bacteria (suggesting that 
the potential effect on gut microbiota would be limited). Three selective analogues were 
identified as being particularly promising, as trophozoites were unable to recover in 
vitro after short exposure times (5 hr). 
 
In vivo toxicity. The top two analogues (135, 139), in addition to robenidine, were 
administered to pre-weaned mice orally, 100 mg/kg, once per day for 3 days as a 
preliminary investigation of toxicity. No behavioural or gross pathological signs of 
toxicity were observed.  
 
Mechanism of action. The mechanism of action of robenidine against its original target, 
coccidia, is poorly understood, and the site and mechanism of action of these 
compounds against other parasites is not known (Lee and Millard, 1972; Wong et al., 
1972). As a part of this study, electron microscopy was used as an initial step to elucidate 
the mechanism of action of robenidine and the two most promising analogues against 
Giardia. Significant cell damage was observed using both SEM and TEM (robenidine) 
162 
 
or SEM (alternative analogues) after 2 hrs of compound exposure. Damage under the 
influence of all three compounds included disintegration of the adhesive disk, which is 
essential for disease progression as it is essential for attachment of Giardia trophozoites 
to the epithelial cells of the host. In addition, the novel analogues (139, 135) also caused 
cell swelling to the point that distinctive cell features, such as the adhesive disc and 
flagella, become unrecognisable. After treatment with 135, aggregations of cells, often 
with an unidentifiable number of cells, were observed. These studies highlight the 
structural and morphological changes induced by very short (≤ 2 hr) exposure to 
robenidine, 139 and 135. This study also highlights the similarities in effect between the 
analogues, such as membrane poration, particularly around the adhesive disc, as well as 
the differences in effect. Robenidine appears to have a much more pronounced effect 
on the adhesive disc than 135 and 139. In addition to the development of membrane 
pores, 135 and 139 cause extreme cellular swelling, which was not observed with 
robenidine in these studies. This could be directly related to the selectivity of 135 and 
139, as, in contrast to robenidine, they were selectively observed to inhibit Giardia 
trophozoites in vitro, with no antibacterial activity. 
 
5. Establishment of an animal model of giardiasis. 
In this thesis, potent (nM) selective antigiardial compounds that had irreversible effects 
on trophozoites were identified. Although promising in vitro efficacy was observed it is 
always necessary to determine in vivo efficacy as not all effects are translated in an 
animal host. In order to test in vivo efficacy, a reliable model of infection is required.  
Initially in this thesis a pig model of giardiasis was attempted, however, this was 
unsuccessful (see point 6 below). Therefore, mice were chosen as an alternative animal 
host. There have been several published reports of Giardia infection models in mice 
established with cysts or trophozoites using both characterised and uncharacterised 
isolates (Byrd et al., 1994; Eissa and Amer, 2012; Singer and Nash, 2000). A reliable 
neonatal mouse model was successfully established using the same Giardia isolate used 
for in vitro efficacy studies. This model incorporated the use of qPCR and fluorescent 
microscopy for quick and reliable intra-study detection of infection.  
 
6. Cross-species transmission of Giardia duodenalis.  
In an attempt to develop a model of giardiasis for the continued development of the 
compounds identified in this thesis, pigs were chosen due to the close similarity of their 
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gastrointestinal tract to that of humans and reports of compounds being metabolised in 
a way that closely mirrors the experience in humans. There have been no previous 
reports of a pig model of giardiasis although Giardia has been reported to infect pigs 
(Armson et al., 2009; Koudela et al., 1991). However, under the experimental conditions 
in this study, a reliable model was not established. 
While disappointing from the point of view of drug discovery, it provided valuable 
information about the cross-species transmission of Giardia in livestock and was one of 
the first studies of its kind in this regard (livestock to livestock transmission). 
 
7.4 Implications of the findings of this thesis 
The findings of this thesis are significant in the development of novel therapeutic options for 
the treatment of infectious diseases. A range of important single-celled pathogens were 
surveyed as potential targets for this novel compound library providing important preliminary 
SAR data and potential for future development of the compounds as antimicrobial agents for 
various pathogens. The majority of this thesis focussed on the characterisation and development 
of these analogues as antigiardial agents. Of the 119 analogues available for antigiardial 
screening two were identified as highly promising, being selective for Giardia over other 
microorganisms (e.g. beneficial gut microflora) and having an improved safety profile over the 
parent drug robenidine. In addition, these two analogues appear to have a multifaceted 
mechanism of action, potentially targeting several essential cell features and processes. The 
implications for this work are potentially far reaching but in particular advancement of human 
and animal health through the control of infectious diseases. 
7.5 Future work arising from this thesis 
Questions arising from this thesis that could direct future work: 
1. Further investigation into structural modifications of the lead Gram-negative active 
agents to improve Gram-negative activity of the compound library 
2. In vivo confirmation of antibacterial activity of active analogues against target 
pathogens in an animal host e.g. bacterial blood stream infections in animals 
3. Further in vitro and in vivo efficacy of antileishmanial compounds to evaluate the 
treatment potential of these analogues, including potential screening of the remaining 
analogues in the library to identify additional hits and understand the SAR allowing 
targeted compound design in the future 
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4. Commencement of animal trials to determine the in vivo efficacy of potent and selective 
analogues that inhibit Giardia. 
7.6 Conclusions 
In conclusion, this thesis identified the antibacterial and antiprotozoal activity of a novel library 
of chemicals based on the structure of robenidine, a known anticoccidial agent. Members of the 
library were found to be active against both Gram-positive and Gram-negative bacteria, 
including methicillin resistant S. aureus, vancomycin resistance E. faecalis, E. coli and P. 
aeruginosa, as well as Protist pathogens, including G. duodenalis, T. brucei and L. donovani. 
In addition, the mechanism of action of a selection of analogues against Giardia was probed 
using electron microscopy. Electron microscopy demonstrated significant structural damage to 
giardial trophozoites. Furthermore, chemically diverse analogues appeared to have diverse 
mechanisms of action causing cell swelling and aggregation of trophozoites. Finally, an 
improved murine model of giardiasis was developed based on previously published neonatal 
models using a characterised human strain of G. duodenalis, opening the way for future in vivo 







Appendix 1: Materials and Methods for chemical synthesis of compounds 
described in Chapter 2 
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2,2'-Bis[(4-chlorophenyl)methylene]carbonimidic dihydrazide hydrochloride (1) NCL812 
Synthesized by according to General Method A from 4-chlorobenzaldehyde to afford the 
title compound as a white solid. Supplied by Neoculi Pty Ltd. 
1H NMR (DMSO-d6)  12.04 (br. s, 2H), 8.48 (br. s, 1H), 8.37 (br. s, 2H), 7.97 (d, J = 8.6 
Hz, 4H), 7.57 (d, J = 8.6 Hz, 4H). 
2,2'-Bis(phenylmethylene)carbonimidic dihydrazide hydrochloride (2) 
Synthesized according to General Method B from benzaldehyde to afford the title 
compound as a white solid (88%). 
M.P. 234–237°C. 1H NMR (DMSO-d6)  12.39 (br. s, 2H), 8.55 (s, 2H), 8.46 (s, 2H), 8.01 
– 7.88 (m, 4H), 7.55 – 7.41 (m, 6H). 13C NMR (DMSO-d6)  152.9, 148.9, 133.3, 130.8, 
128.8, 127.9. HRMS: m/z (calcd for C15H15N5, 265.1327; found 265.1246). 
2,2'-Bis[(3-chlorophenyl)methylene]carbonimidic dihydrazide hydrochloride (3) 
Synthesized according to General Method A from 3-chlorobenzaldehyde to afford the title 
compound as a white solid. 
1H NMR (DMSO-d6)  12.17 (br. s, 2H), 8.61 (br. s, 2H), 8.38 (br. s, 2H), 8.16 (s, 2H), 
7.83 (d, J = 7.0 Hz, 2H), 7.56 – 7.50 (m, 4H). 
2,2'-Bis[(2-chlorophenyl)methylene]carbonimidic dihydrazide hydrochloride (4) 
Synthesized according to General Method A from 2-chlorobenzaldehyde to afford the title 
compound as a white solid. 
1H NMR (DMSO-d6)  12.37 (br. s, 2H), 8.83 (br. s, 2H), 8.63 (br. s, 2H), 8.44 – 8.39 (m, 
2H), 7.60 – 7.55 (m, 2H), 7.55 – 7.44 (m, 4H). 
2,2'-Bis[(4-bromophenyl)methylene]carbonimidic dihydrazide hydrochloride (5) 
Synthesized according to General Method B from 4-bromobenzaldehyde to afford the title 
compound as a white solid (89%). 
M.P. 224–226°C. 1H NMR (DMSO-d6)  12.42 (br. s, 2H), 8.60 (s, 2H), 8.42 (s, 2H), 7.91 
(d, J = 8.5 Hz, 4H), 7.69 (d, J = 8.5 Hz, 4H). 13C NMR (DMSO-d6)  152.9, 147.7, 132.6, 
131.7, 129.7, 124.2. HRMS: m/z (calcd for C15H13Br2N5, 422.9517; found 422.9320). 
2,2'-Bis[(3-bromophenyl)methylene]carbonimidic dihydrazide hydrochloride (6) 
Synthesized according to General Method B from 3-bromobenzaldehyde to afford the title 
compound as a white solid (44%). 
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M.P. 248–251°C. 1H NMR (DMSO-d6)  12.45 (br. s, 2H), 8.68 (s, 2H), 8.41 (s, 2H), 8.29 
(s, 2H), 7.87 (d, J = 7.8 Hz, 2H), 7.70 – 7.63 (m, 2H), 7.44 (t, J = 7.9 Hz, 2H). 13C NMR 
(DMSO-d6)  153.0, 147.4, 135.7, 133.3, 130.9, 129.5, 127.6, 122.3. HRMS: m/z (calcd for 
C15H13Br2N5, 422.9517; found 422.9413). 
2,2'-Bis[(2-bromophenyl)methylene]carbonimidic dihydrazide hydrochloride (7) 
Synthesized according to General Method B from 2-bromobenzaldehyde to afford the title 
compound as a white solid (72%). 
M.P. 267–270°C. 1H NMR (DMSO-d6)  8.84 (s, 2H), 8.69 (s, 2H), 8.41 (dd, J = 7.8, 1.7 
Hz, 2H), 7.70 (dd, J = 8.0, 1.0 Hz, 2H), 7.48 (t, J = 7.3 Hz, 2H), 7.44 – 7.37 (m, 2H). 13C 
NMR (DMSO-d6)  152.8, 147.3, 133.1, 132.4, 132.1, 128.5, 127.9, 123.9. HRMS: m/z 
(calcd for C15H13Br2N5, 422.9517; found 422.9355). 
2,2'-Bis[(4-fluorophenyl)methylene]carbonimidic dihydrazide hydrochloride (8) 
Synthesized by according to General Method A from 4-fluorobenzaldehyde to afford the 
title compound as a white solid. 
1H NMR (DMSO-d6)  12.11 (br. s, 1H), 8.52 (br. s, 2H), 8.40 (br. s, 2H), 8.05 – 7.96 (m, 
4H), 7.39 – 7.30 (m, 4H). 
2,2'-Bis[(3-fluorophenyl)methylene]carbonimidic dihydrazide hydrochloride (9) 
Synthesized according to General Method A from 3-fluorobenzaldehyde to afford the title 
compound as a white solid. 
 1H NMR (DMSO-d6)  12.08 (br. s, 2H), 8.38 (br. s, 2H), 7.97 – 7.94 (m, 2H), 7.69 – 7.67 
(m, 2H), 7.56 – 7.53 (m, 2H), 7.35 – 7.31 (m, 2H). 
2,2'-Bis[(2-fluorophenyl)methylene]carbonimidic dihydrazide hydrochloride (10) 
Synthesized according to General Method A from 2-fluorobenzaldehyde to afford the title 
compound as a white solid. 
1H NMR (4DMSO-d6)  12.18 (br. s, 2H), 8.65 (br. s, 2H), 8.58 (br. s, 2H), 8.34 (t, J = 7.6 
Hz, 2H), 7.58 – 7.53 (m, 2H), 7.34 (t, J = 8.2 Hz 4H). 
2,2'-Bis{[4-(trifluoromethyl)phenyl]methylene}carbonimidic dihydrazide hydrochloride (11) 
Synthesized according to General Method A from 4-trifluoromethylbenzaldehyde to afford 
the title compound as a white solid. 
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1H NMR (DMSO-d6)  12.32 (br. s, 2H), 8.69 (br. s, 2H), 8.49 (br. s, 2H), 8.18 (d, J = 7.8 
Hz, 4H), 7.86 (d, J = 8.2 Hz, 4H). 
2,2'-Bis[(4-hydroxyphenyl)methylene]carbonimidic dihydrazide hydrochloride (12) 
Synthesized according to General Method B from 4-hydroxybenzaldehyde to afford the 
title compound as a yellow solid (18%). 
M.P. 246–248°C. 1H NMR (DMSO-d6)  11.92 (br. s, 2H), 10.13 (br. s, 2H), 8.28 (s, 4H), 
7.75 (d, J = 8.5 Hz, 4H), 6.86 (d, J = 8.5 Hz, 4H). 13C NMR (DMSO-d6)  160.1, 152.4, 
148.8, 129.6, 124.3, 115.6. LRMS: m/z (calcd for C15H15N5O2, 297.12; found 297.90). 
2,2'-Bis[(3-hydroxyphenyl)methylene]carbonimidic dihydrazide hydrochloride (13) 
Synthesized according to General Method B from 3-hydroxybenzaldehyde to afford the 
title compound as a pale yellow solid (61%). 
M.P. 121–123°C. 1H NMR (DMSO-d6)  8.00 (s, 2H), 7.26 – 7.08 (m, 6H), 6.98 – 6.43 
(m, 4H). 13C NMR (DMSO-d6, DEPT)  157.6, 143.8, 136.8, 129.5, 118.0, 116.1, 113.0. 
HRMS: m/z (calcd for C15H15N5O2, 297.1226; found 297.1114). 
2,2'-Bis[(2-hydroxyphenyl)methylene]carbonimidic dihydrazide hydrochloride (14) 
Synthesized according to General Method B from 2-hydroxybenzaldehyde as a white solid 
(95%). 
M.P. 263–266°C. 1H NMR (DMSO-d6)  12.19 (s, 2H), 10.25 (s, 2H), 8.70 (s, 2H), 8.34 
(s, 2H), 8.06 (d, J = 7.8 Hz, 2H), 7.35 – 7.23 (m, 2H), 7.00 (d, J = 8.2 Hz, 2H), 6.87 (t, J = 
7.5 Hz, 2H). 13C NMR (DMSO-d6)  156.9, 152.5, 145.4, 132.0, 126.9, 119.5, 119.1, 116.3. 
HRMS: m/z (calcd for C15H15N5O2, 297.1226; found 297.1125). 
2,2'-Bis[(4-methoxyphenyl)methylene]carbonimidic dihydrazide hydrochloride (15) 
Synthesized according to General Method B from 4-methoxybenzaldehyde to afford the 
title compound. 
1H NMR (DMSO-d6)  11.78 (br. s, 2H), 8.31 (br. s, 3H), 7.87 (d, J = 8.6 Hz, 4H), 7.04 (d, 
J = 8.6 Hz, 4H), 3.83 (s, 6H). 
2,2'-Bis[(3-methoxyphenyl)methylene]carbonimidic dihydrazide hydrochloride (16) 
Synthesized according to General Method A from 3-methoxybenzaldehyde to afford the 
title compound as a white solid. 
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1H NMR (DMSO-d6)  11.99 (br. s, 2H), 8.48 (br. s, 2H), 8.36 (br. s, 2H), 7.56 (s, 2H), 
7.46 – 7.38 (m, 4H), 7.08 – 7.05 (m, 2H), 3.84 (s, 6H). 
2,2'-Bis[(2-methoxyphenyl)methylene]carbonimidic dihydrazide hydrochloride (17) 
Synthesized according to General Method A from 2-methoxybenzaldehyde to afford the 
title compound as a white solid. 
1H NMR (400 MHz, DMSO-d6)  12.00 (br. s, 2H), 8.74 (br. s, 2H), 8.38 (br. s, 2H), 8.22 
(d, J = 6.7 Hz, 2H), 7.50 – 7.45 (m, 2H), 7.14 (d, J = 8.2 Hz, 2H), 7.05 (t, J = 7.6 Hz, 2H), 
3.88 (s, 6H). 
2,2'-Bis{[4-(trifluoromethoxy)phenyl]methylene}carbonimidic dihydrazide hydrochloride 
(18) 
Synthesized according to General Method B from 4-trifluoromethoxybenzaldehyde to 
afford the title compound as a white solid (69%). 
M.P. 258–261°C. 1H NMR (DMSO-d6)  12.49 (br. s, 2H), 8.65 (s, 2H), 8.49 (s, 2H), 8.10 
(d, J = 8.6 Hz, 4H), 7.47 (d, J = 8.3 Hz, 4H). 13C NMR (DMSO-d6)  153.0, 149.8 (d, J = 1.6 
Hz), 147.4, 132.6, 129.9, 121.2, 120.0 (q, J = 256.9 Hz). LRMS: m/z (calcd for 
C17H13F6N5O2, 433.10; found 433.80). 
2,2'-Bis{[4-(methylsulfanyl)phenyl]methylene}carbonimidic dihydrazide hydrochloride (19) 
Synthesized according to General Method B from 4-thiomethylbenzaldehyde to afford the 
title compound as an off-white solid (73%). 
M.P. 242–245°C. 1H NMR (DMSO-d6)  12.17 (br. s, 2H), 8.46 (s, 2H), 8.37 (s, 2H), 7.86 
(d, J = 8.2 Hz, 4H), 7.34 (d, J = 8.2 Hz, 4H), 2.53 (s, 6H). 13C NMR (DMSO-d6, DEPT)  




Synthesized according to General Method B from 4-thiotrifluoromethylbenzaldehyde to 
afford the title compound as a white solid (48%). 
M.P. 195°C (Decomp.). 1H NMR (DMSO-d6)  12.68 (s, 1H), 8.73 (s, J = 48.7 Hz, 1H), 
8.53 (s, 1H), 8.11 (d, J = 8.2 Hz, 2H), 7.79 (d, J = 8.1 Hz, 2H). 13C NMR (DMSO-d6)  
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153.06, 147.43, 136.20, 136.16, 129.52 (q, J = 308.0 Hz), 129.05, 125.20 – 125.01 
(Unresolved quartet). LRMS: m/z (calcd for C17H13F6N5S2, 465.05; found 465.60). 
2,2'-Bis[(4-methylphenyl)methylene]carbonimidic dihydrazide hydrochloride (21) 
Synthesized according to General Method A from 4-methylbenzaldehyde to afford the title 
compound as a white solid. 
1H NMR (DMSO-d6)  11.92 (br. s, 2H), 8.41 (br. s, 2H), 8.36 (br. s, 2H), 7.82 (d, J = 8.2 
Hz, 4H), 7.30 (d, J = 7.8 Hz, 4H), 2.37 (s, 6H). 
2,2'-Bis[(3-methylphenyl)methylene]carbonimidic dihydrazide hydrochloride (22) 
Synthesized according to General Method A from 3-methylbenzaldehyde to afford the title 
compound as a white solid. 
 1H NMR (DMSO-d6)  11.96 (br. s, 2H), 8.44 (br. s, 2H), 8.37 (br. s, 2H), 7.76 (s, 2H), 
7.71 (d, J = 7.8 Hz, 2H), 7.38 (t, J = 7.8 Hz, 2H), 7.31 (d, J = 7.8 Hz, 2H), 2.38 (s, 6H). 
2,2'-bis[(2-methylphenyl)methylene]carbonimidic dihydrazide hydrochloride (23) 
Synthesized according to General Method B from 2-methylbenzaldehyde to afford the title 
compound as a white solid. 
1H NMR (DMSO-d6)  11.99 (br. s, 2H), 8.73 (br. s, 2H), 8.41 (br. s, 2H), 8.19 (d, J = 7.8 
Hz, 2H), 7.39 (t, J = 8.0 Hz, 2H), 7.30 (t, J = 7.8 Hz, 4H), 2.46 (s, 6H). 
2,2'-Bis[(4-propylphenyl)methylene]carbonimidic dihydrazide hydrochloride (24) 
Synthesized according to General Method B from 4-propylbenzaldehyde to afford the title 
compound as a white solid (77%). 
M.P. 218–222°C. 1H NMR (DMSO-d6)  8.60 – 8.30 (m, 4H), 7.84 (d, J = 8.1 Hz, 4H), 
7.28 (d, J = 8.1 Hz, 4H), 2.59 (t, J = 7.5 Hz, 4H), 1.64 – 1.54 (m, 4H), 0.88 (t, J = 7.3 Hz, 
6H). 13C NMR (DMSO-d6)  152.8, 148.8, 145.3, 130.9, 128.7, 127.9, 37.2, 23.9, 13.6. 
HRMS: m/z (calcd for C21H27N5, 349.2266; found 349.2112). 
2,2'-Bis[(4-butylphenyl)methylene]carbonimidic dihydrazide hydrochloride (25) 
Synthesized according to General Method B from 4-butylbenzaldehyde to afford the title 
compound as a pale yellow solid (80%). 
M.P. 216–220°C. 1H NMR (DMSO-d6)  12.21 (br. s, 2H), 8.44 (s, 2H), 8.39 (s, 2H), 7.83 
(d, J = 8.2 Hz, 4H), 7.30 (d, J = 8.2 Hz, 4H), 2.63 (t, J = 7.7 Hz, 4H), 1.61 – 1.52 (m, 4H), 
1.36 – 1.26 (m, 4H), 0.90 (t, J = 7.3 Hz, 6H). 13C NMR (DMSO-d6)  152.7, 148.8, 145.5, 
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130.9, 128.7, 127.9, 34.8, 32.9, 21.7, 13.8. HRMS: m/z (calcd for C23H31N5, 377.2579; found 
377.2336). 
2,2'-Bis{[4-(1-methylethyl)phenyl]methylene}carbonimidic dihydrazide hydrochloride (26) 
Synthesized according to General Method B from 4-isopropylbenzaldehyde to afford the 
title compound as a white solid (28%). 
M.P. 193–196°C. 1H NMR (DMSO-d6)  8.62 – 8.29 (m, 4H), 7.85 (d, J = 8.2 Hz, 4H), 
7.33 (d, J = 8.2 Hz, 4H), 2.98 – 2.87 (m, 2H), 1.21 (d, J = 6.9 Hz, 12H). 13C NMR (DMSO-
d6)  152.7, 151.4, 148.8, 131.0, 128.0, 126.7, 33.4, 23.6. HRMS: m/z (calcd for C21H27N5, 
349.2266; found 349.2112). 
2,2'-Bis{[4-(1,1-dimethylethyl)phenyl]methylene}carbonimidic dihydrazide hydrochloride 
(27) 
Synthesized according to General Method B from 4-tert-butylbenzaldehyde to afford the 
title compound as a white solid (50%). 
M.P. 150–155°C. 1H NMR (DMSO-d6)  8.56 – 8.32 (m, 4H), 7.85 (d, J = 8.3 Hz, 4H), 
7.49 (d, J = 8.3 Hz, 4H), 1.31 (s, 18H). 13C NMR (DMSO-d6)  153.7, 152.7, 148.8, 130.7, 
127.8, 125.6, 34.7, 31.0. HRMS: m/z (calcd for C23H31N5, 377.2579; found 377.2454). 
2,2'-Bis{4-(dimethylamino)phenyl]methylene}carbonimidic dihydrazide hydrochloride (28) 
Synthesized according to General Method B from 4-(dimethylamino)benzaldehyde to 
afford the title compound as an orange solid (80%). 
M.P. 161–164°C. 1H NMR (DMSO-d6)  11.92 (br. s, 2H), 8.24 (s, 2H), 8.16 (s, 2H), 7.71 
(d, J = 8.9 Hz, 4H), 6.74 (d, J = 8.9 Hz, 4H), 2.98 (s, 12H). 13C NMR (DMSO-d6)  152.1, 
151.8, 149.0, 129.2, 120.5, 111.5, 39.7. HRMS: m/z (calcd for C19H25N7, 351.2171; found 
351.1966). 
2,2'-Bis([1,1'-biphenyl]-4-ylmethylene)carbonimidic dihydrazide hydrochloride (29) 
Synthesized according to General Method B from 4-phenylbenzaldehyde to afford the title 
compound as a yellow solid (81%). 
M.P. 264–266°C. 1H NMR (DMSO-d6)  12.48 (br. s, 2H), 8.62 (s, 2H), 8.51 (s, 2H), 8.04 
(d, J = 7.5 Hz, 4H), 7.85 – 7.69 (m, 8H), 7.54 – 7.36 (m, 6H). 13C NMR (DMSO-d6)  152.8, 
148.4, 142.2, 139.3, 132.5, 129.1, 128.5, 128.0, 127.0, 126.8. HRMS: m/z (calcd for 
C27H23N5, 417.1953; found 417.1831). 
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2,2'-Bis([1,1'-biphenyl]-2-ylmethylene)carbonimidic dihydrazide hydrochloride (30) 
Synthesized according to General Method B from biphenyl-2-carboxaldehyde to afford the 
title compound as a yellow solid (89%). 
M.P. 129–133°C. 1H NMR (DMSO-d6)  12.27 (br. s, 2H), 8.49 (s, 2H), 8.44 – 8.27 (m, 
4H), 7.57 – 7.44 (m, 10H), 7.41 – 7.33 (m, 6H). 13C NMR (DMSO-d6)  152.6, 147.2, 142.4, 
138.8, 130.6, 130.4, 129.7, 128.7, 127.8, 127.6, 126.8. HRMS: m/z (calcd for C27H23N5, 
417.1953; found 417.1709). 
2,2'-Bis[(3-ethynylphenyl)methylene]carbonimidic dihydrazide hydrochloride (31) 
Synthesized according to General Method B from 4-ethynylbenzaldehyde to afford the 
title compound as a yellow solid (93%). 
M.P. 220°C (Decomp.).  1H NMR (DMSO-d6)  12.27 (br. s, 2H), 8.58 (s, 2H), 8.42 (s, 
2H), 7.96 (d, J = 8.3 Hz, 4H), 7.58 (d, J = 8.2 Hz, 4H), 4.39 (s, 2H). 13C NMR (DMSO-d6)  
152.9, 148.0, 133.7, 132.0, 128.0, 123.7, 83.2, 83.0. LRMS: m/z (calcd for C19H15N5, 313.13; 
found 313.80). 
2,2'-Bis[(2,5-difluorophenyl)methylene]carbonimidic dihydrazide hydrochloride (32) 
Synthesized according to General Method B from 2,5-difluorophenylbenzaldehyde to 
afford the title compound as a white solid (34%). 
1H NMR (DMSO-d6) δ 12.83 (br s, 2H), 8.76 (s, 2H), 8.69 (s, 2H), 8.31 – 8.21 (m, 2H), 
7.45 – 7.31 (m, 4H). 13C NMR (DMSO-d6) δ 158.5 (dd, J = 240.2, 1.2 Hz), 157.2 (dd, J = 
247.2, 1.4 Hz), 152.8, 140.7, 122.5 (dd, J = 12.2, 8.9 Hz), 119.4 (dd, J = 25.1, 9.0 Hz), 117.8 
(dd, J = 24.0, 8.8 Hz), 113.0 (dd, J = 25.9, 2.3 Hz). HRMS: m/z (calcd for C15H11F4N5, 
337.0951; found 338.0877). 
N',2-Bis((E)-4-chloro-2-fluorobenzylidene)hydrazine-1-carboximidhydrazide hydrochloride 
(33) 
Synthesized according to General Method A from 4-chloro-2-fluorobenzaldehyde to 
afford the title compound as a white solid (39%). 
1H NMR (DMSO-d6) δ 12.43 (s, 1H), 8.38 (t, J = 8.3 Hz, 1H), 7.61 (dd, J = 10.5, 1.9 Hz, 
1H), 7.45 (dd, J = 8.6, 1.6 Hz, 1H). 13C NMR (DMSO-d6) δ 160.7 (d, J = 254.5 Hz), 152.8*, 
140.8*, 136.3 (d, J = 10.8 Hz), 128.5, 125.3, 120.2 (d, J = 10.0 Hz), 116.7 (d, J = 24.7 Hz). 
*Poor resolution failed to resolve doublets. 
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2,2'-Bis[(3,4-difluorophenyl)methylene]carbonimidic dihydrazide hydrochloride (34) 
Synthesized according to General Method B from 3,4-difluorobenzaldehyde to afford the 
title compound as a white solid (76%). 
1H NMR (DMSO-d6) δ 8.68 (s, 2H), 8.43 (s, 2H), 8.28 – 8.16 (m, 2H), 7.77 – 7.64 (m, 
2H), 7.58 – 7.46 (m, 2H). 13C NMR (DMSO-d6) δ 153.0, 150.8 (dd, J = 250.6, 13.0 Hz), 
149.9 (dd, J = 245.9, 13.2 Hz), 146.6, 131.2 (dd, J = 6.4, 3.4 Hz), 126.0 (dd, J = 6.4, 2.8 Hz), 
117.8 (d, J = 17.7 Hz), 115.7 (d, J = 18.5 Hz). HRMS: m/z (calcd for C15H11F4N5, 337.0951; 
found 338.0943). 
2,2'-Bis[(2,4-dichlorophenyl)methylene]carbonimidic dihydrazide hydrochloride (35) 
Synthesized according to General Method B from 2,4-dichlorobenzaldehyde to afford the 
title compound as a white solid (47%). 
1H NMR (DMSO-d6) δ 12.84 (br s, 2H), 8.84 (s, 2H), 8.74 (s, 2H), 8.46 (d, J = 8.6 Hz, 
2H), 7.71 (d, J = 1.6 Hz, 2H), 7.54 (dd, J = 8.6, 1.2 Hz, 2H). 13C NMR (DMSO-d6) δ 152.7, 
144.0, 135.9, 134.3, 129.7, 129.3, 129.3, 127.8. HRMS: m/z (calcd for C15H11Cl4N5, 
402.9739; found 403.9786). 
2,2'-Bis[(2,6-dichlorophenyl)methylene]carbonimidic dihydrazide hydrochloride (36) 
Synthesized according to General Method B from 2,6-dichlorobenzaldehyde to afford the 
title compound as a white solid (63%). 
1H NMR (DMSO-d6) δ 12.94 (br s, 2H), 8.68 (s, 2H), 8.33 (s, 2H), 7.60 (d, J = 7.9 Hz, 
4H)*, 7.49 (dd, J = 8.7, 7.4 Hz, 2H)*. 13C NMR (DMSO-d6) δ 153.0, 145.1, 134.1, 131.9, 
129.9, 129.0. HRMS: m/z (calcd for C15H11Cl4N5, 402.9739; found 403.9765). *Poorly 
resolved 1H-NMR spectrum. 
2,2'-Bis[(3,5-dichlorophenyl)methylene]carbonimidic dihydrazide hydrochloride (37) 
Synthesized according to General Method B from 3,5-dichlorobenzaldehyde to afford the 
title compound as a white solid (84%). 
1H NMR (DMSO-d6) δ 12.67 (br s, 2H), 8.81 (s, 2H), 8.40 (s, 2H), 8.06 (d, J = 1.8 Hz, 
4H), 7.68 (t, J = 1.8 Hz, 2H). 13C NMR (DMSO-d6) δ 153.1, 146.1, 136.9, 134.6, 129.7, 
126.2. 
2,2'-Bis[(2-amino-4-chlorophenyl)methylene]carbonimidic dihydrazide hydrochloride (38) 
Synthesized according to General Method B from 2-amino-4-chlorobenzaldehyde to 
afford the title compound as a pale yellow solid (13%). 
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1H NMR (DMSO-d6) δ 11.71 (br s, 2H), 8.40 (s, 2H), 8.37 (s, 2H), 7.29 (d, J = 8.4 Hz, 
2H), 6.87 (d, J = 2.0 Hz, 2H), 6.73 (br s, 4H), 6.59 (dd, J = 8.3, 2.0 Hz, 2H). 13C NMR 
(DMSO-d6) δ 152.1, 151.5, 148.9, 136.0, 134.7, 115.1, 114.5, 112.8. 
2,2'-Bis{[2-(1-hydroxyethylamino)-4-chlorophenyl]methylene}carbonimidic dihydrazide 
hydrochloride (39) 
Synthesized according to General Method A from 4-chloro-2-[(1-
hydroxyethyl)amino]benzaldehyde to afford the title compound as a yellow solid (17%). 
1H NMR (DMSO-d6) δ 11.86 (s, 1H), 8.41 (s, 2H), 7.36 (d, J = 6.8 Hz, 2H), 6.75 (s, 1H), 
6.66 (d, J = 7.9 Hz, 1H), 3.44 (d, J = 6.9 Hz, 1H)*, 1.24 (t, J = 5.3 Hz, 3H), 1.07 (dt, J = 13.8, 
6.8 Hz, 1H). *Signal eclipsed by water. 13C NMR (DMSO-d6) δ 152.0, 148.1, 136.9, 135.1, 
114.7, 113.5, 109.7, 64.9, 56.0, 13.9. 
2,2'-bis[(2-acetamido-4-chlorophenyl)methylene]carbonimidic dihydrazide (40) 
Synthesized according to General Method A from N-(5-chloro-2-formylphenyl)acetamide 
to afford the title compound as an off-white crystalline solid (18%). 
M.P. 259°C (Decomp.). 1H NMR (DMSO-d6) δ 12.29 (s, 1H), 10.29 (s, 1H), 8.55 (s, 1H), 
8.45 (s, 1H), 8.13 (d, J = 8.5 Hz, 1H), 7.71 (s, 1H), 7.35 (dd, J = 8.5, 1.8 Hz, 1H), 2.12 (s, 
3H).  13C NMR (DMSO-d6) δ 169.2, 152.8, 146.4, 138.4, 135.0, 129.7, 125.0, 124.7, 124.3, 
23.6. LRMS: m/z (calcd for C19H19Cl2N7O2, 447.10; found 447.80). 
2,2'-Bis[(2-hydroxy-3-methylphenyl)methylene]carbonimidic dihydrazide hydrochloride (41) 
Synthesized according to General Method B from 2-hydroxy-3-methylbenzaldehyde to 
afford the title compound as a pale yellow solid (93%). 
M.P. 260°C (Decomp.). 1H NMR (DMSO-d6) δ 12.08 (br s, 2H), 9.35 (s, 2H), 8.66 (s, 
2H), 8.48 (s, 2H), 7.67 (d, J = 7.2 Hz, 2H), 7.25 (d, J = 7.2 Hz, 2H), 6.88 (t, J = 7.6 Hz, 2H), 
2.23 (s, 6H). 13C NMR (DMSO-d6) δ 154.6, 152.1, 149.0, 133.4, 127.0, 125.7, 119.7, 119.1, 
16.1. LRMS: m/z (calcd for C17H19N5O2, 325.15; found 325.85). 
2,2'-Bis(4-chloro-2-hydroxyphenylmethylene)carbonimidic dihydrazide hydrochloride (42) 
Synthesized according to General Method A from 4-chlorosalicylicaldehyde to afford the 
title compound as a grey solid (22%). 
1H NMR (DMSO-d6) δ 12.02 (s, 1H), 10.81 (s, 1H), 8.63 (s, 1H), 8.38 (s, 1H), 8.12 (d, J = 
8.3 Hz, 1H), 7.13 – 6.84 (m, 2H). 13C NMR (DMSO) δ 157.5, 128.3, 119.5, 119.0, 115.9. 
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2,2'-Bis{[4-(dimethylamino)-2-hydroxyphenyl]methylene}carbonimidic dihydrazide (43) 
Synthesized according to General Method A from 4-(dimethylamino)salicylic acid to 
afford the title compound as a brown solid (62%). 
M.P. 254°C (Decomp.). 1H NMR (DMSO-d6) δ 11.63 (s, 1H), 9.84 (s, 1H), 8.46 (s, 1H), 
8.02 (s, 1H), 7.74 (d, J = 8.8 Hz, 1H), 6.30 (d, J = 7.4 Hz*, 1H), 6.17 (s, 1H), 2.94 (s, 6H). 
13C NMR (DMSO-d6) δ 158.0, 153.1, 151.4, 146.4, 128.4, 107.5, 104.4, 97.7, 39.7*. *Signal 
eclipsed by the DMSO. LRMS: m/z (calcd for C19H25N7O2, 383.21; found 383.70). *Poorly 
resolved doublet gives reduced coupling constant. 
2,2'-Bis[(2,3-dihydroxyphenyl)methylene]carbonimidic dihydrazide hydrochloride (44) 
Synthesized according to General Method B from 2,3-dihydroxybenzaldehyde to afford 
the title compound as a yellow solid (75%). 
M.P. 217°C (Decomp.). 1H NMR (DMSO-d6) δ 12.06 (br s, 2H), 9.71 (br s, 2H), 9.21 (br 
s, 2H), 8.70 (s, 2H), 8.30 (s, 2H), 7.50 (d, J = 7.9 Hz, 2H), 6.90 (d, J = 7.7 Hz, 2H), 6.70 (t, J 
= 7.7 Hz, 2H). 13C NMR (DMSO-d6) δ 152.4, 146.0, 145.8, 145.7, 120.3, 119.2, 117.5, 117.2. 
HRMS: m/z (calcd for C15H15N5O4, 329.1124; found 330.1100). 
2,2'-Bis[(2,4-dihydroxyphenyl)methylene]carbonimidic dihydrazide hydrochloride (45) 
Synthesized according to General Method B from 2,4-dihydroxybenzaldehyde to afford 
the title compound as a pale yellow solid (73%). 
M.P. 234°C (Decomp.). 1H NMR (DMSO-d6) δ 11.81 (br s, 2H), 10.32 – 9.85 (m, 4H), 
8.52 (s, 2H), 8.12 (s, 2H), 7.85 (d, J = 8.4 Hz, 2H), 6.43 (s, 2H), 6.33 (d, J = 8.5 Hz, 2H).  13C 
NMR (DMSO-d6) δ 161.4, 158.5, 152.0, 145.7, 128.4, 111.2, 108.0, 102.4. HRMS: m/z 
(calcd for C15H15N5O4, 329.1124; found 330.1116). 
2,2'-Bis[(3,4-dihydroxyphenyl)methylene]carbonimidic dihydrazide hydrochloride (46) 
Synthesized according to General Method A from 3,4-dihydroxybenzaldehyde to afford 
the title compound as a pale yellow solid (21%). 
M.P. 250°C (Decomp.). 1H NMR (DMSO-d6) δ 11.80 (br s, 2H), 10.30 – 9.80 (m, 4H), 
8.52 (s, 2H), 8.12 (s, 2H), 7.84 (d, J = 8.6 Hz, 2H), 6.42 (d, J = 1.8 Hz, 2H), 6.33 (d, J = 8.6 
Hz, 2H). 13C NMR (DMSO-d6) δ 161.4, 158.5, 152.0, 145.7, 128.4, 111.2, 108.0, 102.4. 
HRMS: m/z (calcd for C15H15N5O4, 329.1124; found 330.1133). 




Synthesized according to General Method B from 3-hydroxy-4-methoxybenzaldehyde to 
afford the title compound as a yellow solid (61%). 
M.P. 158-161°C. 1H NMR (DMSO-d6) δ 9.21 (br s, 2H), 8.42 – 8.17 (m, 4H), 7.43 (d, J = 
1.9 Hz, 2H), 7.25 (dd, J = 8.4, 1.9 Hz, 2H), 6.99 (d, J = 8.4 Hz, 2H), 3.83 (s, 6H). 13C NMR 
(DMSO-d6) δ 152.5, 150.3, 148.9, 146.7, 126.2, 120.9, 113.8, 111.7, 55.7. HRMS: m/z (calcd 
for C17H19N5O4, 357.1437; found 358.1371). 
2,2'-Bis[(4-hydroxy-3-methoxyphenyl)methylene]carbonimidic dihydrazide hydrochloride 
(48) 
Synthesized according to General Method B from 4-hydroxy-3-methoxybenzaldehyde to 
afford the title compound as a yellow solid (69%). 
M.P. 200-203°C. 1H NMR (DMSO-d6) δ 9.77 (br s, 2H), 8.36 (s, 2H), 8.29 (s, 2H), 7.58 
(d, J = 1.5 Hz, 2H), 7.23 (dd, J = 8.1, 1.2 Hz, 2H), 6.87 (d, J = 8.1 Hz, 2H), 3.86 (s, 6H). 13C 
NMR (DMSO-d6) δ 152.4, 149.7, 149.0, 148.1, 124.7, 122.9, 115.4, 110.4, 55.9. HRMS: m/z 
(calcd for C17H19N5O4, 357.1437; found 358.1447). 
2,2'-Bis[(3,4-dimethoxyphenyl)methylene]carbonimidic dihydrazide hydrochloride (49) 
Synthesized according to General Method B from 3,4-dimethoxybenzaldehyde to afford 
the title compound as a pale yellow solid (100%). 
M.P. 218-220°C. 1H NMR (DMSO-d6) δ 12.09 (br s, 2H), 8.44 (s, 2H), 8.34 (s, 2H), 7.63 
(d, J = 1.4 Hz, 2H), 7.33 (dd, J = 8.3, 1.6 Hz, 2H), 7.03 (d, J = 8.4 Hz, 2H), 3.86 (s, 6H), 3.81 
(s, 6H). 13C NMR (DMSO-d6) δ 152.5, 151.4, 149.2, 148.9, 126.0, 122.9, 111.4, 109.5, 55.9, 
55.7. HRMS: m/z (calcd for C19H23N5O4, 385.1750; found 386.1739). 
2,2'-Bis[(2,3,4-trihydroxyphenyl)methylene]carbonimidic dihydrazide hydrochloride (50) 
Synthesized according to General Method B from 2,3,4-trihydroxybenzaldehyde to afford the 
title compound as a white solid (84%). 
M.P. 225°C (Decomp.). 1H NMR (DMSO-d6) δ 11.75 (br s, 2H), 9.71 (br s, 2H), 9.15 (br s, 
2H), 8.86 – 8.40 (m, 4H), 8.13 (s, 2H), 7.33 (d, J = 8.6 Hz, 2H), 6.42 (d, J = 8.6 Hz, 2H). 13C 
NMR (DMSO-d6) δ 151.9, 149.1, 147.0, 146.8, 132.9, 118.1, 112.1, 108.1. HRMS: m/z 
(calcd for C15H15N5O6, 361.1022; found 362.0995). 
2,2'-Bis[(2,4,5-trihydroxyphenyl)methylene]carbonimidic dihydrazide hydrochloride (51) 
Synthesized according to General Method B from 2,3,5-trihydroxybenzaldehyde to afford 
the title compound as an orange solid (82%). 
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M.P. 260°C (Decomp.). 1H NMR (DMSO-d6) δ 11.72 (br s, 2H), 9.78 (br s, 2H), 9.45 (s, 
2H), 8.48 (s, 2H), 8.34 (br s, 2H), 8.04 (s, 2H), 7.33 (s, 2H), 6.44 (s, 2H). 13C NMR (DMSO-
d6) δ 152.0, 151.4, 150.2, 146.1, 138.9, 112.9, 110.2, 103.4. HRMS: m/z (calcd for 
C15H15N5O6, 361.1022; found 362.1043). 
2,2'-Bis[(3,4,5-trihydroxyphenyl)methylene]carbonimidic dihydrazide hydrochloride (52) 
Synthesized according to General Method B from 3,4,5-trihydroxybenzaldehyde to afford 
the title compound as a pale brown solid (77%). 
M.P. 226°C (Decomp.). 1H NMR (DMSO-d6) δ 9.06 (br s, 6H), 8.25 – 8.01 (m, 4H), 6.83 
(s, 4H). 13C NMR (DMSO-d6) δ 152.2, 149.7, 146.2, 136.5, 123.7, 107.4. HRMS: m/z (calcd 
for C15H15N5O6, 361.1022; found 362.1044). 
2,2'-Bis[(4,5-dihydroxy-3-methoxyphenyl)methylene]carbonimidic dihydrazide hydrochloride 
(53) 
Synthesized according to General Method B from 4,5-dihydroxy-3-methoxybenzaldehyde 
to afford the title compound as a pale brown solid (88%). 
M.P. 144°C (Decomp.). 1H NMR (DMSO-d6) δ 9.12 (br s, 4H), 8.29 (s, 2H), 8.20 (s, 2H), 
7.10 (s, 2H), 6.93 (s, 2H), 3.84 (s, 6H). 13C NMR (DMSO-d6) δ 152.4, 149.5, 148.8, 145.8, 
137.5, 123.7, 110.1, 103.1, 56.3. HRMS: m/z (calcd for C17H19N5O6, 389.1335; found 
390.1275). 
2,2'-Bis[(4-hydroxy-3-nitrophenyl)methylene]carbonimidic dihydrazide hydrochloride (54) 
Synthesized according to General Method B from 4-hydroxy-3-nitrobenzaldehyde to 
afford the title compound as a white solid (80%). 
M.P. 269°C (Decomp.). 1H NMR (DMSO-d6) δ 8.56 (s, 2H), 8.42 (d, J = 2.0 Hz, 2H), 
8.38 (s, 2H), 8.09 (dd, J = 8.7, 2.0 Hz, 2H), 7.29 (d, J = 8.7 Hz, 2H). 13C NMR (DMSO-d6) δ 
153.6, 152.8, 146.9, 137.6, 133.7, 124.7, 124.4, 119.3. HRMS: m/z (calcd for C15H13N7O6, 
388.0917; found 387.0927). 
2,2'-Bis[(2,3,4,5,6-pentafluorophenyl)methylene]carbonimidic dihydrazide hydrochloride 
(55) 
Synthesized according to General Method B from 2,3,4,5,6-pentafluorobenzaldehyde to 
afford the title compound as a white solid (60%). 
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M.P. 234-236°C. 1H NMR (DMSO-d6) δ 8.64 (s, 2H), 8.36 (s, 2H). 
13C NMR (DMSO-d6) 
δ 152.8, 146.0 (m), 143.4 (m), 142.7 (m), 140.1 (m), 138.6 (m), 138.1, 136.1 (m), 108.9 (td, J 
= 12.6, 3.8 Hz. HRMS: m/z (calcd for C15H5F10N5, 445.0358; found 446.0306). 
2,2'-Bis[(2-bromo-4,5-dimethoxyphenyl)methylene]carbonimidic dihydrazide hydrochloride 
(56) 
Synthesized according to General Method B from 2-bromo-4,5-dimethoxybenzaldehyde to 
afford the title compound as a white solid (80%). 
M.P. 233-235°C. 1H NMR (DMSO-d6) δ 12.24 (br s, 2H), 8.66 (s, 2H), 8.49 (br s, 2H), 
7.79 (s, 2H), 7.24 (s, 2H), 3.88 (s, 6H), 3.85 (s, 6H). 13C NMR (DMSO-d6) δ 152.4, 152.0, 
148.7, 147.7, 124.0, 116.1, 115.5, 110.1, 56.3, 56.2. HRMS: m/z (calcd for C19H21Br2N5O4, 
542.9940; found 543.9882). 
2,2'-Bis[(3-bromo-4,5-dimethoxyphenyl)methylene]carbonimidic dihydrazide hydrochloride 
(57) 
Synthesized according to General Method B from 3-bromo-4,5-dimethoxybenzaldehyde to 
afford the title compound as a white solid (45%). 
M.P. 223-224°C. 1H NMR (DMSO-d6) δ 8.66 (s, 2H), 8.37 (s, 2H), 7.79 (d, J = 1.6 Hz, 
2H), 7.68 – 7.62 (m, 2H), 3.92 (s, 6H), 3.78 (s, 6H). 13C NMR (DMSO-d6) δ 153.6, 152.8, 
147.5, 147.2, 130.7, 123.8, 117.1, 111.8, 60.3, 56.5. HRMS: m/z (calcd for C19H21Br2N5O4, 
542.9940; found 543.9850). 
2,2'-Bis(cyclohexylmethylene)carbonimidic dihydrazide (58) 
Synthesized according to General Method B from cyclohexane carboxaldehyde to afford 
the title compound as an orange oil (36%). 
1H NMR (CDCl3)  7.16 (d, J = 4.7 Hz, 2H), 6.10 (br. s, 3H), 2.27 – 2.14 (m, 2H), 1.84 – 
1.61 (m, 10H), 1.37 – 1.13 (m, 10H). 13C NMR (CDCl3)  157.2, 152.7 (br. s), 40.9, 30.6, 
26.1, 25.7. HRMS: m/z (calcd for C15H27N5, 277.2266; found 277.2169). 
2,2'-Bis(4-pyridinylmethylene)Carbonimidic dihydrazide hydrochloride (59) 
Synthesized according to General Method B from 4-pyridinecarboxaldehdye to afford the 
title compound as a yellow solid (74%). 
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M.P. 231–234°C. 1H NMR (DMSO-d6)  8.75 (d, J = 6.1 Hz, 4H), 8.68 (s, 2H), 8.47 (s, 
2H), 8.07 (d, J = 6.1 Hz, 4H). 13C NMR (DMSO-d6)  154.4, 148.0, 145.3, 143.0, 122.1. 
LRMS: m/z (calcd for C13H13N7, 267.12; found 267.90). 
2,2'-Bis(4-chloropyridin-3-ylmethylene)Carbonimidic dihydrazide hydrochloride (60) 
Synthesized according to General Method B from 4-chloro-3-pyridine carboxaldehyde to 
afford the title compound as a yellow solid (84%). 
M.P. 269–272°C. 1H NMR (DMSO-d6)  12.63 (br. s, 2H), 8.90 (d, J = 2.1 Hz, 2H), 8.74 
(s, 2H), 8.56 – 8.42 (m, 4H), 7.66 (d, J = 8.4 Hz, 2H). 13C NMR (DMSO-d6) 153.0, 151.7, 
149.6, 145.0, 137.8, 128.9, 124.5. LRMS: m/z (calcd for C13H11Cl2N7, 335.05; found 335.60). 
2,2'-Bis(2-aminopyridin-3-ylmethylene)Carbonimidic dihydrazide hydrochloride (61) 
Synthesized according to General Method B from 2-amino-3-pyridine carboxaldehyde to 
afford the title compound as a yellow solid (49%). 
M.P. 227–229°C. 1H NMR (DMSO-d6) 11.94 (br. s, 2H), 8.44 (s, 2H), 8.36 (s, 2H), 8.07 
(dd, J = 4.8, 1.7 Hz, 2H), 7.72 (dd, J = 7.6, 1.4 Hz, 2H), 7.19 (s, 4H), 6.67 (dd, J = 7.5, 4.9 
Hz, 2H). 13C NMR (DMSO-d6)  156.1, 152.2, 150.4, 149.5, 141.2, 112.0, 110.1. LRMS: m/z 
(calcd for C13H15N9, 297.15; found 297.70). 
2,2'-Bis(3-phenyl-2-propenylidene)carbonimidic dihydrazide hydrochloride (62) 
Synthesized according to General Method B from trans-cinnamaldehyde to afford the title 
compound as a yellow solid (63%). 
M.P. 176-178°C. 1H NMR (DMSO) δ 12.38 (s, 1H), 8.25 (d, J = 10.2 Hz, 2H), 7.59 (d, J = 
7.3 Hz, 2H), 7.39 (m, 3H), 7.20 (d, J = 16.1 Hz, 1H), 6.94 (dd, J = 16.1, 9.3 Hz, 1H). 13C 
NMR (DMSO-d6) HRMS: m/z 
(calcd for C19H19N5, 317.1640; found 318.1629). 
2,2'-Bis[3-(4-methoxylphenyl)-2-propenylidene]carbonimidic dihydrazide hydrochloride (63) 
Synthesized according to General Method B from 4-methoxycinnamaldehyde to afford the 
title compound as a yellow solid (51%). 
M.P. 204-206°C. 1H NMR (DMSO-d6) δ 12.10 (br s, 2H), 8.23 – 8.07 (m, 4H), 7.55 (d, J 
= 8.7 Hz, 4H), 7.13 (d, J = 16.0 Hz, 2H), 6.99 (d, J = 8.7 Hz, 4H), 6.81 (dd, J = 16.0, 9.4 Hz, 
2H), 3.79 (s, 6H). 13C NMR (DMSO-d6) δ 160.3, 152.1, 151.2, 140.8, 128.8, 128.2, 121.7, 
114.5, 55.3. LRMS: m/z (calcd for C21H23N5O2, 377.19; found 377.80). 
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2,2'-Bis(2,3-diphenyl-2-propenylidene)carbonimidic dihydrazide hydrochloride (64) 
Synthesized according to General Method A from 2,3-diphenylacrolein to afford the title 
compound as a yellow solid (46%). 
M.P. 137-140°C. 1H NMR (DMSO-d6) δ 12.12 (br s, 2H), 8.21 (s, 2H), 7.97 (s, 2H), 7.54 
– 7.47 (m, 6H), 7.42 – 7.36 (m, 6H), 7.31 – 7.21 (m, 8H), 6.84 (d, J = 9.8 Hz, 2H). 13C NMR 
(DMSO-d6) δ 152.0, 150.4, 148.5*, 140.2, 137.6, 130.0, 129.0, 128.7, 128.7, 128.5, 127.4, 
123.0. *Confirmed via HSQC analysis. LRMS: m/z (calcd for C31H27N5, 469.23; found 
469.85). 
2,2'-Bis(2-naphthalenylmethylene)carbonimidic dihydrazide hydrochloride (65) 
Synthesized according to General Method A from 2-naphthaldehyde to afford the title 
compound as a white solid (79%). 
M.P. 183-185°C. 1H NMR (DMSO-d6) δ 8.64 (s, 4H), 8.35 – 8.24 (m, 4H), 8.06 – 7.93 
(m, 6H), 7.64 – 7.54 (m, 4H). 13C NMR (DMSO-d6) δ 152.9, 148.9, 134.1, 132.8, 131.2, 
129.9, 128.5, 128.4, 127.9, 127.6, 126.9, 123.3.  HRMS: m/z (calcd for C23H19N5, 365.1640; 
found 366.1740). 
2,2'-Bis(1H-indol-5-ylmethylene)carbonimidic dihydrazide hydrochloride (66) 
     Synthesized according to General Method B from indole-5-carboxaldehyde to afford the 
title compound as a pink-brown solid (64%). 
M.P. 269°C (Decomp.).  1H NMR (DMSO-d6) δ 11.97 (br s, 2H), 11.45 (s, 2H), 8.47 (s, 
2H), 8.30 (s, 2H), 8.02 (s, 2H), 7.80 (dd, J = 8.6, 0.9 Hz, 2H), 7.48 (d, J = 8.5 Hz, 2H), 7.45 – 
7.40 (m, 2H), 6.53 (s, 2H). 13C NMR (DMSO-d6) δ 152.4, 150.6, 137.4, 127.6, 126.7, 124.5, 
121.8, 120.3, 111.9, 102.0. LRMS: m/z (calcd for C19H17N7, 343.15; found 343.80). 
2,2'-Bis[(5-chlorobenzo[b]thien-3-yl)methylene]carbonimidic dihydrazide hydrochloride 
(67) 
Synthesized according to General Method B from 5-chloro-1-benzothiophene-3-
carbaldehyde to afford the title compound as a pale yellow solid (90%). 
M.P. 285-287°C. 1H NMR (DMSO-d6) δ 8.66 (s, 2H), 8.60 (d, J = 1.9 Hz, 2H), 8.52 (br s, 
2H), 8.49 (s, 2H), 8.09 (d, J = 8.6 Hz, 2H), 7.50 (dd, J = 8.6, 2.0 Hz, 2H). 13C NMR (DMSO-
d6) δ 152.9, 145.4, 138.9, 136.9, 136.5, 131.1, 129.5, 126.0, 125.0, 124.2. LRMS: m/z (calcd 
for C19H13Cl2N5S2, 445.00; found 445.75). 
2,2'-Bis[1-phenylethylidene]carbonimidic dihydrazide hydrochloride (68) 
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Synthesized according to General Method B from acetophenone to afford the title 
compound as a white solid (60%). 
M.P. 253-254°C. 1H NMR (DMSO-d6) δ 11.91 (br s, 2H), 8.66 (br s, 2H), 8.10 – 8.00 (m, 
4H), 7.51 – 7.41 (m, 6H), 2.45 (s, 6H). 13C NMR (DMSO-d6) δ 154.2, 153.3, 136.7, 129.9, 
128.3, 127.0, 15.0. LRMS: m/z (calcd for C17H19N5, 293.16; found 294.00). 
2,2'-Bis[1-(4-chlorophenyl)ethylidene]carbonimidic dihydrazide hydrochloride (69) 
Synthesized according to General Method A from 4-chlorobenzaldehyde to afford the title 
compound. 
1H NMR (DMSO-d6) δ 11.68 (br. s, 2H), 8.78 (br. s, 1H), 8.10 (d, J = 8.6 Hz, 4H), 7.52 (d, 
J = 8.6 Hz, 4H), 2.43 (s, 6H). 
2,2'-Bis[1-(4-bromophenyl)ethylidene]carbonimidic dihydrazide hydrochloride (70) 
Synthesized according to General Method B from 4-bromobenzaldehyde to afford the title 
compound as a white solid (94%). 
M.P. 299°C (Decomp.).  1H NMR (DMSO-d6) δ 11.63 (s, 2H), 8.76 (s, 2H), 8.01 (d, J = 
8.6 Hz, 4H), 7.65 (d, J = 8.6 Hz, 4H), 2.41 (s, 6H). 13C NMR (DMSO-d6) δ 154.1, 152.4, 
135.9, 131.3, 129.1, 123.6, 14.7.  LRMS: m/z (calcd for C17H17Br2N5, 450.98; found 449.70). 
2,2'-Bis{1-[4-(trifluoromethyl)phenyl]ethylidene}carbonimidic dihydrazide hydrochloride 
(71) 
Synthesized according to General Method A from 4-trifluoromethylbenzaldehyde to afford 
the title compound. 
1H NMR (DMSO-d6) δ 11.71 (br. s, 2H), 8.91 (br. s, 1H), 8.28 (d, J = 7.8 Hz, 4H), 7.82 (d, 
J = 8.2 Hz, 4H), 2.49 (br. s, 6H). 
2,2'-Bis[1-(4-chlorophenyl)propylidene]carbonimidic dihydrazide hydrochloride (72) 
Synthesized according to General Method B from 4-chloropropiophenone to afford the 
title compound as a white solid (47%). 
M.P. 246-247°C. 1H NMR (DMSO-d6) δ 11.68 (s, 2H), 8.78 (s, 2H), 8.09 (d, J = 8.4 Hz, 
4H), 7.52 (d, J = 8.6 Hz, 4H), 2.92 (q, J = 7.5 Hz, 4H), 1.12 (t, J = 7.4 Hz, 6H). 13C NMR 
(DMSO-d6) δ 156.6, 154.2, 134.7, 134.2, 128.9, 128.5, 20.4, 10.9. LRMS: m/z (calcd for 
C19H21Cl2N5, 389.12; found 389.90). 
2,2'-Bis[1-(4-chlorophenyl)butylidene]carbonimidic dihydrazide hydrochloride (73) 
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Synthesized according to General Method B from 4-chlorobutyrophenone to afford the 
title compound as a white solid (26%). 
M.P. 246-247°C. 1H NMR (DMSO-d6) δ 12.18 (s, 2H), 8.71 (s, 2H), 8.08 (d, J = 8.0 Hz, 
4H), 7.50 (d, J = 8.3 Hz, 4H), 3.01 – 2.87 (m, 4H), 1.58 – 1.46 (m, 4H), 1.01 (t, J = 7.1 Hz, 
6H). 13C NMR (DMSO-d6) δ 155.5, 154.2, 134.6, 128.9, 128.4, 28.7, 19.5, 13.6. LRMS: m/z 
(calcd for C21H25Cl2N5, 417.15; found 417.80). 
2,2'-Bis[1-(4-chlorophenyl)pentylidene]carbonimidic dihydrazide hydrochloride (74) 
Synthesized according to General Method B from 1-(4-chlorophenyl)pentan-1-one to 
afford the title compound as a pale yellow solid (53%). 
M.P. 140-142°C. 1H NMR (DMSO-d6) δ 12.09 (s, 2H), 8.69 (s, 2H), 8.07 (d, J = 8.6 Hz, 
4H), 7.50 (d, J = 8.6 Hz, 4H), 3.01 – 2.88 (m, 4H), 1.49 – 1.39 (m, 8H), 0.88 (t, J = 6.6 Hz, 
6H). 13C NMR (DMSO-d6) δ 155.8, 154.4, 134.7, 129.0, 128.5, 28.3, 27.0, 22.0, 13.9. 
LRMS: m/z (calcd for C23H29Cl2N5, 445.18; found 445.80). 
2,2'-Bis[1-(4-chlorophenyl)-2-hydroxyethylidene]carbonimidic dihydrazide (75) 
Synthesized according to General Method A from 1-(4-chlorophenyl)-2-hydroxyethanone 
to afford the title compound as a yellow solid (6%). 
1H NMR (DMSO) δ 8.67 (s, 2H), 7.97 (s, 4H), 7.50 (d, J = 8.6 Hz, 4H), 4.81 (s, 4H). 
LRMS: m/z (calcd for C17H17Cl2N5O2, 393.08; found 393.60). 
2,2'-bis(1-phenyl-2-aminoethylidene)carbonimidic dihydrazide trihydrochloride (76) 
Synthesized according to General Method B from 2-aminoacetophenone hydrochloride to 
afford the title compound as a white solid (8%). 
M.P. 250°C (Decomp.).  1H NMR (DMSO-d6) δ 10.87 (br s, 1H), 9.52 (br s, 1H), 8.76 (br 
s, 3H), 7.61-7.44 (m, 8H), 7.39 (br s, 3H), 7.26 (br s, 3H), 4.06 (br s, 2H). 13C NMR (DMSO-
d6) δ 154.4, 150.8, 130.9, 130.2, 129.6, 127.6, 43.0. LRMS: m/z (calcd for C17H23N7, 324.25; 
found 323.75). 
2,2'-Bis(phenylcarboxymethylene)carbonimidic dihydrazide hydrochloride (77) 
     Synthesized according to General Method B from phenylglycoxylic acid to afford the title 
compound as an off-white crystalline solid (13%). 
M.P. 306°C (Decomp.).  1H NMR (DMSO-d6) δ 14.09 (s, 1H), 8.12 (d, J = 6.9 Hz, 2H), 
7.97 (dd, J = 6.4, 3.0 Hz, 2H), 7.56 (ddd, J = 8.2, 6.7, 2.9 Hz, 7H). 13C NMR (DMSO-d6) δ 
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159.4, 151.3, 149.5, 143.0, 132.0, 131.9, 131.2, 130.2, 129.4, 128.4, 128.3, 128.2. LRMS: 
m/z (calcd for C17H15N5O4, 353.11; found 351.75). 
N',2-Bis((E)-1-(p-tolyl)ethylidene)hydrazine-1-carboximidhydrazide hydrochloride (78) 
Synthesized according to General Method A from 1-(p-tolyl)ethan-1-one to afford the title 
compound as an off-white crystalline solid (71%). 
M.P. 288°C (Decomp.).  1H NMR (DMSO-d6) δ 11.66 (s, 1H), 8.61 (s, 1H), 7.94 (d, J = 
8.2 Hz, 2H), 7.25 (d, J = 8.1 Hz, 2H), 2.41 (s, 3H), 2.35 (s, 3H). 13C NMR (DMSO-d6) δ 
154.0, 153.3, 139.7, 133.9, 129.0, 127.0, 20.9, 14.9. 
2,2'-Bis{1-[4-(t-butyl)phenyl]ethylidene}carbonimidic dihydrazide hydrochloride (79) 
Synthesized according to General Method A from 4′-(t-butyl)acetophenone to afford the 
title compound as a yellow crystalline solid. 
M.P. 310°C (Decomp.).  1H NMR (DMSO-d6) δ 11.74 (s, 1H), 8.60 (s, 1H), 7.95 (d, J = 
8.6 Hz, 2H), 7.45 (d, J = 8.6 Hz, 2H), 2.42 (s, 3H), 1.31 (s, 9H). 13C NMR (DMSO-d6) δ 
154.1, 153.3, 152.6, 134.0, 126.8, 125.0, 34.5, 30.9, 14.9. 
2,2'-Bis[1-(4-piperazinylphenyl)ethylidene]carbonimidic dihydrazide hydrochloride (80) 
Synthesized according to General Method A from 1-(4-(piperazin-1-yl)phenyl)ethan-1-one 
to afford the title compound as a mustard-yellow solid (1%). 
1H NMR (400 MHz, DMSO-d6) δ 7.73 (d, J = 8.8 Hz, 2H), 6.92 (d, J = 8.9 Hz, 2H), 3.22 – 
3.13 (m, 4H), 2.99 – 2.86 (m, 4H), 2.24 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ 156.9, 










Materials and methods: 
Chemicals and bacterial strains are sourced as sited in chapter 2. 
Optimisation of future susceptibility testing for robenidine analogues 
MIC assays were originally performed following strict CLSI guidelines, however results were 
not reproducible and growth was seen above the MIC (Figure A2.1) therefore several 
modifications to the assays were tested to identify the optimum conditions required for 
repeatability and reproducibility of the antibacterial activity of the robenidine analogues. 
Antimicrobials and bacterial suspensions were prepared according to CLSI guidelines. 
 Optimisation in broth 
Either CAMH broth or LB broth was used (BD Scientific). Due to the insoluble nature of the 
robenidine analogues, they were diluted at 100 X higher than the final required concentration 
and 2 μl added to appropriate wells of the assay plate. Broth was added to a final volume of 
180 μl and 20 μl of bacterial suspension diluted to give a final concentration of ~ 5 x 105 
cells/ml. The assay was incubated for 20-24 hrs at 37°C before interpretation of the results. 
 Optimisation in agar 
Either CAMH agar of LB agar (0.7% agar) was prepared and kept warm. The drugs were 
prepared as for optimisation of broth assays and 2 μl spotted into appropriate wells. The 
bacterial suspension was prepared according to CLSI guidelines and diluted in agar to yield a 
final concentration of ~5 X 105 cells/ml. While still warm 198 μl of agar containing bacteria 
was added to each well and allowed to set. Assays were incubated at 37°C for 20-24 hours 
before interpretation of results. 
Results:  
During routine assays with the parent analogue, robenidine, several inconsistencies were 
noticed including consistent growth above the concentration identified as the MIC and failure 
of the assay to identify an MIC for robenidine on multiple occasions. To identify the problem 
with the assay an analysis involving several different batches of the compound and different 
assay broths was performed. Due to the insoluble nature of the compound, all assays involved 
serial dilution of the compounds in DMSO before addition of the required amount directly to 
the assay and dilution in the growth media. Seven separate batches were tested consisting of 3 
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commercial and 4 synthesised by the chemists at Newcastle University. Four of the seven 
batches had been stored at 4°C while the rest were stored at room temperature. There was no 
significant difference found in the results between different batches of robenidine under the 
conditions tested (data not shown). Both CAMH broth and agar (CLSI recommended media) 
and LB broth and agar were tested for reproducibility of results and clarity of the MIC with 
robenidine. LB broth, agar and CAMH agar all gave reproducible results, between 1-8 μg/ml, 
with no growth observed above the MIC. CAMH broth, as observed in the past, resulted in 
inconsistent, if any reportable MIC with values ranging from 0.25 - >128 μg/ml (Figure A2.1). 
This phenomenon was even observed within the duplicates of a single assay. Optical density 
of the bacterial growth at different concentrations of robenidine in various assay conditions 
demonstrates the high error observed in CAMH broth compared to the agar methods and LB 
broth. This assay was performed in duplicate by three independent researchers and despite the 
large variance in inoculum (between 1.5 and 5.9 CFU/ml) the results did not appear to be 








































































































Figure A2.1 Optimisation of the minimum inhibitory concentration assay for the testing of robenidine and associated 
analogues. Robenidine (812) was tested in various cation adjusted Mueller Hinton broth and agar and Luria Bertaini broth 
and agar to identify the most reproducible assay system. Robenidine was serially diluted in DMSO and added directly to the 
test. The increase in absorbance in the agar assays is due to the turbidity of the robendine compound in the agar. Clockwise 
from top left: cation adjusted Mueller Hinton broth, Luria Bertanini broth, cation adjusted Mueller Hinton agar and Luria 
Bertanini agar. Key: black circles – S. aureus ATCC 29213, white squares – S. aureus ATCC 6538, broken line – detection 








Materials and methods: 
Bacterial strains and chemicals were sourced as outlined in chapter 3 
Ampicillin induced spheroplasts 
An overnight broth culture was diluted to approximately 1 x 109 cells/ml in CAMH broth 
supplemented with 50 μg/ml ampicillin, 0.4 M sucrose and 8 mM MgSO4. The culture was 
incubated for ~ 2 hrs, until the majority of cells had become spherical, as observed under phase 
contrast microscope. 
Lysozyme induced spheroplasts 
A 1:100 dilution of an overnight broth culture was performed in CAMH broth. The inoculated 
broth was grown until an OD600 of 0.4 was reached. The bacteria were harvested via 
centrifugation (4000 rpm, 3 min), washed with an equal volume of Tris(HCl) pH 8 and 
suspended to a final concentration of ~5 x 108 cells/ml in Tris buffer (pH8) supplemented with 
0.5 M sucrose. Lysozyme was added to a final concentration of 20, 60, 100 or 500 μg/ml, for 
Gram-negative and Gram-positive organisms respectively, while continually stirring. For 
Gram-negative organisms the culture was incubated at room temperature for a maximum of 10 
minutes before the addition of EDTA to a final concentration of 10 mM. Gram-positive 
organisms were incubated with lysozyme for upto 3 hrs, no EDTA was added. Spheroplast 
formation was determined by osmotic sensitivity and microscopy. 
Lysozyme and ampicillin induced spheroplasts 
A 1:4 dilution of overnight culture was prepared in CAMH broth supplemented with 0.4 M 
sucrose and 50 μg/ml ampicillin. The culture was incubated at 37°C for 1 hr before the addition 
of 100 μg/ml lysozyme. Changes in morphology were observed under the microscope using 
trypan blue dye. 
Ampicillin and penicillin induced spheroplasts 
Cultures were diluted as above in CAMH broth supplemented with 0.4 M sucrose, 8 mM 
MgSO4 and 1 mg/ml penicillin, 1 mg/ml ampicillin or both ampicillin and penicillin (1 mg/ml). 
Cultures were incubated for 24 hours with samples taken periodically to assess morphology 
and the development of spheroplasts using phase contrast microscopy or trypan blue staining. 
Identification of the optimum regeneration media of E. coli spheroplasts 
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E. coli spheroplasts were induced using the ampicillin method described above. Briefly, two 
colonies of an overnight culture of the required bacterial strain (E. coli ATCC 25922) were 
used to inoculate ~20 ml of CAMH broth which was further incubated for 18 hours at 37°C. A 
1:3 dilution of the overnight culture into fresh CAMH broth (total 20 ml volume) supplemented 
with 50 mg/ml ampicillin, 0.4 M Sucrose and 8 mM MgSO4 was performed and this culture 
was monitored for the formation of spheroplasts using a phase contrast microscope. The 
number of cells before induction of spheroplasts, after induction of spheroplasts and after 
exposure of spheroplasts to water was determined on the following agar combinations: brain 
heart infusion soft agar with sucrose (agar 0.8%, sucrose 0.4 M), brain heart infusion agar with 
sucrose (agar 1.5%, sucrose 0.4M), brain heart infusion agar (agar 1.5%), sheep blood agar, 
plate count agar with sucrose (sucrose 0.4 M) or plate count agar. Samples were incubated 
overnight at 37°C before calculation of spheroplast formation frequency and spheroplast 
regeneration frequency. 
Results: 
Several spheroplast induction procedures were performed to identify the most reliable method 
for the development of spheroplasts. Numerous different species of bacteria were also 
investigated in the hope that the compounds could be tested against a range of target organisms. 
Four methods of spheroplast induction were tested involving ampicillin, penicillin and 
lysozyme. The lysozyme method was found to be the most impractical with the ability to induce 
spheroplasts in E.coli but these died rapidly. The ampicillin method resulted in the consistent 
induction of spheroplasts in E. coli, the organism with highest priority for this assay as it is 
considered a representative organism for Gram-negative bacteria. These spheroplasts were 
induced after 2 hours and were viable for at least 7 days in media supplemented with 0.4 M 
sucrose, 8 mM MgSO4 and 50 μg/ml ampicillin (Table A3.1). The development of S. aureus 
spheroplasts was much harder to determine, due to the native spherical shape of the organism, 
but could be identified by an increase in size, loss of a purple gram-stain and extreme sensitivity 
to osmotic changes. Based on these 3 identifying features of Gram-positive spheroplasts, 
ampicillin at 50 μg/ml was able to induce a spheroplast state in S. aureus. Of the other 
organisms tested, spheroplast induction could only be observed in Lactobacillus reuterii and 
Bacillus coagulans on one occasion, however this was not repeatable and the number of 
spheroplasts formed in the cultures was very small. A combination of ampicillin and lysozyme 
to induce spheroplasts was attempted in S. aureus, Lactobacillus acidophilus, L. reuterii and 
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B. coagulans and was unsuccessful in all situations. Similarly, an attempt to induce 
spheroplasts in L. acidophilus, L. reuterii and B. coagulans with a combination of penicillin 
and ampicillin failed. 
The optimum regeneration media for E. coli spheroplasts was found to be brain heart infusion 
agar, followed by sheep blood agar. Plate count agar with sucrose was the least effective for 
regeneration of spheroplasts (Table A3.2). The temperature at which spheroplasts were 




Table A3.1 The induction of spheroplast transformation in various species of bacteria. Four treatments were tested to induce 
spheroplast formation in both Gram-positive and Gram-negative bacteria. “-“ = not tested 
 Treatment Used to Induce Spheroplast Transformation 





E. coli ATCC 
25922 
Yes viable for 
≥ 7 days 
Yes but died 
rapidly 
- - 
S. aureus ATCC 
25923 
Yes 
Possibly – cells 
died rapidly 
No - 
Bacillus cereus No - - - 
Bacillus subtilis No - - - 
Lactobacillus 
acidophilus 






- No No 
Bacillus 
coagulans 
Yes – after 3 
days – not 
repeatable 





Table A3.2 The regeneration of E. coli spheroplasts on various solid media. Agar of various constitutions and concentrations were used to identify the optimum media for the regeneration of E. 
coli spheroplasts. Cultures of E. coli were exposed to sub-lethal concentrations of ampicillin to induce the formation of spheroplasts before overnight incubation on agar. The CFU/ml before 
spheroplast generation and after water treatment (a sample of spheroplasts were diluted 1:10, to destroy any spheroplasts, in water before overnight incubation at 37°C) were determined on 
plate count agar. Error ± SD. Soft agar had an agar concentration of 0.8%. Sucrose was added at a concentration of 0.4 M. 
Agar composition 








Number of cells 
after exposure to 
water (CFU/ml) (Y) 
Number of 
spheroplasts 
(CFU/ml) (X – Y) 
Spheroplast 
formation 
frequency (X – 
Y/X)% 
Regeneration 
frequency ((X – 
Y)/Z)% 
Soft Brain heart 
infusion agar with 
sucrose 
3.03 x107 3.03 x 106 1.00 x 104 3.02 x 106 99.67 9.97 
Brain heart infusion 
agar with sucrose 
3.03 x107 1.13 x 107 1.00 x 104 1.13 x 107 99.91 37.11 
Brain heart infusion 
agar 
3.03 x107 2.17 x 107 1.00 x 104 2.16 x 107 99.95 71.34 
Sheep blood agar 3.03 x107 1.94 x 107 1.00 x 104 1.94 x 107 99.95 63.87 
Plate count agar with 
sucrose 
3.03 x107 6.67 x 105 1.00 x 104 6.57 x 105 98.50 2.16 
Plate count agar 3.03 x107 4.00 x 105 1.00 x 104 3.90 x 105 97.50 1.29 
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Figure A3.1 Ideal temperature to incubate E. coli spheroplasts. Spheroplasts were induced using sub-lethal concentrations of 
ampicillin and incubated at 27°C (squares) or 37°C (circles) for 24 hours. The experiment was repeated in triplicate and error 
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